Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-1|1|108|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-2|1|296|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-3|1|296|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-4|1|296|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-5|1|296|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-6|1|296|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-7|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-8|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-9|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-10|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-11|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-12|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-13|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-14|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-15|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-16|1|360|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-17|1|437|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-18|1|437|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-19|1|437|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-20|1|437|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-21|1|437|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-22|1|438|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-23|1|438|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-24|1|438|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-25|1|438|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-26|1|438|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-27|1|456|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-28|1|456|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-29|1|456|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-30|1|456|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-31|1|456|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-32|1|520|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-33|1|520|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-34|1|520|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-35|1|520|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-36|1|520|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-37|1|522|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-38|1|543|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-39|1|543|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-40|1|543|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-41|1|543|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-42|1|543|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-43|1|570|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-44|1|582|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC METASTASIS TO COSTAL MUSCLE.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study 
|1003-20-1-45|1|583|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-46|1|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-47|1|640|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-48|1|642|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-49|1|647|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-50|1|649|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-51|1|651|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-52|1|668|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-53|1|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-54|1|676|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-55|1|683|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-56|1|684|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart Metastases  Muscle trac to costal muscle. Metastases  Lung txac of submax. region metas. to lung.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-57|1|692|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-58|1|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-59|1|708|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ Head neck missing,MPATH: 212 - inflammation|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-60|1|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-61|1|721|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-62|1|725|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-63|1|747|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-64|1|751|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-65|1|753|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-66|1|771|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-67|1|774|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-68|1|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-69|1|778|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-70|1|780|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-71|1|781|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-72|1|783|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-73|1|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-74|1|784|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-75|1|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-76|1|796|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-77|1|797|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-78|1|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-79|1|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-80|1|806|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-81|1|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-82|1|807|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-83|1|810|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-84|1|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-85|1|820|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-86|1|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-87|1|830|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-88|1|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-89|1|841|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-90|1|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-91|1|844|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-92|1|851|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to  parathymic ln. Metastases  Muscle trac to costal muscle. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-93|1|851|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-94|1|854|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-95|1|862|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-96|1|864|Hyperplastic changes|Cardiovascular system|MPAN/ gross dx tbon is mpan.Polyarteritis nodosa|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-97|1|864|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-98|1|865|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC METASTASIS TO COSTAL MUSCLE.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-99|1|865|Neoplasia malignant|Bloodvessels among cardiovascular system|TVVS/ Seminal vesicle|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-100|1|866|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-101|1|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-102|1|873|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-103|1|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-104|1|876|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-105|1|877|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-106|1|878|Other deterministic changes|Whole body|MCDU/ jr and ll.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-107|1|889|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-108|1|890|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-109|1|891|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-110|1|895|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-111|1|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-112|1|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-113|1|905|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-114|1|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-115|1|923|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic. Metastases  Lymphoret.System txac of the region of the throat to mediastinal ln. Metastases  Muscle trac to costal muscle. Metastases  Lung txac of the region of the throat to the lung.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-116|1|923|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-117|1|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-118|1|929|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-119|1|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-120|1|932|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-121|1|933|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-122|1|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-123|1|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-124|1|940|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-125|1|953|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of spine.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-126|1|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/ undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-127|1|957|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-128|1|960|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-129|1|960|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-130|1|961|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-131|1|961|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-132|1|968|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-133|1|972|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-134|1|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-135|1|981|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-136|1|986|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-137|1|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-138|1|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-139|1|994|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-140|1|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-141|1|996|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-142|1|996|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-143|1|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-144|1|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-145|1|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-146|1|1009|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-147|1|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-148|1|1024|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-149|1|1030|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac metastasis to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-150|1|1039|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-151|1|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-152|1|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-153|1|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-154|1|1050|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-155|1|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/ll.,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-156|1|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-157|1|1058|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac to sternum and pleura. Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-158|1|1059|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-159|1|1067|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-160|1|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-161|1|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-162|1|1086|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac to mediastinum & parietal pleura. Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-163|1|1088|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-164|1|1089|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-165|1|1095|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar muscle. Muscle|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-166|1|1096|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-167|1|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-168|1|1112|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-169|1|1121|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-170|1|1123|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-171|1|1128|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-172|1|1129|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-173|1|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-174|1|1137|n/a|n/a|n/a|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-175|1|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-176|1|1144|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-177|1|1147|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-178|1|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-179|1|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Metastases  trac invasion site not specified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-180|1|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-181|1|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-182|1|1186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-183|1|1192|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-184|1|1197|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/ auricular|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-185|1|1201|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Liver Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-186|1|1219|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-187|1|1226|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-188|1|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-189|1|1235|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-190|1|1248|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-191|1|1250|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ tissue number j6773a.|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-192|1|1255|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-193|1|1257|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-194|1|1263|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-195|1|1283|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-196|1|1305|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-197|1|1338|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-198|1|1338|Other deterministic changes|Whole body|MCDU/ |
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-199|1|1380|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-1|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|159 records survival 835 ± 15 lifespan study|1003-20-1-200|1|1406|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-1|2|109|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-2|2|269|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-3|2|269|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-4|2|269|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-5|2|269|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-6|2|269|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-7|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-8|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-9|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-10|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-11|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-12|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-13|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-14|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-15|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-16|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-17|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-18|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-19|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-20|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-21|2|276|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-22|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-23|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-24|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-25|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-26|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-27|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-28|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-29|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-30|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-31|2|360|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-32|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-33|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-34|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-35|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-36|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-37|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-38|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-39|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-40|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-41|2|437|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-42|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-43|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-44|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-45|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-46|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-47|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-48|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-49|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-50|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-51|2|444|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-52|2|467|Neoplasia unclassified|Other local manifestations and miscellaneus|TOWU: TULS TO OVARY.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-53|2|498|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-54|2|498|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-55|2|498|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-56|2|529|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-57|2|548|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-58|2|555|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMVS OF THIGH INVASION BUT SITE NOT STATED.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-59|2|585|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-60|2|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-61|2|600|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-62|2|639|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-63|2|651|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-64|2|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-65|2|680|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMLS OF BELLY WALL METAST TO VISCERAL ABDOM WALL.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-66|2|683|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION BUT METASTIC SITE NOT IDENTIFIED.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-67|2|723|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-68|2|726|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-69|2|733|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-70|2|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-71|2|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-72|2|750|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-73|2|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-74|2|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-75|2|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-76|2|777|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-77|2|779|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-78|2|780|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-79|2|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-80|2|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-81|2|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-82|2|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-83|2|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-84|2|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs on occasion mixed otherwise tlhs/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-85|2|799|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-86|2|809|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-87|2|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-88|2|820|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-89|2|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-90|2|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-91|2|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-92|2|844|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-93|2|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-94|2|856|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-95|2|859|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-96|2|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-97|2|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ tkid of gross in tlll.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-98|2|865|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-99|2|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs or spleen type c/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-100|2|872|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-101|2|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-102|2|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ tlxs/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-103|2|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-104|2|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-105|2|904|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-106|2|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-107|2|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-108|2|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-109|2|923|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ forearm left. Muscle|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-110|2|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-111|2|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-112|2|927|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum w/secondary peritonitis.Enteritis acute,MPATH: 212 - inflammation|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-113|2|927|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-114|2|937|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/ Adenoma,MPATH: 218 - neoplasm|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-115|2|939|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-116|2|942|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute,MPATH: 212 - inflammation|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-117|2|943|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWM: TMLS OF BACK WITH WIDESPREAD INVASION.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-118|2|944|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-119|2|948|Neoplasia unclassified|Other local manifestations and miscellaneus|TOWU: TULS TO OVARY.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-120|2|963|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ belly wall. Metastases  tmls of belly wall metast to visceral abdom wall.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-121|2|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ lsl on 01/11/75.  tlhs/rjmf on 01/29/75 - tlhs.  tlhs/jhr on 2/10/77.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-122|2|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-123|2|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-124|2|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-125|2|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-126|2|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-127|2|982|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ skin of face.,MPATH: 218 - neoplasm|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-128|2|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-129|2|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Ovary,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-130|2|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ lsl 12/19/74.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-131|2|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-132|2|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-133|2|1006|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION BUT METASTIC SITE NOT IDENTIFIED.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-134|2|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-135|2|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-136|2|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-137|2|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-138|2|1020|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-139|2|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-140|2|1022|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-141|2|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ tlxs/jhr,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-142|2|1023|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-143|2|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-144|2|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ hematology diagnosis tlml; verified by rjmf & tf  2/9/77.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-145|2|1030|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-146|2|1031|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-147|2|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-148|2|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls/lsl and tlhs/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-149|2|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-150|2|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-151|2|1047|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-152|2|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-153|2|1060|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUFO/ vaginal orifice.Fibroma,MPATH: 270 - adenoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-154|2|1068|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ back. Metastases  tmls of back with widespread invasion.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-155|2|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-156|2|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-157|2|1085|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-158|2|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ hematology diagnosis.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-159|2|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-160|2|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-161|2|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-162|2|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-163|2|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  trac invasion site unspecified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-164|2|1101|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ splenitis; acute severe.,MPATH: 213 - acute inflammation|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-165|2|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-166|2|1107|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ region of throat and ear.,MPATH: 218 - neoplasm|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-167|2|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-168|2|1109|n/a|n/a|n/a|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-169|2|1118|Neoplasia malignant|Endocrine system|TGAC/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-170|2|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-171|2|1138|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ unknown; chest region. Metastases  Lymphoret.System txvs of chest to regional ln. Metastases  Kidney txvs of chest to kidney & adrenal.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-172|2|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-173|2|1146|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-174|2|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-175|2|1149|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-176|2|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-177|2|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-178|2|1157|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-179|2|1170|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-180|2|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-181|2|1177|Neoplasia malignant|Bloodvessels among cardiovascular system|TDVS/ Urinary bladder|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-182|2|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-183|2|1193|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases  Lymphoret.System tbos of femur to regional ln.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-184|2|1201|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-185|2|1202|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle Metastases  tmvs of thigh invasion but site not stated.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-186|2|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-187|2|1204|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-188|2|1210|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-189|2|1212|Neoplasia systemic|Haematolymphatic system|TLML/ based on hematology.|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-190|2|1214|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-191|2|1224|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion but metastic site not identified.,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-192|2|1233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-193|2|1238|Other deterministic changes|Whole body|MCDU/ |
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-194|2|1256|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-195|2|1278|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-196|2|1305|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-197|2|1319|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-198|2|1341|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ hodgkin's like.,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-199|2|1389|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-2|n/a,AC|1| 100|shamexposed|0|grays|External exposure| code AC 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|145 records survival 863 ± 15 lifespan study|1003-20-2-200|2|1390|Hyperplastic changes|Cardiovascular system|MPAN/ ovary and kidney.Polyarteritis nodosa|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-1|3|172|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-2|3|184|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-3|3|353|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-4|3|353|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-5|3|353|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-6|3|353|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-7|3|353|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-8|3|391|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-9|3|410|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-10|3|410|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-11|3|410|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-12|3|410|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-13|3|410|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-14|3|417|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-15|3|417|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-16|3|417|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-17|3|417|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-18|3|417|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-19|3|437|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-20|3|437|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-21|3|437|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-22|3|437|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-23|3|437|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-24|3|457|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-25|3|457|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-26|3|457|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-27|3|457|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-28|3|457|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-29|3|521|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-30|3|521|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-31|3|521|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-32|3|521|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-33|3|521|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-34|3|531|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-35|3|542|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-36|3|542|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-37|3|542|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-38|3|542|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-39|3|542|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-40|3|550|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-41|3|550|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-42|3|550|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-43|3|550|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-44|3|550|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-45|3|590|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System tmrs of diaphragm region to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-46|3|597|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-47|3|608|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-48|3|631|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-49|3|660|Other deterministic changes|Whole body|MCDU/ |
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-50|3|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-51|3|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-52|3|692|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ rjmf & jr.acute,MPATH: 212 - inflammation|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-53|3|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-54|3|724|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-55|3|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-56|3|729|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-57|3|750|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-58|3|757|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-59|3|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-60|3|766|Other deterministic changes|Whole body|MCDU/  Metastases Kidney|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-61|3|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-62|3|778|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-63|3|784|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-64|3|798|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-65|3|799|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-66|3|806|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMRS OF DIAPHRAGM REGION TO LIVER.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-67|3|808|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-68|3|812|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-69|3|813|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-70|3|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-71|3|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-72|3|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-73|3|849|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-74|3|849|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-75|3|850|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-76|3|851|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-77|3|851|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-78|3|852|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-79|3|852|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-80|3|855|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-81|3|863|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-82|3|863|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-83|3|866|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-84|3|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-85|3|866|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ diaphragm region. Metastases Lung tmrs of diaphragm region to lung. Metastases Liver Metastases Heart,MPATH: 428 - rhabdomyosarcoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-86|3|869|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-87|3|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-88|3|882|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-89|3|887|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-90|3|898|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-91|3|898|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-92|3|900|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-93|3|901|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-94|3|901|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-95|3|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-96|3|902|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-97|3|904|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-98|3|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-99|3|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-100|3|915|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-101|3|923|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-102|3|925|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/ Transitional cell,MPATH: 549 - carcinoma|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-103|3|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-104|3|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-105|3|927|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-106|3|928|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-107|3|928|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-108|3|931|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-109|3|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-110|3|931|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-111|3|932|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-112|3|934|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ region of flank.Skin|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-113|3|937|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-114|3|941|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-115|3|942|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-116|3|948|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-117|3|952|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-118|3|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-119|3|956|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-120|3|968|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-121|3|971|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-122|3|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-123|3|972|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-124|3|974|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-125|3|983|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-126|3|984|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-127|3|997|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-128|3|1001|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-129|3|1001|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMRS OF DIAPHRAGM REGION TO LIVER.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-130|3|1002|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-131|3|1004|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-132|3|1004|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-133|3|1006|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-134|3|1011|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-135|3|1015|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-136|3|1019|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-137|3|1023|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-138|3|1023|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-139|3|1029|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-140|3|1029|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-141|3|1029|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-142|3|1030|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-143|3|1031|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-144|3|1034|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-145|3|1034|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-146|3|1037|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-147|3|1037|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-148|3|1044|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-149|3|1044|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-150|3|1054|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-151|3|1057|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-152|3|1059|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-153|3|1060|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-154|3|1064|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-155|3|1068|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-156|3|1070|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-157|3|1070|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-158|3|1071|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-159|3|1072|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-160|3|1079|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-161|3|1080|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-162|3|1086|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-163|3|1093|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-164|3|1106|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-165|3|1109|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-166|3|1109|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-167|3|1111|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-168|3|1116|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-169|3|1122|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMRS OF DIAPHRAGM REGION TO LIVER.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-170|3|1122|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-171|3|1129|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-172|3|1135|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-173|3|1136|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-174|3|1137|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-175|3|1137|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-176|3|1139|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-177|3|1141|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-178|3|1144|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-179|3|1148|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-180|3|1152|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-181|3|1165|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-182|3|1171|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-183|3|1171|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-184|3|1178|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-185|3|1190|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-186|3|1190|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-187|3|1193|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-188|3|1204|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-189|3|1205|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-190|3|1211|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-191|3|1220|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-192|3|1228|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-193|3|1235|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-194|3|1235|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-195|3|1247|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-196|3|1265|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-197|3|1313|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-198|3|1348|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-199|3|1380|n/a|n/a|n/a|
1003-20-3|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|158 records survival 859 ± 14 lifespan study|1003-20-3-200|3|1403|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-1|4|172|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-2|4|205|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-3|4|299|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-4|4|347|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-5|4|403|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-6|4|463|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-7|4|487|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-8|4|500|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-9|4|502|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-10|4|540|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-11|4|572|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-12|4|574|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-13|4|604|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-14|4|612|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-15|4|621|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ appears like togc.,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-16|4|632|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-17|4|640|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-18|4|652|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ mesenteric ln. Lymphoret.tissue|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-19|4|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-20|4|669|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  Metastases Lung tmac (mamm.) to lung; this is the tadn of the gross dx.,MPATH: 1 - cell and tissue damage|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-21|4|671|Other deterministic changes|Whole body|MCDU/ |
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-22|4|671|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-23|4|673|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-24|4|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-25|4|679|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-26|4|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-27|4|685|Other deterministic changes|Whole body|MCDU/ |
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-28|4|695|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-29|4|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-30|4|707|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-31|4|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-32|4|722|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-33|4|722|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-34|4|731|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-35|4|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-36|4|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-37|4|749|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Lung|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-38|4|751|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-39|4|755|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-40|4|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-41|4|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-42|4|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-43|4|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-44|4|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-45|4|789|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-46|4|797|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-47|4|800|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-48|4|802|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-49|4|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-50|4|810|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-51|4|813|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-52|4|819|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-53|4|827|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-54|4|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-55|4|831|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-56|4|832|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-57|4|833|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-58|4|834|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-59|4|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-60|4|839|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-61|4|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-62|4|840|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-63|4|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-64|4|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ this is the tute of the gross dx.,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-65|4|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-66|4|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-67|4|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-68|4|855|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-69|4|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-70|4|857|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-71|4|859|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-72|4|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-73|4|870|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-74|4|870|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-75|4|874|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-76|4|876|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-77|4|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-78|4|884|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-79|4|890|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-80|4|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-81|4|892|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-82|4|893|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-83|4|895|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-84|4|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ possibly tlxs (giant cells)/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-85|4|899|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-86|4|903|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/ auricular|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-87|4|905|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-88|4|907|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-89|4|911|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-90|4|914|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-91|4|919|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-92|4|922|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-93|4|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-94|4|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-95|4|925|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-96|4|925|Other deterministic changes|Whole body|MCDU/ |
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-97|4|926|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-98|4|929|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-99|4|930|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-100|4|937|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-101|4|938|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-102|4|939|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-103|4|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-104|4|943|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-105|4|946|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-106|4|947|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-107|4|948|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-108|4|952|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAC/  Metastases  Muscle tmac (mamm.) to adjacent muscle. Metastases Liver Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-109|4|954|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-110|4|954|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-111|4|955|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-112|4|959|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-113|4|964|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-114|4|965|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-115|4|965|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-116|4|965|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-117|4|967|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-118|4|967|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-119|4|969|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-120|4|971|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-121|4|975|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-122|4|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-123|4|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-124|4|982|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-125|4|983|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-126|4|984|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-127|4|988|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-128|4|990|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-129|4|991|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-130|4|1001|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-131|4|1004|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-132|4|1011|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-133|4|1013|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-134|4|1014|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-135|4|1018|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-136|4|1018|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-137|4|1023|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-138|4|1023|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-139|4|1026|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-140|4|1037|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAC (MAMM.) TO LIVER.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-141|4|1038|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-142|4|1039|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-143|4|1045|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-144|4|1051|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-145|4|1051|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-146|4|1053|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-147|4|1062|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-148|4|1062|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-149|4|1062|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-150|4|1063|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-151|4|1074|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-152|4|1079|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-153|4|1079|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-154|4|1081|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-155|4|1093|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAC (MAMM.) TO LIVER.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-156|4|1094|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-157|4|1096|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-158|4|1098|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-159|4|1108|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-160|4|1112|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-161|4|1113|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-162|4|1116|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-163|4|1121|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-164|4|1127|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-165|4|1128|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-166|4|1131|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-167|4|1137|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-168|4|1139|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-169|4|1139|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-170|4|1143|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-171|4|1143|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-172|4|1146|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-173|4|1147|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-174|4|1151|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-175|4|1151|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-176|4|1155|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-177|4|1155|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-178|4|1160|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAC (MAMM.) TO LIVER.|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-179|4|1161|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-180|4|1162|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-181|4|1170|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-182|4|1179|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-183|4|1192|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-184|4|1208|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-185|4|1211|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-186|4|1239|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-187|4|1241|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-188|4|1242|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-189|4|1243|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-190|4|1243|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-191|4|1253|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-192|4|1268|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-193|4|1297|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-194|4|1313|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-195|4|1316|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-196|4|1323|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-197|4|1361|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-198|4|1366|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-199|4|1370|n/a|n/a|n/a|
1003-20-4|n/a,DC|1| 100|shamexposed|0|grays|External exposure| code DC 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 818 ± 15 lifespan study|1003-20-4-200|4|1373|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-1|5|113|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-2|5|205|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METASTATIC TO THYMIC REGION.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-3|5|303|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-4|5|303|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-5|5|303|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-6|5|303|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-7|5|303|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-8|5|417|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-9|5|417|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-10|5|417|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-11|5|417|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-12|5|417|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-13|5|491|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE UNSPECIFIED.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-14|5|494|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-15|5|494|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-16|5|494|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-17|5|494|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-18|5|494|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-19|5|513|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-20|5|513|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-21|5|513|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-22|5|513|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-23|5|513|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-24|5|515|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-25|5|523|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-26|5|530|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-27|5|568|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-28|5|569|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-29|5|569|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-30|5|569|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-31|5|569|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-32|5|569|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-33|5|570|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-34|5|570|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-35|5|570|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-36|5|570|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-37|5|570|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-38|5|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-39|5|608|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-40|5|647|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-41|5|657|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-42|5|681|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-43|5|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-44|5|686|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-45|5|686|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE UNSPECIFIED.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-46|5|701|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-47|5|708|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-48|5|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-49|5|750|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-50|5|754|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-51|5|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-52|5|766|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-53|5|768|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-54|5|773|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-55|5|781|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-56|5|782|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-57|5|786|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-58|5|789|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa Metastases  Muscle trac to costal muscle.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-59|5|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-60|5|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAST. TO PARATHYMIC LN.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-61|5|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-62|5|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-63|5|819|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-64|5|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-65|5|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-66|5|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac metast. to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-67|5|860|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-68|5|862|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-69|5|869|Other deterministic changes|Whole body|MCDU/ brain hemorrhage possible cod.  testicle atrophic/not coded; epididymus focal stasis and empty tubules/not coded.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-70|5|870|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-71|5|872|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of pelvic cavity. Muscle|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-72|5|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-73|5|878|Other deterministic changes|Reproductive system|MSVS/ Stasis seminal vesicle|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-74|5|879|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-75|5|881|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-76|5|885|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-77|5|886|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-78|5|890|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-79|5|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-80|5|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-81|5|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-82|5|899|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-83|5|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-84|5|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Metastases  Lymphoret.System trac metastatic to thymic region.,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-85|5|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-86|5|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-87|5|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-88|5|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-89|5|920|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-90|5|921|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Metastases  Muscle trac to costal muscle.,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-91|5|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-92|5|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-93|5|923|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-94|5|928|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-95|5|933|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-96|5|934|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-97|5|938|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-98|5|938|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-99|5|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-100|5|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-101|5|945|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-102|5|945|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-103|5|946|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-104|5|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/ undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-105|5|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-106|5|960|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-107|5|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-108|5|963|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-109|5|963|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-110|5|965|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-111|5|965|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-112|5|967|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-113|5|967|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-114|5|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-115|5|973|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-116|5|976|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-117|5|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-118|5|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-119|5|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-120|5|981|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-121|5|982|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-122|5|982|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-123|5|986|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-124|5|991|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-125|5|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-126|5|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-127|5|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-128|5|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-129|5|1004|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-130|5|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-131|5|1011|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-132|5|1012|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-133|5|1012|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-134|5|1012|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-135|5|1014|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-136|5|1022|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-137|5|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-138|5|1037|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-139|5|1038|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ Eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-140|5|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-141|5|1040|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-142|5|1041|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-143|5|1046|n/a|n/a|n/a|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-144|5|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-145|5|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-146|5|1062|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-147|5|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-148|5|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-149|5|1077|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-150|5|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-151|5|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-152|5|1084|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-153|5|1084|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-154|5|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-155|5|1094|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-156|5|1099|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-157|5|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-158|5|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-159|5|1110|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-160|5|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-161|5|1125|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|TYCS/ Chondrosarcoma,MPATH: 511 - Myeloproliferation (genetic)|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-162|5|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-163|5|1127|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-164|5|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-165|5|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-166|5|1143|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-167|5|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-168|5|1146|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac metast. to parathymic ln. Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-169|5|1148|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-170|5|1148|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-171|5|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-172|5|1151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-173|5|1153|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-174|5|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-175|5|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Kidney tmfs of costal muscle to kidney.,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-176|5|1183|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-177|5|1184|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-178|5|1185|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-179|5|1185|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-180|5|1190|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-181|5|1196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-182|5|1196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-183|5|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-184|5|1202|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-185|5|1218|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-186|5|1222|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-187|5|1230|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-188|5|1232|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-189|5|1234|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-190|5|1236|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-191|5|1247|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-192|5|1252|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-193|5|1259|Other deterministic changes|Whole body|MCDU/ |
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-194|5|1282|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Metastases Lung|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-195|5|1297|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ costal muscle.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-196|5|1303|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-197|5|1318|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-198|5|1342|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-199|5|1366|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-5|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|169 records survival 864 ± 15 lifespan study|1003-20-5-200|5|1387|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-1|6|240|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-2|6|240|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-3|6|240|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-4|6|240|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-5|6|240|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-6|6|352|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-7|6|446|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-8|6|491|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-9|6|498|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-10|6|516|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-11|6|544|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-12|6|547|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMEI/ Middle ear infection|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-13|6|592|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-14|6|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ gross dx tute & tove probably tlhs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-15|6|599|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-16|6|604|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-17|6|621|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMEI/ Middle ear infection|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-18|6|621|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-19|6|639|Neoplasia unclassified|Other local manifestations and miscellaneus|TOWX: TXAC OF PANCREAS TO OVARY.|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-20|6|641|Neoplasia unclassified|Other local manifestations and miscellaneus|THWN: TNNS OF PELVIC REGION TO LIVER.|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-21|6|672|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-22|6|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-23|6|682|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-24|6|684|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-25|6|685|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-26|6|693|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ pancreas. Metastases Ovary,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-27|6|702|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-28|6|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-29|6|713|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-30|6|714|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-31|6|716|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-32|6|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-33|6|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-34|6|724|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-35|6|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ gross dx tute is tlhs/jhr & tulo/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-36|6|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-37|6|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-38|6|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-39|6|742|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-40|6|746|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-41|6|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-42|6|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-43|6|771|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-44|6|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-45|6|773|Neoplasia unclassified|Other local manifestations and miscellaneus|THWN: TNNS OF PELVIC REGION TO LIVER.|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-46|6|780|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-47|6|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-48|6|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-49|6|792|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-50|6|798|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-51|6|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls/lsl; tlhs/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-52|6|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-53|6|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-54|6|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-55|6|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-56|6|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-57|6|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-58|6|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-59|6|835|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-60|6|844|Other deterministic changes|Whole body|MCDU/ chronic kidney disease (mcrd) seems to be most likely cadidate for cod.|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-61|6|847|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-62|6|857|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-63|6|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-64|6|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-65|6|868|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-66|6|869|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute,MPATH: 212 - inflammation|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-67|6|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-68|6|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-69|6|890|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-70|6|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-71|6|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-72|6|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases Kidney,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-73|6|896|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-74|6|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  Lung txac of pancreas to lung.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-75|6|899|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-76|6|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-77|6|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-78|6|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ lsl & rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-79|6|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-80|6|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-81|6|912|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-82|6|914|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-83|6|918|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-84|6|920|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-85|6|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-86|6|922|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-87|6|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ lsl dx; rjmf agrees.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-88|6|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-89|6|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-90|6|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-91|6|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-92|6|937|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-93|6|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ based on hematology; tlls/lsl dx.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-94|6|940|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|TBFS/ spine.,MPATH: 551 - sarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-95|6|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-96|6|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-97|6|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-98|6|956|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ neck mammary gland.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-99|6|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-100|6|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-101|6|960|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-102|6|964|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-103|6|969|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-104|6|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-105|6|972|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-106|6|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-107|6|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-108|6|977|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-109|6|977|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMEI/ Middle ear infection|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-110|6|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-111|6|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-112|6|984|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-113|6|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-114|6|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-115|6|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-116|6|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-117|6|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-118|6|998|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-119|6|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-120|6|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-121|6|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-122|6|1004|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-123|6|1005|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-124|6|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-125|6|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-126|6|1012|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-127|6|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-128|6|1013|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-129|6|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-130|6|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-131|6|1018|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-132|6|1018|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-133|6|1019|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-134|6|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-135|6|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-136|6|1022|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ base of tail. Metastases Lung|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-137|6|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-138|6|1037|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ rupture with hemorrhage.|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-139|6|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-140|6|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlus/lsl; tlxs/rjmf; tlls/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-141|6|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-142|6|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-143|6|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-144|6|1053|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TULS/ ,MPATH: 551 - sarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-145|6|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-146|6|1059|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-147|6|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-148|6|1063|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ Eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-149|6|1063|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-150|6|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-151|6|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-152|6|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-153|6|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-154|6|1070|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/ Ovary or testis,MPATH: 62 - cyst|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-155|6|1074|Neoplasia unclassified|Other local manifestations and miscellaneus|TOWX: TXAC OF PANCREAS TO OVARY.|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-156|6|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-157|6|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-158|6|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-159|6|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-160|6|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-161|6|1098|Neoplasia benign|Integumentary system,MA: 0000151 - skin|TSDO/ region of back shoulder (marking gland?). Sebaceous gland,MPATH: 407 - fibroma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-162|6|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-163|6|1100|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-164|6|1102|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-165|6|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-166|6|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-167|6|1113|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-168|6|1113|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-169|6|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-170|6|1118|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-171|6|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-172|6|1124|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ region of pelvis. Metastases  Muscle tnns of pelvic region to adjacent skeletal muscle. Metastases Liver,MPATH: 437 - neurofibrosarcoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-173|6|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-174|6|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-175|6|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-176|6|1132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-177|6|1132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-178|6|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-179|6|1141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-180|6|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-181|6|1150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-182|6|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-183|6|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-184|6|1167|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ tongue.,MPATH: 549 - carcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-185|6|1176|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-186|6|1184|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-187|6|1191|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-188|6|1192|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-189|6|1201|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-190|6|1205|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-191|6|1233|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-192|6|1240|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-193|6|1255|Neoplasia systemic|Haematolymphatic system|TLPS/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-194|6|1262|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-195|6|1311|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-196|6|1311|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-197|6|1314|Other deterministic changes|Whole body|MCDU/ |
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-198|6|1359|n/a|n/a|n/a|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-199|6|1366|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-6|n/a,EC|1| 100|shamexposed|0|grays|External exposure| code EC 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|194 records survival 832 ± 13 lifespan study|1003-20-6-200|6|1398|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-1|7|249|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-2|7|296|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-3|7|296|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-4|7|296|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-5|7|296|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-6|7|296|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-7|7|373|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-8|7|400|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-9|7|421|Other deterministic changes|Whole body|MCDU/ hrg in cerebrum. Metastases Liver|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-10|7|456|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-11|7|464|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-12|7|464|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-13|7|464|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-14|7|464|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-15|7|464|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-16|7|487|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-17|7|487|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-18|7|487|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-19|7|487|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-20|7|493|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-21|7|493|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-22|7|493|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-23|7|493|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-24|7|493|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-25|7|536|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-26|7|537|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-27|7|544|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-28|7|545|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ thigh. Metastases Lung|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-29|7|555|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-30|7|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-31|7|577|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-32|7|577|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-33|7|577|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-34|7|577|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-35|7|579|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-36|7|596|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-37|7|600|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-38|7|602|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-39|7|607|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ lsl concurs.acute,MPATH: 212 - inflammation|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-40|7|638|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-41|7|648|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-42|7|697|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-43|7|699|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-44|7|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-45|7|715|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-46|7|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-47|7|723|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/ auricular|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-48|7|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-49|7|729|Other deterministic changes|Whole body|MCDU/ Thorax, head neck missing|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-50|7|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-51|7|733|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-52|7|740|Other deterministic changes|Whole body|MCDU/ |
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-53|7|746|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-54|7|747|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-55|7|747|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-56|7|747|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-57|7|751|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-58|7|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-59|7|758|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-60|7|759|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-61|7|763|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-62|7|764|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-63|7|769|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-64|7|781|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-65|7|789|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-66|7|796|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-67|7|798|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-68|7|800|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-69|7|803|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle. Metastases Heart Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-70|7|804|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-71|7|814|Other deterministic changes|Whole body|MCDU/ |
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-72|7|818|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-73|7|818|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-74|7|820|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-75|7|826|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ massive around thorax.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-76|7|827|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-77|7|831|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-78|7|844|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-79|7|849|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-80|7|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-81|7|854|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-82|7|856|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-83|7|857|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-84|7|859|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-85|7|862|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-86|7|863|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-87|7|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-88|7|869|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-89|7|880|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-90|7|885|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-91|7|886|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-92|7|892|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-93|7|894|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-94|7|894|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ Head neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-95|7|897|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-96|7|909|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-97|7|912|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-98|7|913|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-99|7|915|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-100|7|916|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF THIGH TO LUNG.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-101|7|922|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-102|7|922|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Lung tmfs of thorax to lung.,MPATH: 268 - adenocarcinoma|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-103|7|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-104|7|930|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-105|7|931|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-106|7|932|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-107|7|940|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-108|7|940|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-109|7|943|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-110|7|947|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-111|7|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ gross dx obs is  due to tlxs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-112|7|951|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-113|7|960|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-114|7|960|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-115|7|964|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-116|7|968|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-117|7|968|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-118|7|969|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-119|7|976|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-120|7|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-121|7|982|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-122|7|982|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-123|7|982|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-124|7|982|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-125|7|982|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-126|7|982|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-127|7|983|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-128|7|985|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-129|7|986|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-130|7|988|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-131|7|989|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-132|7|989|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-133|7|989|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-134|7|989|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-135|7|989|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-136|7|989|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-137|7|996|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-138|7|1016|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-139|7|1024|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-140|7|1024|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-141|7|1027|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-142|7|1031|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-143|7|1032|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS OF THORAX TO LUNG.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-144|7|1032|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-145|7|1032|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-146|7|1035|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-147|7|1041|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-148|7|1046|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-149|7|1048|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-150|7|1056|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-151|7|1060|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-152|7|1065|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-153|7|1068|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-154|7|1083|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-155|7|1085|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-156|7|1087|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-157|7|1089|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-158|7|1090|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-159|7|1106|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-160|7|1106|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-161|7|1129|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-162|7|1129|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-163|7|1129|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-164|7|1130|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-165|7|1130|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-166|7|1131|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-167|7|1132|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-168|7|1133|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-169|7|1138|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-170|7|1139|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-171|7|1143|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-172|7|1143|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-173|7|1144|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-174|7|1147|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS OF THORAX TO LUNG.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-175|7|1147|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-176|7|1150|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-177|7|1160|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-178|7|1162|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF THIGH TO LUNG.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-179|7|1170|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-180|7|1173|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-181|7|1176|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-182|7|1180|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-183|7|1186|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-184|7|1191|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-185|7|1204|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-186|7|1206|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-187|7|1206|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-188|7|1211|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-189|7|1225|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-190|7|1243|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-191|7|1254|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-192|7|1268|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-193|7|1288|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF THIGH TO LUNG.|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-194|7|1294|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-195|7|1310|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-196|7|1318|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-197|7|1323|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-198|7|1325|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-199|7|1346|n/a|n/a|n/a|
1003-20-7|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 840 ± 18 lifespan study|1003-20-7-200|7|1376|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-1|8|242|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-2|8|242|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-3|8|242|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-4|8|242|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-5|8|242|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-6|8|333|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-7|8|355|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-8|8|355|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-9|8|355|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-10|8|355|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-11|8|355|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-12|8|386|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-13|8|386|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-14|8|386|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-15|8|386|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-16|8|386|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-17|8|411|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-18|8|411|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-19|8|411|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-20|8|411|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-21|8|411|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-22|8|418|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-23|8|424|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-24|8|435|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-25|8|435|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-26|8|435|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-27|8|435|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-28|8|435|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-29|8|439|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-30|8|439|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-31|8|439|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-32|8|439|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-33|8|439|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-34|8|460|Other deterministic changes|Whole body|MCDU/ |
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-35|8|467|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-36|8|467|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-37|8|467|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-38|8|467|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-39|8|467|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-40|8|470|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-41|8|470|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-42|8|470|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-43|8|470|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-44|8|470|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-45|8|470|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-46|8|484|Other deterministic changes|Whole body|MCDU/ |
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-47|8|488|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-48|8|495|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-49|8|495|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-50|8|495|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-51|8|495|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-52|8|495|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-53|8|498|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-54|8|498|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-55|8|498|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-56|8|498|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-57|8|516|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-58|8|519|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-59|8|519|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-60|8|519|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-61|8|519|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-62|8|519|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-63|8|523|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-64|8|523|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-65|8|523|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-66|8|523|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-67|8|526|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-68|8|542|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-69|8|544|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-70|8|544|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-71|8|544|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-72|8|544|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-73|8|544|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-74|8|544|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-75|8|547|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-76|8|554|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-77|8|554|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-78|8|554|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-79|8|554|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-80|8|554|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-81|8|582|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-82|8|582|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-83|8|582|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-84|8|582|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-85|8|582|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-86|8|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-87|8|600|Other deterministic changes|Whole body|MCDU/ |
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-88|8|600|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-89|8|623|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-90|8|643|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-91|8|647|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-92|8|649|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-93|8|649|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-94|8|649|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-95|8|649|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-96|8|649|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-97|8|657|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-98|8|682|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-99|8|703|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-100|8|705|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-101|8|705|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-102|8|718|Other deterministic changes|Whole body|MCDU/ |
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-103|8|750|Other deterministic changes|Whole body|MCDU/ |
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-104|8|765|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-105|8|771|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-106|8|781|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-107|8|806|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-108|8|808|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-109|8|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-110|8|821|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-111|8|837|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-112|8|841|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-113|8|844|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-114|8|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-115|8|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-116|8|855|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-117|8|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ gross dx tute is tlhs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-118|8|858|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-119|8|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-120|8|868|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-121|8|871|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-122|8|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-123|8|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-124|8|879|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-125|8|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-126|8|892|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-127|8|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-128|8|902|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-129|8|908|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-130|8|909|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-131|8|922|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-132|8|931|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-133|8|932|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-134|8|932|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-135|8|936|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-136|8|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-137|8|940|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-138|8|940|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-139|8|946|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-140|8|948|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-141|8|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-142|8|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-143|8|951|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-144|8|952|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-145|8|960|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-146|8|972|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-147|8|982|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-148|8|987|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-149|8|989|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-150|8|993|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-151|8|993|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-152|8|993|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-153|8|997|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-154|8|1003|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-155|8|1003|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-156|8|1008|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-157|8|1010|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-158|8|1012|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-159|8|1013|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-160|8|1021|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-161|8|1029|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-162|8|1035|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-163|8|1037|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-164|8|1045|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-165|8|1046|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-166|8|1046|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-167|8|1046|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-168|8|1058|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-169|8|1066|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-170|8|1078|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-171|8|1080|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-172|8|1080|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-173|8|1081|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-174|8|1082|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-175|8|1085|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-176|8|1100|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-177|8|1101|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-178|8|1103|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-179|8|1103|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-180|8|1110|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-181|8|1111|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-182|8|1111|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-183|8|1111|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-184|8|1112|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-185|8|1132|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-186|8|1135|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-187|8|1135|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-188|8|1151|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-189|8|1158|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-190|8|1163|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-191|8|1164|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-192|8|1172|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-193|8|1186|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-194|8|1209|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-195|8|1214|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-196|8|1234|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-197|8|1235|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-198|8|1241|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-199|8|1284|n/a|n/a|n/a|
1003-20-8|n/a,HC|1| 100|shamexposed|0|grays|External exposure| code HC 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|120 records survival 816 ± 18 lifespan study|1003-20-8-200|8|1315|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-1|9|284|Neoplasia systemic|Haematolymphatic system|TLML/  Metastases Lung|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-2|9|389|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-3|9|528|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCFS OF CHEST AREA TO LUNG.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-4|9|555|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWS: TSEC OF SKIN OF MANDIBLE TO CERVICAL LN.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-5|9|592|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-6|9|602|Neoplasia unclassified|Other local manifestations and miscellaneus|THWZ: TZAC TO LIVER.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-7|9|606|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-8|9|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-9|9|614|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-10|9|615|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC INVASION COSTAL MUSCLE.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-11|9|627|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-12|9|638|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-13|9|640|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-14|9|650|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-15|9|659|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-16|9|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-17|9|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-18|9|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-19|9|691|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-20|9|694|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-21|9|704|Neoplasia unclassified|Other local manifestations and miscellaneus|THWZ: TZAC TO LIVER.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-22|9|716|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-23|9|720|Other deterministic changes|Whole body|MCDU/ Trunk missing|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-24|9|722|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Liver, Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-25|9|725|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-26|9|738|Other deterministic changes|Reproductive system|MSVS/ prostate; urethra hyperplasia? statis? cowpers gland hyperplasia & statis; heart dilated.Stasis seminal vesicle|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-27|9|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-28|9|755|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-29|9|760|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-30|9|766|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-31|9|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-32|9|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-33|9|769|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-34|9|772|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-35|9|774|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO UNIDENTIFIED LN.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-36|9|775|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-37|9|786|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ base of tail. Muscle|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-38|9|786|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-39|9|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-40|9|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-41|9|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  costal muscle., Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-42|9|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-43|9|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-44|9|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ fibrocytic type.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-45|9|814|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-46|9|816|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ forearm.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-47|9|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-48|9|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-49|9|832|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSFS OF BACK AND RIGHT HIND LEG INVASION OF SKELETAL MUSCLE.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-50|9|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-51|9|845|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-52|9|848|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-53|9|850|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/ chronic,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-54|9|855|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-55|9|858|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-56|9|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-57|9|875|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion not identified.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-58|9|876|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/ chronic,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-59|9|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-60|9|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-61|9|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-62|9|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-63|9|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-64|9|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-65|9|885|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-66|9|888|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site not specified.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-67|9|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-68|9|889|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-69|9|890|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-70|9|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to unidentified ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-71|9|892|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-72|9|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-73|9|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-74|9|900|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-75|9|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-76|9|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-77|9|906|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-78|9|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-79|9|911|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,  Head/neck missing, eyes missing,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-80|9|912|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-81|9|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-82|9|917|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-83|9|917|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-84|9|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-85|9|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Metastases  Lymphoret.System trac metast. to parathymic ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-86|9|929|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-87|9|932|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO PLEURA AND MUSCLE.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-88|9|934|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ sternal marrow.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-89|9|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-90|9|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-91|9|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-92|9|942|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-93|9|945|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-94|9|946|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-95|9|949|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-96|9|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-97|9|953|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Kidney Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-98|9|957|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ skin of back and right hind leg. Metastases  Muscle tsfs of back and right hind leg invasion of skeletal muscle.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-99|9|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-100|9|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-101|9|964|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-102|9|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-103|9|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-104|9|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-105|9|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-106|9|980|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-107|9|983|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ cystic ileitis.Enteritis acute,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-108|9|983|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-109|9|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-110|9|988|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases   mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-111|9|990|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-112|9|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-113|9|997|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-114|9|998|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ foreleg.,MPATH: 428 - rhabdomyosarcoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-115|9|998|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-116|9|999|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-117|9|1002|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-118|9|1005|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-119|9|1005|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-120|9|1008|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-121|9|1010|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-122|9|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-123|9|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-124|9|1016|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-125|9|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-126|9|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-127|9|1025|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-128|9|1026|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Metastases  Muscle trac to costal muscle.,MPATH: 242 - hemangiosarcoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-129|9|1028|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac invasion costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-130|9|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-131|9|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based on hematology/tlml.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-132|9|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  Muscle trac to pleura and muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-133|9|1039|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-134|9|1040|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-135|9|1040|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-136|9|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-137|9|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-138|9|1047|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-139|9|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-140|9|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-141|9|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-142|9|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-143|9|1071|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-144|9|1073|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ stomach.,MPATH: 549 - carcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-145|9|1080|n/a|n/a|n/a|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-146|9|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-147|9|1088|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart Metastases Liver Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-148|9|1088|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-149|9|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-150|9|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-151|9|1102|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-152|9|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-153|9|1111|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-154|9|1112|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-155|9|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-156|9|1120|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-157|9|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-158|9|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-159|9|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-160|9|1124|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-161|9|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-162|9|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-163|9|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-164|9|1129|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ skin of mandible. Metastases  Lymphoret.System tsec of skin of mandible to cervical ln.,MPATH: 218 - neoplasm|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-165|9|1133|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-166|9|1135|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-167|9|1137|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-168|9|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-169|9|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-170|9|1149|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-171|9|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-172|9|1150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-173|9|1151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-174|9|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-175|9|1157|Other deterministic changes|Whole body|MCDU/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-176|9|1181|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-177|9|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-178|9|1183|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-179|9|1185|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-180|9|1187|Metabolic abnormalities|Other local manifestations and miscellaneus|MATA/ liver.|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-181|9|1189|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-182|9|1189|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-183|9|1199|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-184|9|1206|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-185|9|1215|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-186|9|1219|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-187|9|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-188|9|1230|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-189|9|1248|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  tpac to brain.,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-190|9|1257|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-191|9|1263|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/  Metastases Liver Metastases  Lymphoret.System tzac to cervical ln.,MPATH: 278 - follicular adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-192|9|1271|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-193|9|1275|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-194|9|1284|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-195|9|1286|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-196|9|1290|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-197|9|1307|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-198|9|1310|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-199|9|1313|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-9|n/a,SO|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|200 records survival 843± 13 lifespan study|1003-20-9-200|9|1333|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-1|10|159|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-2|10|497|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-3|10|501|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-4|10|558|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-5|10|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-6|10|566|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-7|10|576|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-8|10|588|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-9|10|590|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-10|10|639|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-11|10|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-12|10|662|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-13|10|663|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/  Metastases  Lymphoret.System tmaa to regional ln.,MPATH: 218 - neoplasm|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-14|10|663|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ very invasive of abdomen.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-15|10|665|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-16|10|667|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-17|10|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-18|10|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-19|10|711|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-20|10|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-21|10|728|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart Metastases Kidney Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-22|10|729|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-23|10|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-24|10|748|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-25|10|752|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: TNNS OF AXILLARY REGION TO ADJACENT MUSCLE.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-26|10|755|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: TNNS OF AXILLARY REGION TO ADJACENT MUSCLE.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-27|10|756|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-28|10|763|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-29|10|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-30|10|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-31|10|775|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-32|10|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-33|10|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-34|10|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-35|10|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-36|10|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-37|10|804|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-38|10|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-39|10|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-40|10|819|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-41|10|820|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-42|10|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-43|10|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-44|10|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-45|10|842|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ tail.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-46|10|842|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to chest muscle.,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-47|10|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-48|10|847|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/ Adenoma,MPATH: 218 - neoplasm|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-49|10|847|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-50|10|854|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-51|10|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-52|10|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-53|10|865|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thoracic spine. Metastases Kidney Metastases  Muscle tbos of toracic spine metast to adjacent muscle.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-54|10|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-55|10|872|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ cecum.,MPATH: 551 - sarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-56|10|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-57|10|877|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abdominal mesentery., Head neck missing|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-58|10|877|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-59|10|887|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ base of skull and adjacent tissues. Metastases  tbos of skull base to an unstated site.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-60|10|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-61|10|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-62|10|905|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-63|10|906|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-64|10|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-65|10|907|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine. Metastases  Muscle tbos of lumbar spine invasion of lumbar muscles.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-66|10|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-67|10|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-68|10|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-69|10|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-70|10|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-71|10|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-72|10|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-73|10|926|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWA: TANS TO KIDNEY.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-74|10|928|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ origin unknown; peritoneal. Metastases  Muscle tnns invasion of costal muscle from peritoneal region.,MPATH: 437 - neurofibrosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-75|10|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-76|10|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-77|10|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-78|10|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-79|10|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-80|10|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  trac metast to  brown fat.,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-81|10|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-82|10|945|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-83|10|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-84|10|950|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-85|10|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-86|10|953|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-87|10|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-88|10|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-89|10|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-90|10|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-91|10|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-92|10|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-93|10|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-94|10|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-95|10|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-96|10|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-97|10|971|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-98|10|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-99|10|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-100|10|974|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-101|10|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-102|10|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-103|10|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  Lymphoret.System trac to mediastinal nodes.,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-104|10|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-105|10|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-106|10|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-107|10|983|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-108|10|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-109|10|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-110|10|991|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-111|10|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-112|10|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-113|10|1007|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-114|10|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-115|10|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-116|10|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-117|10|1013|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-118|10|1014|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-119|10|1018|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ inguinal region.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-120|10|1019|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/ ,MPATH: 278 - follicular adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-121|10|1020|Neoplasia malignant|Other local manifestations and miscellaneus|TMSS/ TMSS/ TMSS/ TMSS/ pelvic region. Metastases  Lymphoret.System trac  metast to mediastinal ln.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-122|10|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-123|10|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-124|10|1028|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ spine, specific location not specified.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-125|10|1037|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-126|10|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-127|10|1038|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/ ,MPATH: 218 - neoplasm|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-128|10|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-129|10|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-130|10|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-131|10|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-132|10|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-133|10|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-134|10|1048|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-135|10|1049|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-136|10|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-137|10|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-138|10|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-139|10|1053|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ region of hip.Skin|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-140|10|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-141|10|1057|Hyperplastic changes|Cardiovascular system|MPAN/ generalized.Polyarteritis nodosa|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-142|10|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-143|10|1057|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ gluteal muscle. Muscle|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-144|10|1061|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-145|10|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-146|10|1069|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-147|10|1072|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ dorsal chest. Metastases  Muscle tsfs of dorsal chest to adjacent muscle.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-148|10|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-149|10|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-150|10|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-151|10|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-152|10|1076|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ costal and lumbar vertebrae region.,MPATH: 428 - rhabdomyosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-153|10|1080|n/a|n/a|n/a|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-154|10|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-155|10|1083|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle tans to adjacent muscle. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-156|10|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-157|10|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-158|10|1092|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-159|10|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Lymphoret.System trac to unspecified ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-160|10|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-161|10|1104|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ abdominal cavity.,MPATH: 437 - neurofibrosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-162|10|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-163|10|1114|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-164|10|1116|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-165|10|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-166|10|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-167|10|1129|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-168|10|1138|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-169|10|1143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-170|10|1151|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-171|10|1154|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-172|10|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-173|10|1165|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-174|10|1171|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-175|10|1176|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-176|10|1180|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-177|10|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-178|10|1183|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/ Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-179|10|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-180|10|1198|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-181|10|1207|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-182|10|1211|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Kidney tmfs of chest muscle to kidney.,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-183|10|1223|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-184|10|1230|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ ear, face and throat.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-185|10|1233|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-186|10|1237|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-187|10|1238|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull. Metastases  tbos of skull to brain.|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-188|10|1240|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ axillary region. Metastases  Muscle tnns of axillary region to adjacent muscle. Metastases Skin tnns of axillary region to regional skin.,MPATH: 437 - neurofibrosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-189|10|1242|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-190|10|1247|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ thorax. Metastases  Muscle tnns of thorax to costal muscle.,MPATH: 437 - neurofibrosarcoma|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-191|10|1249|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-192|10|1257|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-193|10|1285|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-194|10|1286|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-195|10|1287|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-196|10|1290|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-197|10|1332|Other deterministic changes|Whole body|MCDU/ |
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-198|10|1338|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-199|10|1348|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-10|n/a,S0|1| 100|shamexposed|0|grays|External exposure| code SO 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 852± 13 lifespan study|1003-20-10-200|10|1471|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-1|11|125|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-2|11|211|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ grossly cod ascribed to ttyl. quote from summary sheet "thymic lymphoma cod lymphocytic leukemia".,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-3|11|220|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWY: TYRS TO MEDIASTINAL LN.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-4|11|228|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-5|11|268|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-6|11|268|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-7|11|268|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-8|11|268|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-9|11|268|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-10|11|281|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-11|11|418|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-12|11|456|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-13|11|456|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-14|11|456|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-15|11|456|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-16|11|456|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-17|11|457|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-18|11|457|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-19|11|457|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-20|11|457|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-21|11|457|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-22|11|464|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-23|11|464|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-24|11|464|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-25|11|464|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-26|11|464|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-27|11|485|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-28|11|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-29|11|504|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-30|11|507|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-31|11|507|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-32|11|507|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-33|11|507|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-34|11|507|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-35|11|513|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-36|11|513|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-37|11|513|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-38|11|513|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-39|11|513|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-40|11|520|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-41|11|520|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-42|11|520|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-43|11|520|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-44|11|520|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-45|11|530|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-46|11|535|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-47|11|538|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY AND TKWR ON TKAC.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-48|11|539|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-49|11|551|Neoplasia benign|Liver among hepato-pancreatic system diseases|THAA/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-50|11|563|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-51|11|565|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDFS/ fibrosarcoma of bladder.,MPATH: 551 - sarcoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-52|11|565|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-53|11|569|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-54|11|569|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-55|11|569|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-56|11|569|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-57|11|569|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-58|11|569|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-59|11|576|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-60|11|576|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-61|11|576|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-62|11|576|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-63|11|576|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-64|11|577|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-65|11|577|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-66|11|577|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-67|11|577|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-68|11|577|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-69|11|578|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-70|11|590|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-71|11|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-72|11|598|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-73|11|599|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head/neck trunk, eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-74|11|600|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ ventral abdominal wall.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-75|11|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-76|11|606|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-77|11|631|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-78|11|632|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-79|11|650|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWX: VASCULAR TUMOR (VS), SOURCE NOT KNOWN, TO HEART.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-80|11|651|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-81|11|653|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-82|11|655|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-83|11|658|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-84|11|661|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-85|11|666|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-86|11|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-87|11|672|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-88|11|677|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-89|11|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-90|11|691|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-91|11|708|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-92|11|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-93|11|712|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-94|11|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-95|11|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ tvas; tadn not found.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-96|11|723|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-97|11|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-98|11|732|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-99|11|733|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-100|11|744|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-101|11|745|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-102|11|757|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-103|11|757|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-104|11|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlxs & tlls; in write-up/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-105|11|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-106|11|769|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-107|11|771|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-108|11|773|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Trunk Thorax missing,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-109|11|778|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-110|11|785|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-111|11|789|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-112|11|792|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TYRS/ Heart Metastases  Lymphoret.System tyrs to mediastinal ln.,MPATH: 428 - rhabdomyosarcoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-113|11|797|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-114|11|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ thao?/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-115|11|800|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-116|11|801|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-117|11|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-118|11|804|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung Metastases Heart|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-119|11|805|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-120|11|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-121|11|813|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-122|11|816|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-123|11|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-124|11|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-125|11|831|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-126|11|831|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-127|11|835|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-128|11|837|Other deterministic changes|Whole body|MCDU/ probably acute infection.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-129|11|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-130|11|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-131|11|843|Hyperplastic changes|Other local manifestations and miscellaneus|MPRH/ Prostata|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-132|11|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-133|11|852|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-134|11|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-135|11|856|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-136|11|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-137|11|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-138|11|866|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-139|11|872|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-140|11|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-141|11|882|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-142|11|888|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-143|11|891|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-144|11|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-145|11|893|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-146|11|894|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-147|11|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-148|11|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-149|11|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-150|11|917|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-151|11|919|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-152|11|921|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-153|11|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ epithelioid splenic lesion.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-154|11|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-155|11|930|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-156|11|932|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-157|11|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-158|11|933|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-159|11|934|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-160|11|937|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-161|11|943|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-162|11|948|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-163|11|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-164|11|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-165|11|956|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPNA/ Pancreatitis|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-166|11|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-167|11|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-168|11|965|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-169|11|965|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-170|11|976|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-171|11|984|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-172|11|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-173|11|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-174|11|992|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-175|11|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-176|11|995|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY AND TKWR ON TKAC.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-177|11|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-178|11|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to pleural and costal muscle. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-179|11|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-180|11|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-181|11|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-182|11|1010|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-183|11|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-184|11|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  trac invasion site not specified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-185|11|1013|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar spine. Muscle|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-186|11|1018|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWY: TYRS TO MEDIASTINAL LN.|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-187|11|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-188|11|1031|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-189|11|1041|Other deterministic changes|Whole body|MCDU/ |
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-190|11|1044|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-191|11|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-192|11|1083|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-193|11|1083|n/a|n/a|n/a|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-194|11|1096|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-195|11|1097|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of femur. Muscle|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-196|11|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-197|11|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-198|11|1118|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ pelvis. Metastases Heart|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-199|11|1132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-11|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 711± 15 lifespan study|1003-20-11-200|11|1265|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-1|12|130|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-2|12|166|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-3|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-4|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-5|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-6|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-7|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-8|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-9|12|171|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-10|12|186|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-11|12|186|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-12|12|186|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-13|12|186|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-14|12|186|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-15|12|228|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-16|12|228|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-17|12|228|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-18|12|228|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-19|12|228|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-20|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-21|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-22|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-23|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-24|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-25|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-26|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-27|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-28|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-29|12|269|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-30|12|276|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-31|12|276|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-32|12|276|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-33|12|276|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-34|12|276|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-35|12|313|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-36|12|344|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-37|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-38|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-39|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-40|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-41|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-42|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-43|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-44|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-45|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-46|12|353|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-47|12|360|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-48|12|360|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-49|12|360|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-50|12|360|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-51|12|360|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-52|12|386|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-53|12|431|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-54|12|435|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-55|12|435|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-56|12|435|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-57|12|435|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-58|12|435|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-59|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-60|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-61|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-62|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-63|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-64|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-65|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-66|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-67|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-68|12|437|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-69|12|442|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-70|12|442|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-71|12|442|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-72|12|442|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-73|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-74|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-75|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-76|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-77|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-78|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-79|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-80|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-81|12|444|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-82|12|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-83|12|480|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ rjmf "ttyg is tlls?".,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-84|12|484|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-85|12|493|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-86|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-87|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-88|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-89|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-90|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-91|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-92|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-93|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-94|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-95|12|498|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-96|12|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-97|12|519|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-98|12|519|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-99|12|519|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-100|12|519|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-101|12|519|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-102|12|526|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-103|12|526|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-104|12|526|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-105|12|526|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-106|12|526|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-107|12|533|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute,MPATH: 212 - inflammation|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-108|12|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-109|12|563|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ large mass largely in mesentery; hemangioma?|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-110|12|575|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ thigh w/hrg.|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-111|12|577|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-112|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-113|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-114|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-115|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-116|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-117|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-118|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-119|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-120|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-121|12|582|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-122|12|586|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-123|12|593|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-124|12|596|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-125|12|631|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-126|12|646|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TULS/ ,MPATH: 551 - sarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-127|12|650|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-128|12|653|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-129|12|657|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-130|12|662|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-131|12|666|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-132|12|666|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-133|12|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-134|12|675|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ thigh.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-135|12|691|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-136|12|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ hnp as much cod as ntyg/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-137|12|719|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-138|12|730|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ acute severe enteritis.Enteritis acute,MPATH: 212 - inflammation|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-139|12|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-140|12|742|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-141|12|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-142|12|744|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/ acute/chronic,MPATH: 212 - inflammation|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-143|12|745|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-144|12|746|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-145|12|747|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-146|12|750|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-147|12|757|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-148|12|769|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-149|12|769|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-150|12|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-151|12|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-152|12|777|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-153|12|778|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ kidney not found; grossly had lesion - cyst?  mhnp?,MPATH: 242 - hemangiosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-154|12|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-155|12|789|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ region of eye. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-156|12|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-157|12|799|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-158|12|802|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-159|12|807|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-160|12|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-161|12|808|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-162|12|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-163|12|817|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-164|12|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-165|12|838|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-166|12|852|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-167|12|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-168|12|858|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-169|12|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-170|12|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-171|12|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-172|12|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-173|12|870|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ massive internal and external chest.|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-174|12|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/ gross dx tkid.Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-175|12|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-176|12|911|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-177|12|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-178|12|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ gross dx tove is tlls/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-179|12|940|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-180|12|946|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-181|12|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-182|12|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/ Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-183|12|966|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-184|12|976|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-185|12|989|n/a|n/a|n/a|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-186|12|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-187|12|993|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-188|12|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-189|12|1007|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWB: TBOS OF HEART REGION INVASION OF SPINAL CORD.|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-190|12|1013|Other deterministic changes|Whole body|MCDU/ |
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-191|12|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-192|12|1062|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-193|12|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-194|12|1070|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  Metastases Lung|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-195|12|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ possibly tlml based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-196|12|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-197|12|1104|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-198|12|1114|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of heart. Metastases  tbos of heart region invasion of spinal cord.|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-199|12|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-12|n/a,AI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|93 records survival 690± 19 lifespan study|1003-20-12-200|12|1255|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-1|13|170|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-2|13|390|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute see rjmf dx., Head neck missing,MPATH: 212 - inflammation|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-3|13|404|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ gross cod given as tadn and pnc contributed.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-4|13|409|Other deterministic changes|Whole body|MCDU/ summary sheet cod cdu; autopsy sheet "unknown". cod unknown/jhr.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-5|13|423|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-6|13|423|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-7|13|431|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-8|13|431|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-9|13|431|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-10|13|431|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-11|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-12|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-13|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-14|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-15|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-16|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-17|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-18|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-19|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-20|13|437|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-21|13|474|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-22|13|486|Other deterministic changes|Whole body|MCDU/ no histology exam reported; cod unknown/jhr.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-23|13|493|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-24|13|493|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-25|13|493|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-26|13|493|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-27|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-28|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-29|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-30|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-31|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-32|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-33|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-34|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-35|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-36|13|494|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-37|13|500|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF THIGH TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-38|13|502|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ taca.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-39|13|530|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-40|13|534|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-41|13|537|Neoplasia systemic|Haematolymphatic system|TLML/  Metastases  trac invasion site unspecified. Metastases Lung tmfs (origin site not specified) to lung.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-42|13|542|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-43|13|542|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-44|13|542|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-45|13|542|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-46|13|542|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-47|13|543|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS (ORIGIN SITE NOT SPECIFIED) TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-48|13|543|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS (ORIGIN SITE NOT SPECIFIED) TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-49|13|543|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ 0rigin subcut. throat; dx "undifferentiated sarcoma"/rjmf.,MPATH: 446 - squamous cell carcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-50|13|543|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS (ORIGIN SITE NOT SPECIFIED) TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-51|13|543|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS (ORIGIN SITE NOT SPECIFIED) TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-52|13|543|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-53|13|544|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-54|13|544|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-55|13|547|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-56|13|548|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-57|13|550|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-58|13|550|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-59|13|550|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-60|13|550|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-61|13|550|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-62|13|557|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-63|13|558|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-64|13|561|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-65|13|574|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-66|13|591|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-67|13|600|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-68|13|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-69|13|601|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-70|13|603|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-71|13|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-72|13|608|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/ hrg from gonad.Testis|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-73|13|616|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCVS OF THIGH TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-74|13|619|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION OF STERNUM.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-75|13|622|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-76|13|623|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-77|13|633|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-78|13|641|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-79|13|642|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-80|13|643|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-81|13|653|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ possibly adeno ca of prostate.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-82|13|654|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-83|13|660|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-84|13|660|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-85|13|672|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-86|13|673|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-87|13|679|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-88|13|684|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-89|13|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-90|13|689|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TYRS/ Heart Metastases Liver,MPATH: 428 - rhabdomyosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-91|13|690|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-92|13|692|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/ auricular|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-93|13|695|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-94|13|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-95|13|698|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-96|13|704|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region of thigh.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-97|13|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-98|13|712|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ Head neck missing|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-99|13|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-100|13|722|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-101|13|732|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ invading muscle of abd. wall.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-102|13|734|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-103|13|734|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-104|13|738|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-105|13|739|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  Metastases Lung,MPATH: 549 - carcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-106|13|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-107|13|746|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-108|13|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-109|13|761|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE UNSPECIFIED.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-110|13|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-111|13|773|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ arises in pelvis.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-112|13|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-113|13|779|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-114|13|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlls/lsl; tlxs/jhr; tlsa (lymphosarcoma)/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-115|13|789|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-116|13|790|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-117|13|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-118|13|792|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT STATED.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-119|13|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-120|13|803|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-121|13|803|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-122|13|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-123|13|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-124|13|814|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-125|13|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-126|13|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-127|13|821|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-128|13|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-129|13|832|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-130|13|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-131|13|841|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-132|13|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-133|13|843|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-134|13|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-135|13|845|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-136|13|855|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-137|13|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ tlll/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-138|13|873|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-139|13|874|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-140|13|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-141|13|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-142|13|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-143|13|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-144|13|882|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-145|13|886|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-146|13|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-147|13|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-148|13|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-149|13|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-150|13|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-151|13|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-152|13|900|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-153|13|901|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-154|13|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-155|13|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-156|13|908|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-157|13|908|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ hemorrhage could possibly have been spleen also, Eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-158|13|909|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abdominal cavity.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-159|13|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-160|13|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-161|13|917|Neoplasia malignant|Endocrine system|TGAC/  Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-162|13|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-163|13|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-164|13|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-165|13|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-166|13|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-167|13|939|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-168|13|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-169|13|958|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/ epididymis.Testis|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-170|13|960|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-171|13|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-172|13|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-173|13|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site not stated.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-174|13|983|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-175|13|984|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion of sternum.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-176|13|987|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-177|13|991|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site not specified.,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-178|13|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Metastases  trac metastatic sites not given.,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-179|13|995|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-180|13|1003|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-181|13|1015|n/a|n/a|n/a|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-182|13|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-183|13|1025|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-184|13|1029|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of pelvis. Muscle|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-185|13|1032|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-186|13|1046|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-187|13|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-188|13|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-189|13|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-190|13|1065|Other deterministic changes|Whole body|MCDU/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-191|13|1073|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-192|13|1086|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-193|13|1107|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-194|13|1112|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-195|13|1112|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-196|13|1114|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-197|13|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-198|13|1132|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-199|13|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-13|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|156records survival 691± 14 lifespan study|1003-20-13-200|13|1222|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-1|14|185|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-2|14|185|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-3|14|185|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-4|14|185|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-5|14|185|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-6|14|192|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-7|14|276|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-8|14|276|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-9|14|276|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-10|14|276|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-11|14|334|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ diagnosed grossly as basal cell carcinoma of anal region; ascribed as cod. on summary sheet it is "tang".,MPATH: 446 - squamous cell carcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-12|14|379|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-13|14|379|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-14|14|379|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-15|14|379|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-16|14|379|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-17|14|381|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-18|14|386|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-19|14|386|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-20|14|386|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-21|14|386|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-22|14|386|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-23|14|401|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-24|14|416|Other deterministic changes|Whole body|MCDU/ cod on autopsy sheet tadn; on summary sheet cdu; cod unknown/jhr.|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-25|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-26|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-27|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-28|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-29|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-30|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-31|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-32|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-33|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-34|14|435|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-35|14|437|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-36|14|444|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-37|14|460|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-38|14|463|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-39|14|463|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-40|14|463|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-41|14|463|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-42|14|463|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-43|14|463|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-44|14|470|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-45|14|470|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-46|14|470|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-47|14|470|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-48|14|470|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-49|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-50|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-51|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-52|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-53|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-54|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-55|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-56|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-57|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-58|14|491|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-59|14|500|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pelvic origin.|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-60|14|501|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-61|14|509|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-62|14|512|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-63|14|515|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-64|14|515|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-65|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-66|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-67|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-68|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-69|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-70|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-71|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-72|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-73|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-74|14|526|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-75|14|533|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-76|14|543|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-77|14|547|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-78|14|547|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-79|14|547|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-80|14|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-81|14|554|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-82|14|554|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-83|14|554|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-84|14|554|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-85|14|554|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-86|14|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-87|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-88|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-89|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-90|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-91|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-92|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-93|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-94|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-95|14|575|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-96|14|586|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-97|14|587|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-98|14|589|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-99|14|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-100|14|625|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-101|14|635|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-102|14|642|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-103|14|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ lung mass?,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-104|14|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-105|14|645|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-106|14|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-107|14|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-108|14|660|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-109|14|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-110|14|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-111|14|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-112|14|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-113|14|675|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-114|14|680|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/ Ovary or testis,MPATH: 62 - cyst|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-115|14|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-116|14|684|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-117|14|694|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ region of throat.,MPATH: 446 - squamous cell carcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-118|14|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-119|14|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-120|14|703|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-121|14|705|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-122|14|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-123|14|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-124|14|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-125|14|711|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-126|14|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-127|14|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-128|14|726|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-129|14|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlss/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-130|14|744|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-131|14|746|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-132|14|747|Neoplasia unclassified|Kidney among urinary system diseases,MA: 0000368 - kidney|TKTC/ tkac/lsl; acidophilic t w/papillary cysts; osteoid.Transitional cells,MPATH: 218 - neoplasm|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-133|14|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-134|14|748|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ hrg secondary to pancreatic vasc. t.|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-135|14|750|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ most likely is the primary/jhr. Metastases  Muscle tkac metas. to costal muscle. Metastases Lung,MPATH: 549 - carcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-136|14|751|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-137|14|761|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ probably arose from pelvic lns. Lymphoret.tissue|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-138|14|765|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-139|14|774|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-140|14|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-141|14|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-142|14|796|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-143|14|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-144|14|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-145|14|809|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-146|14|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac metastasis to sternal bone marrow. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-147|14|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-148|14|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-149|14|828|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ also (?) tsvs & txvs (urinary bladder).,MPATH: 242 - hemangiosarcoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-150|14|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-151|14|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-152|14|842|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-153|14|844|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-154|14|846|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-155|14|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-156|14|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-157|14|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-158|14|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-159|14|866|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-160|14|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-161|14|879|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-162|14|879|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-163|14|879|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-164|14|880|Other deterministic changes|Whole body|MCDU/ |
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-165|14|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-166|14|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-167|14|900|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ probably togc as well for cod.acute,MPATH: 212 - inflammation|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-168|14|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-169|14|910|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ Head/neck missing, eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-170|14|914|Neoplasia benign|Ovary among reproductive system diseases|TOTO/ malign. theca. cell tumor. Metastases Lung|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-171|14|921|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKPA/ Papillary cystadenoma,MPATH: 418 - liposarcoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-172|14|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-173|14|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-174|14|928|n/a|n/a|n/a|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-175|14|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-176|14|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-177|14|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-178|14|952|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-179|14|959|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-180|14|967|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-181|14|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-182|14|972|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/ acute/chronic,MPATH: 212 - inflammation|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-183|14|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-184|14|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ovary missing.,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-185|14|990|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-186|14|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-187|14|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-188|14|998|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-189|14|1004|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-190|14|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-191|14|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ leukemic hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-192|14|1019|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ anal region etc. Muscle|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-193|14|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-194|14|1042|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-195|14|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-196|14|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-197|14|1113|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-198|14|1131|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 1 - cell and tissue damage|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-199|14|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-14|n/a,BI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|124records survival 673± 16 lifespan study|1003-20-14-200|14|1208|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-1|15|255|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-2|15|255|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-3|15|255|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-4|15|255|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-5|15|255|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-6|15|359|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-7|15|411|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-8|15|415|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWG: TGAC TO SALIVARY GLAND (EXTENSION).|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-9|15|456|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-10|15|456|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-11|15|456|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-12|15|456|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-13|15|456|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-14|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-15|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-16|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-17|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-18|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-19|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-20|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-21|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-22|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-23|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-24|15|457|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-25|15|460|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ rjmf sheet tadn=trac.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-26|15|463|Neoplasia malignant|Other local manifestations and miscellaneus|TMSS/ TMSS/ TMSS/ TMSS/ subcut. flank and chest.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-27|15|476|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-28|15|479|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-29|15|496|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-30|15|498|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-31|15|513|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-32|15|513|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-33|15|513|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-34|15|513|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-35|15|513|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-36|15|515|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-37|15|520|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-38|15|520|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-39|15|520|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-40|15|520|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-41|15|520|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-42|15|521|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-43|15|521|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-44|15|521|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-45|15|521|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-46|15|521|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-47|15|526|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-48|15|537|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ salivary gland adenocarcinoma.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-49|15|547|Other deterministic changes|Whole body|MCDU/ tumor found at gross a fungal granuloma Metastases Lung tmss of flank and chest to lung.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-50|15|552|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIT/ Toxic hepatitis,MPATH: 212 - inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-51|15|554|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-52|15|560|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-53|15|567|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-54|15|569|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-55|15|569|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-56|15|569|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-57|15|569|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-58|15|569|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-59|15|575|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-60|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-61|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-62|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-63|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-64|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-65|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-66|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-67|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-68|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-69|15|577|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-70|15|602|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-71|15|611|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-72|15|614|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-73|15|632|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWX: TRAC TO UNSPECIFIED SITE (ADENO CA METASTASIS; SOURCE?)|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-74|15|641|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-75|15|659|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-76|15|664|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-77|15|664|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-78|15|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-79|15|678|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIT/ Toxic hepatitis,MPATH: 212 - inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-80|15|679|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-81|15|682|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-82|15|684|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-83|15|687|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-84|15|688|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-85|15|688|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-86|15|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-87|15|697|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-88|15|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-89|15|706|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-90|15|706|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-91|15|712|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-92|15|714|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-93|15|718|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-94|15|719|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-95|15|719|Other deterministic changes|Whole body|MCDU/  Metastases Heart|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-96|15|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-97|15|738|Other deterministic changes|Whole body|MCDU/ brain hrg lethal/jhr but apparently not looked at.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-98|15|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-99|15|743|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ region of chest.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-100|15|744|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ acute enteritis.Enteritis acute,MPATH: 212 - inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-101|15|745|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-102|15|745|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-103|15|746|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-104|15|747|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-105|15|751|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-106|15|753|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-107|15|762|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-108|15|764|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE UNSPECIFIED.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-109|15|770|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-110|15|774|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-111|15|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-112|15|783|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to muscle of forearm.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-113|15|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-114|15|791|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-115|15|791|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-116|15|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-117|15|801|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-118|15|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-119|15|803|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ ,MPATH: 213 - acute inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-120|15|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-121|15|806|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-122|15|813|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-123|15|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-124|15|817|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-125|15|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-126|15|824|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-127|15|826|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-128|15|828|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-129|15|829|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-130|15|831|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-131|15|833|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-132|15|835|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-133|15|836|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-134|15|838|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-135|15|839|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-136|15|839|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-137|15|840|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-138|15|842|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-139|15|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-140|15|845|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-141|15|848|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-142|15|848|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-143|15|848|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lung trac to unspecified site (adeno ca metastasis; source?),MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-144|15|848|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-145|15|855|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-146|15|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-147|15|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-148|15|871|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ forearm region. Muscle|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-149|15|871|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-150|15|873|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ cecum.,MPATH: 551 - sarcoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-151|15|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-152|15|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-153|15|878|Neoplasia malignant|Endocrine system|TGAC/  Metastases  tgac to salivary gland (extension).|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-154|15|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tile gross dx is tlhs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-155|15|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-156|15|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-157|15|885|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-158|15|887|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-159|15|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-160|15|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-161|15|893|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-162|15|897|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-163|15|903|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-164|15|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-165|15|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-166|15|929|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-167|15|931|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-168|15|938|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-169|15|938|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-170|15|945|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-171|15|949|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-172|15|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-173|15|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-174|15|965|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-175|15|966|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-176|15|967|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-177|15|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-178|15|973|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-179|15|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-180|15|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-181|15|988|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-182|15|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-183|15|997|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-184|15|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-185|15|1014|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-186|15|1016|n/a|n/a|n/a|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-187|15|1022|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-188|15|1028|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-189|15|1032|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-190|15|1046|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-191|15|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-192|15|1079|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-193|15|1088|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-194|15|1111|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-195|15|1116|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-196|15|1121|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-197|15|1141|Other deterministic changes|Whole body|MCDU/ |
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-198|15|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-199|15|1164|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-15|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151records survival 691± 14 lifespan study|1003-20-15-200|15|1192|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-1|16|116|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-2|16|156|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-3|16|171|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-4|16|202|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-5|16|202|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-6|16|202|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-7|16|202|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-8|16|202|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-9|16|261|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-10|16|379|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-11|16|379|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-12|16|379|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-13|16|379|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-14|16|379|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-15|16|383|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-16|16|386|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-17|16|386|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-18|16|386|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-19|16|386|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-20|16|386|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-21|16|435|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-22|16|435|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-23|16|435|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-24|16|435|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-25|16|435|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-26|16|442|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-27|16|442|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-28|16|442|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-29|16|442|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-30|16|442|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-31|16|463|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-32|16|463|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-33|16|463|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-34|16|463|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-35|16|463|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-36|16|470|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-37|16|470|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-38|16|470|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-39|16|470|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-40|16|470|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-41|16|491|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-42|16|491|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-43|16|491|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-44|16|491|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-45|16|491|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-46|16|498|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-47|16|498|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-48|16|498|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-49|16|498|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-50|16|498|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-51|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-52|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-53|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-54|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-55|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-56|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-57|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-58|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-59|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-60|16|519|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-61|16|521|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAST TO MEDIASTINAL LN.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-62|16|535|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-63|16|539|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-64|16|545|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/ acute/chronic,MPATH: 212 - inflammation|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-65|16|545|Other deterministic changes|Whole body|MCDU/ mpnc possibly cod.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-66|16|547|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-67|16|547|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-68|16|547|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-69|16|547|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-70|16|547|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-71|16|554|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-72|16|554|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-73|16|554|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-74|16|554|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-75|16|554|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-76|16|568|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-77|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-78|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-79|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-80|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-81|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-82|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-83|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-84|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-85|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-86|16|582|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-87|16|586|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-88|16|587|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-89|16|597|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-90|16|600|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-91|16|618|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAST TO MEDIASTINAL LN.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-92|16|627|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-93|16|630|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-94|16|631|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-95|16|632|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-96|16|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-97|16|643|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-98|16|644|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-99|16|646|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-100|16|647|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-101|16|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-102|16|659|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-103|16|660|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-104|16|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-105|16|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-106|16|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-107|16|673|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-108|16|674|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle, Eyes missing|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-109|16|675|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region ventral chest wall. Metastases Lung|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-110|16|676|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-111|16|692|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-112|16|705|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-113|16|707|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-114|16|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-115|16|722|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-116|16|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-117|16|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-118|16|729|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-119|16|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-120|16|732|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-121|16|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-122|16|737|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-123|16|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ?/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-124|16|740|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-125|16|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-126|16|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-127|16|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-128|16|753|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/  Muscle|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-129|16|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-130|16|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-131|16|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-132|16|766|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-133|16|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-134|16|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-135|16|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-136|16|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-137|16|782|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-138|16|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-139|16|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-140|16|794|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-141|16|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-142|16|802|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/ acute/chronic,MPATH: 212 - inflammation|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-143|16|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-144|16|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlxs/lsl. Metastases  Lymphoret.System trac metast to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-145|16|807|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-146|16|810|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-147|16|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-148|16|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-149|16|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-150|16|813|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-151|16|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-152|16|834|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-153|16|834|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-154|16|834|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ origin pelvic/anal region?,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-155|16|836|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-156|16|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-157|16|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-158|16|859|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-159|16|860|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-160|16|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-161|16|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-162|16|862|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum and ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-163|16|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-164|16|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-165|16|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-166|16|876|Neoplasia benign|Ovary among reproductive system diseases|TOTO/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-167|16|877|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-168|16|877|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ spine, lumbar region. Metastases  Heart tbvs of lumbar spine metast. to heart. Metastases  Kidney tbvs of lumbar spine metast. to kidney.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-169|16|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-170|16|889|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-171|16|893|Neoplasia malignant|Endocrine system|TGAC/  Metastases  tgac to brain.|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-172|16|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-173|16|898|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-174|16|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-175|16|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/ Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-176|16|906|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-177|16|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-178|16|914|n/a|n/a|n/a|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-179|16|933|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ w/hrg.,MPATH: 242 - hemangiosarcoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-180|16|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/ tlhs/jhr.undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-181|16|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ gross dx tliv is tlhs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-182|16|942|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ colon.,MPATH: 551 - sarcoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-183|16|943|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-184|16|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-185|16|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-186|16|974|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Metastases Lung,MPATH: 242 - hemangiosarcoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-187|16|1004|Neoplasia benign|Bloodvessels among cardiovascular system|TBVO/ sternal marrow|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-188|16|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-189|16|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-190|16|1036|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ skin of face. Metastases Harderian gland Metastases  tsec of skin of face invasion of orbital adnexa.,MPATH: 218 - neoplasm|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-191|16|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-192|16|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-193|16|1054|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  Metastases Lung|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-194|16|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-195|16|1073|Other deterministic changes|Whole body|MCDU/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-196|16|1076|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-197|16|1107|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ |
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-198|16|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-199|16|1128|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-16|n/a,EI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 687± 14 lifespan study|1003-20-16-200|16|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-1|17|141|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-2|17|255|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-3|17|255|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-4|17|255|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-5|17|255|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-6|17|255|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-7|17|358|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-8|17|379|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-9|17|397|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ dx ttyl at autopsy; quote from micro-exam sheet "conclusion pulm. t. and thymic lymphoma".,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-10|17|407|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-11|17|456|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-12|17|457|Neoplasia unclassified|Other local manifestations and miscellaneus|THWK: TKAC TO LIVER.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-13|17|457|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-14|17|460|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEFS/ ,MPATH: 551 - sarcoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-15|17|462|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-16|17|463|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-17|17|463|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-18|17|463|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-19|17|463|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-20|17|463|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-21|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-22|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-23|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-24|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-25|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-26|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-27|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-28|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-29|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-30|17|464|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-31|17|465|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-32|17|467|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-33|17|470|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-34|17|488|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-35|17|490|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-36|17|507|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-37|17|507|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-38|17|507|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-39|17|507|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-40|17|507|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-41|17|513|Neoplasia malignant|Bloodvessels among cardiovascular system|TVVS/ lsl dx; txvs origin pelvic region/jhr.Seminal vesicle|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-42|17|518|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-43|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-44|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-45|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-46|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-47|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-48|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-49|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-50|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-51|17|520|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-52|17|532|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-53|17|533|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-54|17|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-55|17|551|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-56|17|556|Neoplasia unclassified|Other local manifestations and miscellaneus|THWX: METASTATIC TUMOR POSSIBLY FROM LUNG.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-57|17|564|Neoplasia malignant|Reproductive system,MA: 0000411 - testis|TTQC/ tubular adeno ca of testis.Embryonal carcinoma,MPATH: 218 - neoplasm|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-58|17|565|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  Metastases  tkac to aorta adventitia. Metastases Heart Metastases Lung Metastases Liver Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 549 - carcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-59|17|569|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-60|17|569|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-61|17|569|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-62|17|569|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-63|17|569|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-64|17|570|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-65|17|570|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-66|17|570|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-67|17|570|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-68|17|574|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-69|17|577|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-70|17|577|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-71|17|577|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-72|17|577|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-73|17|586|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-74|17|588|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-75|17|592|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of left forearm. Metastases Lung Metastases Liver,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-76|17|597|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-77|17|599|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ hip; large. Muscle|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-78|17|601|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-79|17|606|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-80|17|614|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-81|17|616|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-82|17|618|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ vascular t of pelvic region.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-83|17|621|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-84|17|623|Other deterministic changes|Lower respiratory system|MPNC/ Lung congestion|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-85|17|627|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-86|17|635|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-87|17|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-88|17|637|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-89|17|647|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-90|17|648|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-91|17|648|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-92|17|657|Neoplasia unclassified|Other local manifestations and miscellaneus|THWC: TCFS OF LEFT FOREARM TO LIVER.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-93|17|657|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-94|17|659|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar region. Muscle|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-95|17|659|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-96|17|664|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ death diagnosis based on gross observations.,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-97|17|674|Hyperplastic changes|Cardiovascular system|MPAN/ cardiac (myocardium).Polyarteritis nodosa|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-98|17|675|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-99|17|677|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-100|17|677|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-101|17|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-102|17|681|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-103|17|688|Other deterministic changes|Lower respiratory system|MPNC/ Lung congestion|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-104|17|691|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ hepatoma with minimum deviation/lsl.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-105|17|698|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ region of throat.,MPATH: 446 - squamous cell carcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-106|17|699|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-107|17|707|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-108|17|714|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh muscle. Muscle|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-109|17|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-110|17|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/ Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-111|17|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-112|17|730|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Kidney Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-113|17|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-114|17|749|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/ Plaque pylorique region,MPATH: 491 - polyp|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-115|17|750|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-116|17|760|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ death probably brought about by hemorrhage from tevs. micro evidence missing though.,MPATH: 242 - hemangiosarcoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-117|17|760|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-118|17|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-119|17|764|Neoplasia unclassified|Other local manifestations and miscellaneus|THWX: METASTATIC TUMOR POSSIBLY FROM LUNG.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-120|17|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-121|17|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-122|17|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-123|17|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ rjmf questions diagnosis.  lsl and jhr agree.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-124|17|784|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-125|17|790|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-126|17|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-127|17|799|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-128|17|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-129|17|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ facial sinuses and perikidney tissues.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-130|17|802|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRVS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-131|17|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-132|17|809|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-133|17|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-134|17|812|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-135|17|812|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-136|17|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-137|17|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-138|17|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-139|17|841|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-140|17|842|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ most tissue missing.,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-141|17|842|Other deterministic changes|Whole body|MCDU/  Metastases  Muscle trac to costal muscle.|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-142|17|848|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-143|17|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-144|17|851|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-145|17|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-146|17|854|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-147|17|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-148|17|856|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-149|17|859|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-150|17|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ lsl no dx.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-151|17|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-152|17|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ some areas look like tlls.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-153|17|863|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-154|17|863|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-155|17|866|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-156|17|866|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-157|17|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-158|17|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-159|17|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-160|17|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-161|17|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-162|17|874|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-163|17|880|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-164|17|883|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRVS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-165|17|892|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-166|17|895|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-167|17|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-168|17|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-169|17|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-170|17|925|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-171|17|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-172|17|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-173|17|932|n/a|n/a|n/a|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-174|17|944|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute Metastases  trac to aorta.,MPATH: 212 - inflammation|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-175|17|945|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-176|17|950|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-177|17|950|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ lower jaw region.,MPATH: 218 - neoplasm|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-178|17|951|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-179|17|953|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-180|17|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-181|17|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-182|17|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-183|17|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-184|17|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-185|17|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-186|17|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-187|17|983|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-188|17|984|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-189|17|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-190|17|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-191|17|1006|Other deterministic changes|Whole body|MCDU/ |
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-192|17|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-193|17|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-194|17|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-195|17|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-196|17|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-197|17|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-198|17|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-199|17|1220|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-17|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|152 records survival 666± 14 lifespan study|1003-20-17-200|17|1258|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-1|18|118|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-2|18|118|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-3|18|118|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-4|18|118|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-5|18|118|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-6|18|226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ at autopsy diagnosed ttyg; quote from summary sheet "thymic lymphoma lymphocytic leuk.".,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-7|18|247|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ cod at autopsy given as ntyg; rjmf suggests that finding should hold. i am inclined to accept the autopsy finding of enlarged thymus.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-8|18|344|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-9|18|379|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-10|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-11|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-12|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-13|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-14|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-15|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-16|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-17|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-18|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-19|18|386|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-20|18|389|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWO: TOGC METAST., BUT SITE NOT STATED.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-21|18|410|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-22|18|428|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWX: SECONDARY IN LUNG.  SUSPECT MAMMARY ORIGIN BUT TUMOR TISSUE NOT FOUND W/SUCH A TUMOR FORM.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-23|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-24|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-25|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-26|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-27|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-28|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-29|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-30|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-31|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-32|18|435|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-33|18|450|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-34|18|451|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-35|18|463|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-36|18|463|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-37|18|463|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-38|18|463|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-39|18|463|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-40|18|466|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-41|18|470|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-42|18|470|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-43|18|470|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-44|18|470|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-45|18|470|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-46|18|478|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-47|18|491|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-48|18|491|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-49|18|491|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-50|18|491|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-51|18|491|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-52|18|494|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-53|18|497|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-54|18|498|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-55|18|498|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-56|18|498|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-57|18|498|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-58|18|498|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-59|18|498|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-60|18|513|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-61|18|519|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-62|18|519|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-63|18|519|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-64|18|519|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-65|18|519|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-66|18|521|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-67|18|526|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-68|18|526|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-69|18|526|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-70|18|526|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-71|18|526|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-72|18|528|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  Metastases Lung, Head neck missing|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-73|18|529|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-74|18|536|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-75|18|541|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-76|18|547|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-77|18|547|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-78|18|547|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-79|18|547|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-80|18|547|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-81|18|554|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-82|18|554|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-83|18|554|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-84|18|554|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-85|18|554|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-86|18|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-87|18|575|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-88|18|575|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-89|18|575|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-90|18|575|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-91|18|575|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-92|18|578|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-93|18|582|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-94|18|582|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-95|18|582|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-96|18|582|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-97|18|585|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-98|18|589|Other deterministic changes|Whole body|MCDU/  Metastases  Lymphoret.System trac metastases to mediastinal ln.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-99|18|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-100|18|600|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-101|18|603|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-102|18|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-103|18|612|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-104|18|628|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of face. Metastases Heart txfs of face region to heart.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-105|18|637|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-106|18|642|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-107|18|648|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMFS OF ABDOM. WALL TO LIVER.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-108|18|648|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-109|18|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-110|18|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-111|18|651|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-112|18|652|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung Metastases  Muscle trac to costal muscle.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-113|18|654|Other deterministic changes|Whole body|MCDU/ death due to marrow and splenic failure/jhr.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-114|18|655|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWC: TXFS OF FACE REGION TO HEART.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-115|18|661|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ angiosarcoma of pelvic region; 2nd. site.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-116|18|675|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/ Eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-117|18|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-118|18|687|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-119|18|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-120|18|693|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-121|18|696|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-122|18|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-123|18|697|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-124|18|699|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ Head neck missing,MPATH: 1 - cell and tissue damage|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-125|18|701|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-126|18|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-127|18|703|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWO: TOGC METAST., BUT SITE NOT STATED.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-128|18|703|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-129|18|707|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ t metastasis/rjmf.,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-130|18|718|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-131|18|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/ Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-132|18|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-133|18|721|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-134|18|722|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-135|18|727|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-136|18|730|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvic region. Metastases Lung|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-137|18|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-138|18|748|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of belly wall. Muscle|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-139|18|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-140|18|767|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-141|18|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-142|18|768|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|TMAT/ ,MPATH: 255 - adenoacanthoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-143|18|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck, thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-144|18|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-145|18|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-146|18|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-147|18|783|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWO: TOGC TO LUNG.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-148|18|786|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ abd. wall.muscle Metastases  tmfs of abdom. wall metast. to pancreas. Metastases Liver Metastases  Kidney tmfs of abdom. wall metast. to kidney.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-149|18|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-150|18|790|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWX: SECONDARY IN LUNG.  SUSPECT MAMMARY ORIGIN BUT TUMOR TISSUE NOT FOUND W/SUCH A TUMOR FORM.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-151|18|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-152|18|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-153|18|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-154|18|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-155|18|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-156|18|817|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/ ,MPATH: 218 - neoplasm|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-157|18|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-158|18|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-159|18|829|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-160|18|831|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-161|18|833|Other deterministic changes|Whole body|MCDU/ mcrd possible cod coupled w/chronic peritonitis.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-162|18|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr; gross dx tove is tlxs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-163|18|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-164|18|842|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-165|18|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-166|18|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-167|18|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-168|18|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-169|18|856|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-170|18|859|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMFS OF ABDOM. WALL TO LIVER.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-171|18|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-172|18|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ early; liver & peyer's patches only.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-173|18|867|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-174|18|871|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-175|18|878|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-176|18|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-177|18|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-178|18|895|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull.|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-179|18|898|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-180|18|902|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-181|18|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-182|18|906|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  Metastases Lung,MPATH: 549 - carcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-183|18|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr. Metastases  trac to diaphragm.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-184|18|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-185|18|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-186|18|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-187|18|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Lung secondary in lung.  suspect mammary origin but tumor tissue not found w/such a tumor form.,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-188|18|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-189|18|978|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  Metastases Liver|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-190|18|984|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-191|18|989|Neoplasia unclassified|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TAUO/ ,MPATH: 218 - neoplasm|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-192|18|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-193|18|999|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  Metastases Lung,MPATH: 549 - carcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-194|18|1000|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-195|18|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-196|18|1014|Other deterministic changes|Whole body|MCDU/ |
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-197|18|1015|n/a|n/a|n/a|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-198|18|1021|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-199|18|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-18|n/a,HI|1| 100|gamma-rays Co-60|8.85|grays|External exposure| code EI 24 fractions 360 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|125 records survival 641± 14 lifespan study|1003-20-18-200|18|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Metastases  togc metast., but site not stated.,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-1|19|181|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-2|19|181|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-3|19|181|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-4|19|181|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-5|19|181|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-6|19|255|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-7|19|255|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-8|19|255|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-9|19|255|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-10|19|255|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-11|19|348|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-12|19|380|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-13|19|387|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-14|19|393|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-15|19|404|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-16|19|409|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/ in left atrium w/calcification.auricular|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-17|19|416|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-18|19|425|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod ntyg on autopsy sheet and tllb on summary sheet.,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-19|19|435|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-20|19|435|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-21|19|435|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-22|19|435|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-23|19|435|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-24|19|436|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ gross cod given as ttyg.,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-25|19|437|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-26|19|437|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-27|19|437|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-28|19|437|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-29|19|437|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-30|19|437|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-31|19|438|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-32|19|438|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-33|19|438|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-34|19|438|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-35|19|443|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-36|19|453|Other deterministic changes|Whole body|MCDU/ no diagnosis histologically.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-37|19|465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-38|19|486|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-39|19|486|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-40|19|486|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-41|19|486|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-42|19|486|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-43|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-44|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-45|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-46|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-47|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-48|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-49|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-50|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-51|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-52|19|494|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-53|19|498|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC UPON OR IN COSTAL MUSCLE.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-54|19|508|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-55|19|509|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-56|19|510|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-57|19|519|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-58|19|522|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-59|19|528|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-60|19|540|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-61|19|540|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-62|19|543|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-63|19|543|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-64|19|543|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-65|19|543|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-66|19|543|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-67|19|544|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-68|19|546|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis Metastases  Muscle trac upon or in costal muscle.,MPATH: 212 - inflammation|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-69|19|547|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ vascular sa around anal region.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-70|19|548|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-71|19|549|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-72|19|549|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-73|19|549|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-74|19|550|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-75|19|550|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-76|19|550|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-77|19|550|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-78|19|550|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-79|19|551|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-80|19|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-81|19|575|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-82|19|575|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-83|19|585|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-84|19|586|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-85|19|588|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-86|19|588|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC UPON OR IN COSTAL MUSCLE.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-87|19|593|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-88|19|595|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-89|19|596|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-90|19|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-91|19|605|Other deterministic changes|Whole body|MCDU/ gross dx bac-bacteremia; no micro code mbac.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-92|19|606|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-93|19|607|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-94|19|616|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-95|19|618|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-96|19|620|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-97|19|622|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-98|19|628|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-99|19|631|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-100|19|632|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-101|19|633|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-102|19|634|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-103|19|634|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-104|19|635|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDFS/  Metastases  Muscle tdfs invasion of adjacent muscle. Metastases Liver,MPATH: 551 - sarcoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-105|19|638|Other deterministic changes|Whole body|MCDU/ tlhs (spleen)/lsl.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-106|19|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-107|19|649|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ squamous cell ca from unknown origin; invasion or metastasis to cns.,MPATH: 218 - neoplasm|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-108|19|655|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-109|19|657|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-110|19|665|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute,MPATH: 212 - inflammation|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-111|19|686|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-112|19|688|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-113|19|694|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-114|19|698|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-115|19|699|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-116|19|700|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-117|19|701|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ base of tail.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-118|19|704|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-119|19|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-120|19|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-121|19|720|Neoplasia malignant|Endocrine system|TGAC/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-122|19|720|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-123|19|723|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-124|19|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-125|19|734|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-126|19|734|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ visceral lymph node probably.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-127|19|735|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-128|19|741|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ origin omentum; w/hrg.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-129|19|742|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-130|19|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-131|19|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-132|19|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-133|19|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-134|19|757|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-135|19|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-136|19|763|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ca of duodenum.,MPATH: 218 - neoplasm|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-137|19|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-138|19|766|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-139|19|768|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-140|19|769|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-141|19|770|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-142|19|772|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-143|19|772|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-144|19|774|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-145|19|778|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-146|19|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-147|19|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-148|19|781|Acute infections|Lower digestive tract,MA: 0000054 - peritoneal cavity|MXWI/  Metastases Lung,MPATH: 212 - inflammation|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-149|19|788|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/ Testis Metastases Lung|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-150|19|792|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-151|19|793|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-152|19|796|Neoplasia malignant|Endocrine system|TGAC/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-153|19|798|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-154|19|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-155|19|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-156|19|809|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  Metastases Lung,MPATH: 549 - carcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-157|19|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-158|19|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-159|19|821|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-160|19|824|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-161|19|826|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-162|19|835|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-163|19|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-164|19|843|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-165|19|847|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-166|19|851|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-167|19|857|n/a|n/a|n/a|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-168|19|858|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-169|19|859|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-170|19|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-171|19|866|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-172|19|872|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-173|19|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ w/osteoid.,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-174|19|886|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ facial origin. Metastases  Muscle tsfs of face to costal muscle. Metastases Lung Metastases  Lymphoret.System tsfs of face to thoracic ln.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-175|19|891|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ abdominal wall region. Muscle|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-176|19|898|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-177|19|898|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-178|19|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-179|19|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-180|19|930|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ looks like secondary tgac. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-181|19|931|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ not seen; most probable cod.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-182|19|931|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-183|19|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac metast site not listed.,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-184|19|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-185|19|941|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-186|19|942|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ skin of thorax.Skin|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-187|19|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-188|19|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-189|19|970|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-190|19|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-191|19|981|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-192|19|1004|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ caecum.,MPATH: 551 - sarcoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-193|19|1008|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-194|19|1012|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-195|19|1029|Other deterministic changes|Whole body|MCDU/ |
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-196|19|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-197|19|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-198|19|1094|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ telangiectatic.|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-199|19|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-19|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|148 records survival 619 ± 14 lifespan study|1003-20-19-200|19|1213|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-1|20|246|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-2|20|341|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ jointly rjmf & jhr 5/22/73 called this tluc (unclassified); summary sheet dx, tlhc, also cod. note: no tluc/tlhc/tlus/tlhs codes in use.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-3|20|355|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ gross dx ttyg is tlls(?).,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-4|20|383|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod ttyl w/pnc and clr (thorax) contributing.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-5|20|386|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ cod given as ntyg; quote from summary sheet "reticulum cell sarcoma type b.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-6|20|400|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-7|20|424|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-8|20|444|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-9|20|460|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-10|20|471|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  mediastinal ln., Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-11|20|477|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-12|20|479|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-13|20|481|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ clr and asc non-tumor diagnosis cod; ntyg on autopsy sheet and tlhs on summary,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-14|20|488|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-15|20|488|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ liver abscess.acute,MPATH: 212 - inflammation|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-16|20|502|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-17|20|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlhs(?).,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-18|20|503|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-19|20|508|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-20|20|511|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-21|20|511|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-22|20|521|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ origin subcutaneous region of chest wall. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-23|20|524|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-24|20|526|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCFS OF CHEST WALL TO LUNG.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-25|20|530|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-26|20|531|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-27|20|535|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMLS OF THIGH REGION TO REGIONAL LN.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-28|20|536|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-29|20|540|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Muscle trac metastisis to muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-30|20|544|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-31|20|544|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-32|20|554|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-33|20|556|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-34|20|568|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-35|20|576|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-36|20|578|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-37|20|582|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-38|20|583|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-39|20|584|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-40|20|586|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-41|20|589|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-42|20|592|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlls??/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-43|20|592|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-44|20|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-45|20|601|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-46|20|603|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-47|20|603|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-48|20|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-49|20|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-50|20|608|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-51|20|608|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-52|20|608|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-53|20|614|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-54|20|618|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-55|20|624|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-56|20|624|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-57|20|627|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-58|20|629|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-59|20|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-60|20|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-61|20|637|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-62|20|640|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-63|20|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlls/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-64|20|643|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-65|20|650|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-66|20|652|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-67|20|652|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ acute,MPATH: 212 - inflammation|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-68|20|654|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMLS OF THIGH REGION TO REGIONAL LN.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-69|20|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-70|20|663|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ tlus/lsl.acute. Head neck missing,MPATH: 212 - inflammation|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-71|20|665|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-72|20|666|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-73|20|673|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-74|20|673|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METASTASES TO MEDIASTINAL LN.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-75|20|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-76|20|677|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-77|20|677|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-78|20|683|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-79|20|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-80|20|684|Neoplasia malignant|Endocrine system|TGAC/  Metastases Lung|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-81|20|686|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvic region.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-82|20|687|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMAB TO MAMMARY LN.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-83|20|692|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-84|20|693|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-85|20|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-86|20|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-87|20|701|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-88|20|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-89|20|706|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-90|20|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-91|20|709|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac metastasis to heart.,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-92|20|709|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-93|20|713|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-94|20|715|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-95|20|715|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-96|20|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-97|20|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-98|20|723|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-99|20|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-100|20|727|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-101|20|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-102|20|731|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-103|20|736|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-104|20|740|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-105|20|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-106|20|746|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-107|20|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-108|20|747|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-109|20|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-110|20|751|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/ Predominantly ductal Metastases  Lymphoret.System tmab to mammary ln.,MPATH: 218 - neoplasm|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-111|20|753|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-112|20|756|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-113|20|759|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Kidney Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-114|20|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-115|20|759|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-116|20|763|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-117|20|767|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-118|20|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-119|20|777|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal spine.,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-120|20|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-121|20|783|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ large vascular mass (relates to mhrg) in abdom. cav. Metastases  Lymphoret.System trac to mediastinal ln.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-122|20|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-123|20|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-124|20|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-125|20|788|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of ovary.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-126|20|789|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-127|20|790|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-128|20|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-129|20|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ lhs/lsl; tllb(?)/jhr; rjmf not convinced.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-130|20|793|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-131|20|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-132|20|799|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-133|20|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-134|20|801|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-135|20|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-136|20|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-137|20|811|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-138|20|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-139|20|816|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System togc to lumbar ln.,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-140|20|822|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-141|20|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-142|20|826|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-143|20|827|Other deterministic changes|Whole body|MCDU/ Head/neck missing, eyes missing|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-144|20|827|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-145|20|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-146|20|835|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ tkvs/lsl.,MPATH: 549 - carcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-147|20|835|Other deterministic changes|Whole body|MCDU/  Metastases  togc to spleen.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-148|20|837|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  Metastases Lung Metastases Lung|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-149|20|838|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-150|20|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-151|20|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-152|20|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-153|20|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-154|20|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-155|20|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-156|20|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-157|20|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-158|20|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-159|20|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-160|20|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-161|20|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-162|20|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ gross dx tove is tlls.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-163|20|864|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-164|20|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Metastases  GI tract tzac to stomach & intestinal wall. Metastases Lung Metastases  Lymphoret.System tzac to cervical ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-165|20|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-166|20|872|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-167|20|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-168|20|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-169|20|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-170|20|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-171|20|883|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-172|20|884|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-173|20|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-174|20|889|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-175|20|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-176|20|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-177|20|901|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ region of thigh. Metastases  Lymphoret.System tmls of thigh region to regional ln.|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-178|20|902|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-179|20|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-180|20|910|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-181|20|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-182|20|938|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-183|20|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-184|20|953|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ region of forearm (humerus).muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-185|20|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-186|20|963|n/a|n/a|n/a|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-187|20|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-188|20|981|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-189|20|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-190|20|988|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-191|20|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-192|20|996|Other deterministic changes|Whole body|MCDU/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-193|20|996|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-194|20|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-195|20|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-196|20|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-197|20|1010|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-198|20|1042|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-199|20|1054|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ ,MPATH: 549 - carcinoma|
1003-20-20|n/a,DI|1| 100|gamma-rays Co-60|11.1|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 610 ± 11 lifespan study|1003-20-20-200|20|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-1|21|187|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-2|21|315|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-3|21|405|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWB: TBVS OF RIB INVASION OF REGIONAL SKIN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-4|21|408|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-5|21|419|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-6|21|423|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-7|21|431|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-8|21|464|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC INVASION OF COSTAL MUSCLE.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-9|21|480|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-10|21|491|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-11|21|530|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-12|21|542|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-13|21|543|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-14|21|560|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-15|21|570|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-16|21|582|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-17|21|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-18|21|600|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-19|21|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-20|21|609|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ Acute and subacute,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-21|21|614|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-22|21|616|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-23|21|618|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-24|21|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-25|21|624|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-26|21|626|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-27|21|631|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSFS OF FLANK INVASION OF ADJ. MUSCLES.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-28|21|634|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-29|21|635|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-30|21|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-31|21|645|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAST. TO PARATHYMIC LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-32|21|645|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/ Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-33|21|646|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/ acute/chronic,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-34|21|649|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-35|21|654|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-36|21|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-37|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-38|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-39|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-40|21|666|Other deterministic changes|Lower respiratory system|MPNC/ Lung congestion|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-41|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-42|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-43|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-44|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-45|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-46|21|666|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-47|21|666|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases   mediastinal ln. Heart, Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-48|21|671|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-49|21|673|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-50|21|673|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-51|21|673|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-52|21|673|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-53|21|673|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-54|21|676|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-55|21|683|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ forehead invading cranial cavity.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-56|21|683|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-57|21|687|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ sq cell ca of colon., Eyes missing,MPATH: 549 - carcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-58|21|694|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-59|21|698|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-60|21|700|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-61|21|707|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-62|21|708|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-63|21|709|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  mediastinal ln., Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-64|21|711|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscles.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-65|21|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-66|21|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-67|21|718|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-68|21|721|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-69|21|727|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-70|21|729|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-71|21|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-72|21|729|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-73|21|729|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-74|21|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-75|21|731|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of hip. Muscle|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-76|21|733|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ Head neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-77|21|741|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-78|21|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-79|21|746|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-80|21|749|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-81|21|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-82|21|754|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-83|21|754|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSFS OF FLANK INVASION OF ADJ. MUSCLES.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-84|21|755|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-85|21|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-86|21|764|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-87|21|766|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-88|21|768|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ ,MPATH: 1 - cell and tissue damage|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-89|21|769|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/ chronic hepatitis,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-90|21|771|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-91|21|772|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-92|21|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-93|21|775|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-94|21|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-95|21|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-96|21|779|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-97|21|780|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-98|21|784|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-99|21|784|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-100|21|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-101|21|788|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-102|21|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-103|21|793|Other deterministic changes|Whole body|MCDU/  Metastases  Muscle trac to costal muscle.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-104|21|795|Other deterministic changes|Lower respiratory system|MPNC/ Lung congestion|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-105|21|796|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-106|21|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Metastases  Skin tbvs of rib invasion of regional skin.,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-107|21|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-108|21|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-109|21|803|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-110|21|803|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-111|21|806|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ Head/neck missing, eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-112|21|809|Neoplasia unclassified|Other local manifestations and miscellaneus|TSWB: TBVS OF RIB INVASION OF REGIONAL SKIN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-113|21|810|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-114|21|811|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-115|21|813|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-116|21|813|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-117|21|817|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO PLEURA AND MUSCLE.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-118|21|819|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-119|21|820|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-120|21|820|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-121|21|822|Neoplasia systemic|Haematolymphatic system|TLML/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-122|21|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-123|21|823|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-124|21|824|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|TVFS/ Fibrosarcoma,MPATH: 551 - sarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-125|21|827|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-126|21|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-127|21|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-128|21|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-129|21|834|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Metastases  Muscle trac to costal muscle.,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-130|21|834|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-131|21|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-132|21|835|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-133|21|837|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-134|21|838|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-135|21|839|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-136|21|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-137|21|839|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-138|21|841|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-139|21|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-140|21|846|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-141|21|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-142|21|848|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-143|21|848|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-144|21|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-145|21|848|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-146|21|848|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site not stated or not known.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-147|21|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-148|21|849|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-149|21|850|Hyperplastic changes|Cardiovascular system|MPAN/ Polyarteritis nodosa|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-150|21|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-151|21|851|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-152|21|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-153|21|853|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-154|21|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-155|21|855|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ duodenum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-156|21|857|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-157|21|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-158|21|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-159|21|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-160|21|869|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-161|21|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-162|21|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-163|21|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-164|21|872|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-165|21|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-166|21|873|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-167|21|874|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-168|21|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-169|21|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-170|21|881|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head/neck missing, eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-171|21|883|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-172|21|884|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-173|21|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-174|21|887|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-175|21|887|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-176|21|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-177|21|888|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-178|21|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-179|21|890|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-180|21|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-181|21|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-182|21|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-183|21|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-184|21|895|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-185|21|897|Other deterministic changes|Whole body|MCDU/  Metastases  Lymphoret.System trac to parathymic ln.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-186|21|897|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-187|21|898|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-188|21|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-189|21|898|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-190|21|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ tlhs/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-191|21|902|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-192|21|903|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-193|21|904|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-194|21|905|Other deterministic changes|Whole body|MCDU/  Metastases  Muscle tbvs of spine to muscle of back.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-195|21|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-196|21|911|Other deterministic changes|Whole body|MCDU/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-197|21|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-198|21|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-199|21|916|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-200|21|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-201|21|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-202|21|920|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-203|21|922|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-204|21|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-205|21|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  tpac invasion of brain.,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-206|21|925|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-207|21|926|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-208|21|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-209|21|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-210|21|927|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-211|21|929|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site not specified.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-212|21|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-213|21|931|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-214|21|933|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-215|21|933|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-216|21|934|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-217|21|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-218|21|940|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/ Murine,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-219|21|940|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-220|21|940|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-221|21|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-222|21|941|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-223|21|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-224|21|946|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-225|21|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-226|21|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-227|21|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-228|21|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-229|21|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-230|21|955|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-231|21|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-232|21|959|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-233|21|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-234|21|964|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System trac metast. to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-235|21|964|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-236|21|965|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ HeartHead neck missing|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-237|21|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-238|21|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-239|21|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Muscle trac invasion of costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-240|21|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-241|21|973|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-242|21|975|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-243|21|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-244|21|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-245|21|977|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-246|21|978|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion not specified.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-247|21|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-248|21|981|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ ileum.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-249|21|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-250|21|984|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ Heart|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-251|21|984|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-252|21|984|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-253|21|987|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-254|21|987|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ region of scrotum and thigh.Skin|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-255|21|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-256|21|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-257|21|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Metastases  Muscle trac invasion to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-258|21|995|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-259|21|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-260|21|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-261|21|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-262|21|996|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adjacent to kidney.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-263|21|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  Lymphoret.System tgac to cervical ln. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-264|21|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-265|21|1003|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion not cited.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-266|21|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-267|21|1005|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Metastases  trac invasion site not given.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-268|21|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-269|21|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-270|21|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-271|21|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-272|21|1011|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-273|21|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-274|21|1013|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-275|21|1016|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-276|21|1016|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-277|21|1018|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-278|21|1026|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-279|21|1027|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to pleura and muscle.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-280|21|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-281|21|1029|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-282|21|1030|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-283|21|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-284|21|1031|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-285|21|1035|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-286|21|1035|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-287|21|1037|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-288|21|1038|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-289|21|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-290|21|1039|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-291|21|1041|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-292|21|1042|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum.,MPATH: 218 - neoplasm|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-293|21|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-294|21|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-295|21|1048|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-296|21|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-297|21|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-298|21|1051|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-299|21|1052|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  sternum,  Head/neck missing, eyes missing.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-300|21|1053|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-301|21|1056|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-302|21|1058|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ on back skin. Metastases  Muscle tsfs of back skin to adjacent muscle.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-303|21|1061|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-304|21|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-305|21|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-306|21|1065|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-307|21|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-308|21|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Liver Metastases  Lymphoret.System trac metast. to parathymic ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-309|21|1067|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-310|21|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-311|21|1072|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-312|21|1073|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-313|21|1075|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-314|21|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-315|21|1076|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-316|21|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-317|21|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-318|21|1080|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ region of flank. Metastases  Muscle tsfs of flank invasion of adj. muscles.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-319|21|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-320|21|1086|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 242 - hemangiosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-321|21|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-322|21|1088|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh and belly. Muscle|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-323|21|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-324|21|1093|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-325|21|1094|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-326|21|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-327|21|1095|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-328|21|1096|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ rib cage.Skin|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-329|21|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-330|21|1100|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-331|21|1101|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-332|21|1104|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-333|21|1105|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-334|21|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-335|21|1109|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-336|21|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-337|21|1111|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-338|21|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-339|21|1114|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-340|21|1114|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-341|21|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-342|21|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-343|21|1121|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-344|21|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-345|21|1124|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ rib.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-346|21|1125|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-347|21|1125|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-348|21|1129|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-349|21|1135|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIC/ jaw; mouth.Enteritis chronic,MPATH: 212 - inflammation|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-350|21|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-351|21|1138|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-352|21|1140|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-353|21|1140|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ rib cage.|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-354|21|1141|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-355|21|1144|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-356|21|1147|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-357|21|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-358|21|1153|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-359|21|1156|n/a|n/a|n/a|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-360|21|1163|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-361|21|1164|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to brown fat.,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-362|21|1167|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-363|21|1167|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-364|21|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-365|21|1177|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-366|21|1179|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-367|21|1181|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-368|21|1181|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh and inguinal region. Muscle|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-369|21|1184|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-370|21|1185|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-371|21|1189|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-372|21|1190|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-373|21|1191|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-374|21|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-375|21|1199|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-376|21|1201|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-377|21|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-378|21|1202|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-379|21|1205|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-380|21|1206|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ shoulder region.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-381|21|1209|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-382|21|1218|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-383|21|1220|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ psoas muscle region. Muscle|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-384|21|1228|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-385|21|1228|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-386|21|1234|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-387|21|1241|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-388|21|1246|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-389|21|1259|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-390|21|1264|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-391|21|1269|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-392|21|1282|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-393|21|1282|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-394|21|1284|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-395|21|1293|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-396|21|1303|Other deterministic changes|Whole body|MCDU/  |
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-397|21|1314|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-398|21|1320|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-399|21|1331|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCA/  Cystitis|
1003-20-21|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|386 records survival 810 ± 10 lifespan study|1003-20-21-400|21|1352|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-1|22|271|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-2|22|295|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMAT, MAMMARY GLAND, TO LUNG.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-3|22|302|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-4|22|442|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEFS/  ,MPATH: 551 - sarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-5|22|453|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-6|22|477|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-7|22|482|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestion|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-8|22|486|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-9|22|491|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-10|22|495|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-11|22|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-12|22|528|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-13|22|530|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-14|22|531|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-15|22|531|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-16|22|543|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-17|22|543|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-18|22|547|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-19|22|547|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-20|22|557|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-21|22|563|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestion|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-22|22|571|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh and spine. Muscle|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-23|22|578|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-24|22|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-25|22|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-26|22|603|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-27|22|613|Other deterministic changes|Whole body|MCDU/   Metastases Heart Metastases  Lymphoret.System trac to parathymic ln.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-28|22|614|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-29|22|614|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-30|22|616|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-31|22|617|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-32|22|618|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-33|22|634|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-34|22|637|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-35|22|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-36|22|641|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-37|22|652|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-38|22|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-39|22|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-40|22|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ gross dx tmgl is tlll.,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-41|22|664|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-42|22|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-43|22|670|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ submaxillary region; starvation followed.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-44|22|670|Neoplasia benign|Lower digestive tract,MA: 0000328 - intestine|TISO/ tlhs/lsl; jejunum.Leiomyoma,MPATH: 218 - neoplasm|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-45|22|671|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-46|22|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-47|22|675|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-48|22|676|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-49|22|676|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases  trac to sternal marrow. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-50|22|683|Other deterministic changes|Whole body|MCDU/ possibly togc was cod but not likely cause.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-51|22|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-52|22|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-53|22|690|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-54|22|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-55|22|691|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-56|22|693|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cerebellar blood clot (?) contributed to cod.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-57|22|694|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ brain.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-58|22|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-59|22|696|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-60|22|697|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ islet cell carcinoma.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-61|22|698|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-62|22|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-63|22|700|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-64|22|708|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-65|22|708|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-66|22|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-67|22|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-68|22|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-69|22|717|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-70|22|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-71|22|722|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-72|22|729|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TULS/  ,MPATH: 551 - sarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-73|22|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-74|22|733|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-75|22|735|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-76|22|736|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-77|22|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-78|22|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-79|22|744|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-80|22|746|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ peritoneal cavity.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-81|22|747|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-82|22|748|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-83|22|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-84|22|752|Hyperplastic changes|Cardiovascular system|MPAN/ generalized disease with heart most severely involved.Polyarteritis nodosa|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-85|22|752|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-86|22|753|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ Head neck missing,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-87|22|754|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-88|22|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-89|22|760|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-90|22|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-91|22|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-92|22|762|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-93|22|764|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of skull. Metastases Lung Metastases Liver|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-94|22|766|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-95|22|767|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOCO/  ,MPATH: 277 - cystadenoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-96|22|771|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-97|22|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-98|22|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-99|22|783|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-100|22|784|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-101|22|788|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-102|22|789|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-103|22|789|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-104|22|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-105|22|792|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-106|22|795|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-107|22|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-108|22|797|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-109|22|798|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-110|22|800|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-111|22|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-112|22|806|Acute infections|Lower digestive tract,MA: 0000054 - peritoneal cavity|MXWI/   Metastases Lung,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-113|22|806|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-114|22|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-115|22|812|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of lumbar spine. Muscle|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-116|22|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-117|22|813|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-118|22|813|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-119|22|815|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-120|22|817|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-121|22|817|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-122|22|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-123|22|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-124|22|823|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ Head neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-125|22|828|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-126|22|831|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-127|22|831|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-128|22|831|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-129|22|832|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ peritonitis, acute diffuse.,MPATH: 213 - acute inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-130|22|832|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-131|22|836|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-132|22|838|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-133|22|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-134|22|840|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-135|22|841|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-136|22|841|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-137|22|841|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-138|22|843|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-139|22|844|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-140|22|844|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-141|22|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-142|22|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-143|22|845|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-144|22|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-145|22|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-146|22|855|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-147|22|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-148|22|857|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-149|22|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-150|22|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-151|22|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-152|22|863|Neoplasia systemic|Haematolymphatic system|TLML/ based upon hematology.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-153|22|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-154|22|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-155|22|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-156|22|866|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-157|22|869|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ serosa of cecum.,MPATH: 551 - sarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-158|22|871|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-159|22|872|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-160|22|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-161|22|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-162|22|875|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-163|22|876|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-164|22|876|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-165|22|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-166|22|878|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-167|22|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-168|22|881|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ peritonitis.,MPATH: 213 - acute inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-169|22|882|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-170|22|882|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-171|22|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-172|22|884|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ spinal cord, lower lumbar region neurolemoma.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-173|22|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Lung Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-174|22|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-175|22|889|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-176|22|889|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-177|22|892|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ also a hyperplasia of pituitary.,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-178|22|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-179|22|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-180|22|896|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma Metastases  tpac invasion of brain.,MPATH: 218 - neoplasm|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-181|22|896|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-182|22|897|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-183|22|898|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-184|22|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-185|22|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-186|22|902|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-187|22|903|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-188|22|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-189|22|906|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-190|22|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-191|22|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-192|22|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-193|22|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-194|22|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-195|22|912|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-196|22|912|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-197|22|912|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ top of shoulder. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-198|22|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-199|22|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-200|22|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-201|22|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-202|22|916|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-203|22|917|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ cecum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-204|22|918|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-205|22|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-206|22|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  GI tract tosc metast. to unidentified intestinal site. Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-207|22|921|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ tongue.,MPATH: 549 - carcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-208|22|922|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-209|22|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-210|22|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-211|22|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-212|22|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-213|22|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-214|22|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-215|22|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-216|22|931|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-217|22|931|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWC: TCFS OF NECK REGION TO PARATHYMIC LN.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-218|22|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-219|22|932|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-220|22|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-221|22|934|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-222|22|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-223|22|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-224|22|936|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-225|22|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-226|22|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-227|22|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-228|22|939|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-229|22|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-230|22|940|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-231|22|941|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-232|22|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-233|22|943|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to thoracic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-234|22|944|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-235|22|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-236|22|948|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-237|22|948|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-238|22|948|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-239|22|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-240|22|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-241|22|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-242|22|949|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-243|22|956|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-244|22|958|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of neck. Metastases  tcfs of neck region to visceral peritoneum. Metastases  Lymphoret.System tcfs of neck region to parathymic ln. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-245|22|961|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac metast. to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-246|22|963|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Lung|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-247|22|963|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-248|22|964|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-249|22|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-250|22|966|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,  Head/neck missing, eyes missing,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-251|22|966|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lower jaw.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-252|22|966|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-253|22|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-254|22|967|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-255|22|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-256|22|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-257|22|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-258|22|969|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Lymphoret.System trac to parathymic ln. Metastases  trac to pericardium.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-259|22|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-260|22|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-261|22|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-262|22|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-263|22|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-264|22|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-265|22|980|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ region of thigh.Skin|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-266|22|980|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ kupfer cell tumor.,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-267|22|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-268|22|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-269|22|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-270|22|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-271|22|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-272|22|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-273|22|992|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-274|22|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-275|22|992|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-276|22|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-277|22|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-278|22|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-279|22|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-280|22|999|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sacral region. Metastases  Lymphoret.System tbos of sacral region to regional ln. Metastases Ovary|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-281|22|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-282|22|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-283|22|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-284|22|1002|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-285|22|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-286|22|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-287|22|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-288|22|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-289|22|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-290|22|1016|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-291|22|1016|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Kidney Metastases  Muscle trac to costal muscle. Metastases  trac to diaphragm. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-292|22|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-293|22|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-294|22|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-295|22|1023|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-296|22|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-297|22|1026|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-298|22|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-299|22|1027|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|TMAT/   Metastases Lung tmat, mammary gland, to lung.,MPATH: 255 - adenoacanthoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-300|22|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-301|22|1030|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-302|22|1031|n/a|n/a|n/a|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-303|22|1032|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-304|22|1033|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-305|22|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-306|22|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-307|22|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-308|22|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-309|22|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-310|22|1041|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-311|22|1043|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ abd. cavity.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-312|22|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-313|22|1047|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ right hip. Muscle|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-314|22|1047|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ thigh region.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-315|22|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-316|22|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-317|22|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-318|22|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-319|22|1051|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ region of thigh.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-320|22|1051|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-321|22|1051|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of flank. Muscle|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-322|22|1053|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-323|22|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-324|22|1066|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-325|22|1068|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-326|22|1068|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-327|22|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-328|22|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-329|22|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-330|22|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-331|22|1075|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKVS/  ,MPATH: 551 - sarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-332|22|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-333|22|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-334|22|1078|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ forelimb. Metastases  Muscle tbos of forelimb invasion of mammary gland. Metastases Lung Metastases Ovary|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-335|22|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-336|22|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-337|22|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-338|22|1081|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-339|22|1083|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-340|22|1084|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-341|22|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-342|22|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-343|22|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-344|22|1087|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ region of throat.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-345|22|1090|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-346|22|1099|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-347|22|1099|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases  togc to visceral peritoneum. Metastases Liver Metastases Lung|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-348|22|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-349|22|1106|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-350|22|1108|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-351|22|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-352|22|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-353|22|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-354|22|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-355|22|1118|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ spinal muscle region. Metastases  Muscle tnns of spinal muscle region to  adjacent muscles.,MPATH: 437 - neurofibrosarcoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-356|22|1118|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-357|22|1119|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ thigh; lower abdomen and thigh.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-358|22|1119|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-359|22|1123|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-360|22|1126|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-361|22|1130|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-362|22|1134|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-363|22|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-364|22|1138|Other deterministic changes|Whole body|MCDU/  |
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-365|22|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-366|22|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-367|22|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-368|22|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-369|22|1153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-370|22|1153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-371|22|1154|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-372|22|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-373|22|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-374|22|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to non-specified ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-375|22|1165|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  tsvs of perineal region to mammary gland.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-376|22|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-377|22|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-378|22|1167|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-379|22|1176|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-380|22|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-381|22|1177|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ colon.Enteritis acute,MPATH: 212 - inflammation|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-382|22|1180|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-383|22|1183|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thoracic spine.|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-384|22|1185|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-385|22|1187|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-386|22|1200|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ lumbar region; tissue # j6773b.Skin|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-387|22|1201|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-388|22|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-389|22|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-390|22|1203|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-391|22|1217|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-392|22|1220|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle tgac to regional muscle. Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-393|22|1220|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-394|22|1228|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases Heart Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-395|22|1241|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-396|22|1257|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tpac to brain.,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-397|22|1262|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-398|22|1267|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ region of mandible.,MPATH: 218 - neoplasm|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-399|22|1326|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-22|n/a,S1|1| 100|gamma-rays Co-60|0.9|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|397 records survival 790 ± 9 lifespan study|1003-20-22-400|22|1331|Neoplasia malignant|Other local manifestations and miscellaneus|TMSS/ TMSS/ TMSS/ TMSS/ muscle in spinal region.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-1|23|270|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-2|23|289|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-3|23|309|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-4|23|311|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-5|23|430|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-6|23|455|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-7|23|465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-8|23|466|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-9|23|489|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-10|23|490|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-11|23|490|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-12|23|494|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-13|23|506|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-14|23|509|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-15|23|512|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-16|23|561|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-17|23|573|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-18|23|587|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-19|23|592|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-20|23|598|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-21|23|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-22|23|609|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-23|23|612|Neoplasia systemic|Haematolymphatic system|TLML/ tlls/jhr.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-24|23|620|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-25|23|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-26|23|629|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-27|23|630|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-28|23|636|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-29|23|636|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-30|23|639|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-31|23|652|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-32|23|656|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-33|23|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-34|23|663|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-35|23|673|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-36|23|673|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-37|23|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-38|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-39|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-40|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-41|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-42|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-43|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-44|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-45|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-46|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-47|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-48|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-49|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-50|23|674|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-51|23|675|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-52|23|682|Other deterministic changes|Whole body|MCDU/ no evidence for ntyg.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-53|23|685|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach and small intestine; blockage.,MPATH: 218 - neoplasm|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-54|23|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSL/  undifferentiated leukemia lymphoret.tissue,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-55|23|700|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-56|23|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-57|23|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-58|23|708|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-59|23|709|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-60|23|714|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  Muscle trac to costal muscle. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-61|23|715|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-62|23|720|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-63|23|726|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-64|23|735|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION NOT SPECIFIED.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-65|23|738|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-66|23|739|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMFS OF MUSCLE OF FACE TO CERVICAL LN.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-67|23|740|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-68|23|742|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-69|23|743|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-70|23|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-71|23|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-72|23|747|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 1 - cell and tissue damage|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-73|23|749|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-74|23|750|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-75|23|751|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-76|23|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-77|23|752|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-78|23|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-79|23|759|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-80|23|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-81|23|761|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-82|23|763|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGSC TO LUNG.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-83|23|767|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ region of eye.muscle Metastases  Lymphoret.System tmfs of muscle of face to cervical ln. Metastases Lung tmfs of muscle of face to lung.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-84|23|774|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-85|23|774|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-86|23|777|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-87|23|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-88|23|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-89|23|787|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-90|23|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-91|23|792|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMFS OF MUSCLE OF FACE TO CERVICAL LN.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-92|23|796|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-93|23|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-94|23|806|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-95|23|808|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ ear.Skin|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-96|23|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-97|23|812|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-98|23|813|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-99|23|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-100|23|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-101|23|818|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-102|23|821|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-103|23|827|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ region of ear. Metastases  Muscle tsec of region of ear to muscles of skull. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-104|23|840|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-105|23|841|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-106|23|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-107|23|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-108|23|855|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-109|23|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-110|23|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-111|23|860|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-112|23|863|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-113|23|863|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-114|23|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-115|23|863|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-116|23|865|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-117|23|872|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-118|23|876|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ Head neck missing|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-119|23|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-120|23|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-121|23|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-122|23|888|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-123|23|888|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-124|23|893|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-125|23|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-126|23|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-127|23|900|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasive, site not identified.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-128|23|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-129|23|904|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-130|23|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-131|23|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-132|23|915|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-133|23|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-134|23|924|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to serosa of aorta.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-135|23|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-136|23|929|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ region of back and chest.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-137|23|929|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ costal muscle. Metastases Heart|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-138|23|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-139|23|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-140|23|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-141|23|940|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ flank region. Metastases Liver,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-142|23|941|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-143|23|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-144|23|942|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-145|23|943|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-146|23|944|Neoplasia unclassified|Endocrine system,MA: 0001247 - harderian gland|TGSC/  undifferentiated tumor Metastases Lung Metastases  trac metastatic to adnexa.,MPATH: 218 - neoplasm|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-147|23|945|n/a|n/a|n/a|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-148|23|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-149|23|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-150|23|957|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-151|23|959|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-152|23|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-153|23|969|Neoplasia malignant|Other local manifestations and miscellaneus|TMSS/ TMSS/ TMSS/ TMSS/ pelvic region possibly carcino-sarcoma. Metastases  Muscle trac to skeletal muscle.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-154|23|974|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tmls of costal muscle to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-155|23|980|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-156|23|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-157|23|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-158|23|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-159|23|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-160|23|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-161|23|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  trac invasion not specified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-162|23|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-163|23|996|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-164|23|997|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-165|23|1006|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-166|23|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-167|23|1011|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-168|23|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-169|23|1013|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-170|23|1013|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-171|23|1015|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-172|23|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-173|23|1024|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-174|23|1025|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-175|23|1027|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ dorsal chest.Skin|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-176|23|1038|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-177|23|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-178|23|1042|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not specified.,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-179|23|1045|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ chest dorsum.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-180|23|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-181|23|1046|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-182|23|1052|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Lymphoret.System trac to mediastinal ln.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-183|23|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-184|23|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-185|23|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-186|23|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-187|23|1080|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-188|23|1081|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ brain.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-189|23|1091|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-190|23|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-191|23|1097|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-192|23|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-193|23|1114|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-194|23|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-195|23|1150|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-196|23|1151|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-197|23|1164|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-198|23|1191|Other deterministic changes|Whole body|MCDU/  |
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-199|23|1208|Other deterministic changes|Whole body|MCDU/   Metastases  trac invasion site not specified.|
1003-20-23|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|185 records survival 727 ± 13 lifespan study|1003-20-23-200|23|1292|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-1|24|184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-2|24|309|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-3|24|323|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-4|24|375|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-5|24|397|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-6|24|424|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-7|24|436|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-8|24|452|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-9|24|487|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-10|24|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-11|24|524|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-12|24|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-13|24|544|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-14|24|550|Neoplasia benign|Ovary among reproductive system diseases|TOTO/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-15|24|564|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ region of throat. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-16|24|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-17|24|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-18|24|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-19|24|626|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWG: TGAC INVASION OF ADNEXA.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-20|24|628|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-21|24|629|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ hemorrhages; no evidence of gross dx ntyg.,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-22|24|630|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-23|24|631|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-24|24|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-25|24|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-26|24|644|Other deterministic changes|Whole body|MCDU/ gross dx tadn not found.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-27|24|645|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ abd. cerv.; site? cod hrg; possibly both tissues are spleen.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-28|24|645|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-29|24|646|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-30|24|656|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAC/   Metastases  tgac invasion of adnexa.,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-31|24|658|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-32|24|659|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-33|24|663|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-34|24|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-35|24|665|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-36|24|668|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWH: THVS TO HEART.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-37|24|668|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-38|24|670|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-39|24|673|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-40|24|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-41|24|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-42|24|678|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-43|24|683|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMFS OF MUSCLES OF HIND LEGS TO LIVER.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-44|24|685|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-45|24|686|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Liver|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-46|24|689|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-47|24|691|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-48|24|695|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-49|24|697|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-50|24|702|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ jaw, severe. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-51|24|708|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-52|24|709|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-53|24|711|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-54|24|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-55|24|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-56|24|712|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-57|24|712|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-58|24|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ trac found at gross is tlll.,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-59|24|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-60|24|719|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-61|24|722|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-62|24|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-63|24|731|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-64|24|735|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-65|24|744|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-66|24|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-67|24|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-68|24|749|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-69|24|750|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-70|24|751|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-71|24|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-72|24|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-73|24|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ tlls/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-74|24|759|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOAC/ Head neck missing,MPATH: 218 - neoplasm|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-75|24|760|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-76|24|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-77|24|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-78|24|768|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-79|24|772|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-80|24|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-81|24|785|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF SPINE AND PELVIC CAVITY REGION TO LUNG.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-82|24|786|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-83|24|786|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-84|24|787|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-85|24|791|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-86|24|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-87|24|800|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvic region blockage.|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-88|24|800|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-89|24|801|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ both hind legs.muscle Metastases Lung tmfs of muscles of hind legs to lung. Metastases  Lymphoret.System tmfs of muscles of hind legs to unidentified ln. Metastases  Kidney tmfs of muscles of hind legs to serosa of kidney. Metastases Liver,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-90|24|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-91|24|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-92|24|805|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ Eyes missing|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-93|24|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-94|24|806|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-95|24|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-96|24|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-97|24|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-98|24|820|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ spine and pelvic cavity region. Metastases Lung|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-99|24|822|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-100|24|825|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-101|24|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-102|24|826|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-103|24|826|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-104|24|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-105|24|830|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ von hippel-lindau disease.,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-106|24|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-107|24|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-108|24|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-109|24|841|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-110|24|844|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-111|24|845|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-112|24|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-113|24|854|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-114|24|856|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-115|24|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-116|24|860|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-117|24|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-118|24|864|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-119|24|865|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-120|24|866|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-121|24|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-122|24|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-123|24|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-124|24|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-125|24|871|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-126|24|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-127|24|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-128|24|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-129|24|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-130|24|887|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-131|24|891|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-132|24|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-133|24|892|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-134|24|900|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-135|24|901|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-136|24|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-137|24|904|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ mesenteric ln. Lymphoret.tissue|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-138|24|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-139|24|904|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-140|24|908|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-141|24|908|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-142|24|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-143|24|911|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-144|24|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-145|24|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-146|24|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-147|24|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-148|24|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-149|24|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-150|24|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-151|24|928|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-152|24|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-153|24|934|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-154|24|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-155|24|938|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-156|24|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-157|24|943|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-158|24|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-159|24|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-160|24|956|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Liver|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-161|24|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-162|24|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-163|24|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-164|24|969|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-165|24|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-166|24|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-167|24|974|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/   Metastases Heart,MPATH: 242 - hemangiosarcoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-168|24|977|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-169|24|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-170|24|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-171|24|985|Other deterministic changes|Whole body|MCDU/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-172|24|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-173|24|999|Other deterministic changes|Lower digestive tract|MIFC/ fat necrosis of intestinal-serosal fat.Fatty changes intestine|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-174|24|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-175|24|1005|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar region of spine. Muscle|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-176|24|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-177|24|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-178|24|1013|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-179|24|1014|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-180|24|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-181|24|1029|n/a|n/a|n/a|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-182|24|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-183|24|1033|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-184|24|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-185|24|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-186|24|1052|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-187|24|1054|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-188|24|1063|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/   Metastases Liver,MPATH: 218 - neoplasm|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-189|24|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-190|24|1079|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sacral spine. Metastases Lung|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-191|24|1089|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNP/  ,MPATH: 212 - inflammation|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-192|24|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-193|24|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-194|24|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-195|24|1121|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-196|24|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-197|24|1142|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-198|24|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-199|24|1167|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-24|n/a,S2|1| 100|gamma-rays Co-60|2.68|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|198 records survival 706 ± 12 lifespan study|1003-20-24-200|24|1356|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-1|25|117|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF JAW TO FACE MUSCLE.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-2|25|127|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-3|25|127|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-4|25|128|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-5|25|129|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-6|25|129|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF JAW TO FACE MUSCLE.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-7|25|129|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-8|25|130|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-9|25|131|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF JAW TO FACE MUSCLE.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-10|25|131|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-11|25|132|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-12|25|134|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNP/ with abscess.,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-13|25|134|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-14|25|134|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-15|25|134|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-16|25|134|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-17|25|137|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-18|25|241|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-19|25|241|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod ttyg.,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-20|25|253|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF JAW TO LUNG.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-21|25|257|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-22|25|258|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-23|25|263|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-24|25|269|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-25|25|278|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-26|25|279|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-27|25|280|Neoplasia unclassified|Other local manifestations and miscellaneus|THWV: TVFS TO LIVER.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-28|25|287|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-29|25|288|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-30|25|289|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF JAW TO LUNG.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-31|25|291|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-32|25|291|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-33|25|292|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-34|25|305|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-35|25|316|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-36|25|327|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-37|25|329|Neoplasia unclassified|Other local manifestations and miscellaneus|TVWX: TXEC OF GENITOURINARY SYSTEM TO SEMINAL VESICLE.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-38|25|330|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-39|25|330|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-40|25|331|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-41|25|332|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-42|25|339|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-43|25|344|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-44|25|346|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF JAW TO LUNG.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-45|25|346|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-46|25|354|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-47|25|355|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-48|25|359|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-49|25|368|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-50|25|372|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-51|25|376|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-52|25|380|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-53|25|381|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-54|25|389|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-55|25|392|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-56|25|396|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-57|25|396|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-58|25|409|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-59|25|415|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-60|25|422|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-61|25|424|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-62|25|426|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-63|25|426|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ carcinoma stomach.,MPATH: 218 - neoplasm|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-64|25|426|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-65|25|434|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-66|25|443|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-67|25|445|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-68|25|448|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-69|25|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-70|25|452|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-71|25|456|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-72|25|458|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-73|25|459|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-74|25|459|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-75|25|459|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-76|25|460|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-77|25|469|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-78|25|470|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-79|25|476|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-80|25|477|Neoplasia unclassified|Other local manifestations and miscellaneus|THWV: TVFS TO LIVER.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-81|25|485|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-82|25|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-83|25|506|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-84|25|508|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-85|25|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-86|25|528|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-87|25|533|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-88|25|534|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-89|25|546|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-90|25|550|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-91|25|561|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar muscle. Muscle|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-92|25|569|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-93|25|569|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-94|25|577|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-95|25|592|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-96|25|597|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ lung not saved.,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-97|25|600|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-98|25|606|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-99|25|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-100|25|609|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO UNSPECIFIED LN.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-101|25|609|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing, eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-102|25|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-103|25|621|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-104|25|624|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-105|25|624|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-106|25|625|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-107|25|625|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ nose. Metastases Liver Metastases Lung Metastases  Kidney tbos of nose to kidney.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-108|25|628|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-109|25|631|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-110|25|634|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon, lower.,MPATH: 218 - neoplasm|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-111|25|659|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ jaw. Metastases  Skin tbos of jaw to face. Metastases  Muscle tbos of jaw to face muscle. Metastases  tbos of jaw to nerve of face.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-112|25|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-113|25|668|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ jaw. Metastases Lung|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-114|25|669|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPRA/  Prostatits|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-115|25|675|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Lung|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-116|25|681|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-117|25|685|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-118|25|687|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-119|25|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-120|25|698|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-121|25|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-122|25|700|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-123|25|704|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ origin genitourinary system; exact area unknown. Metastases  Seminal vesicle txec of genitourinary system to seminal vesicle.,MPATH: 446 - squamous cell carcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-124|25|706|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-125|25|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-126|25|716|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-127|25|721|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-128|25|722|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-129|25|722|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-130|25|724|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-131|25|724|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-132|25|725|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-133|25|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-134|25|732|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|TVFS/  Fibrosarcoma Metastases Lung Metastases  tvfs sarcomatosis in diaphragm. Metastases Liver,MPATH: 551 - sarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-135|25|733|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine.  aorta w/organized clot. Eyes missing|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-136|25|733|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-137|25|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-138|25|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  trac to heart and assoc. structures.,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-139|25|749|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  Head/neck missing, eyes missing,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-140|25|750|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-141|25|750|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-142|25|751|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-143|25|753|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-144|25|771|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-145|25|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-146|25|778|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-147|25|779|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-148|25|781|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-149|25|781|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-150|25|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-151|25|783|Other deterministic changes|Whole body|MCDU/ Trunk + Eyes missing|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-152|25|783|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,  Head/neck missing, eyes missing,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-153|25|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-154|25|785|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-155|25|787|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of shoulder.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-156|25|787|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-157|25|794|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-158|25|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-159|25|796|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-160|25|797|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-161|25|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-162|25|801|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-163|25|803|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-164|25|805|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-165|25|809|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-166|25|814|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,  Head/neck missing, eyes missing,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-167|25|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-168|25|822|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-169|25|822|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-170|25|833|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-171|25|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-172|25|839|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of flank.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-173|25|842|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-174|25|843|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-175|25|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based upon hematology only.,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-176|25|852|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-177|25|852|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-178|25|870|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-179|25|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-180|25|877|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-181|25|887|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-182|25|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-183|25|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-184|25|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-185|25|898|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNUS/ region of thoracic cord.,MPATH: 551 - sarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-186|25|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Lymphoret.System tgac to unspecified ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-187|25|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-188|25|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-189|25|919|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-190|25|919|Neoplasia unclassified|Other local manifestations and miscellaneus|THWV: TVFS TO LIVER.|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-191|25|920|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-192|25|920|Other deterministic changes|Whole body|MCDU/  |
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-193|25|922|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  Head/neck missing, eyes missing,MPATH: 1 - cell and tissue damage|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-194|25|925|Degenerative changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MABA/  Adrenal brown atrophy,MPATH: 127 - atrophy|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-195|25|926|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-196|25|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-197|25|968|n/a|n/a|n/a|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-198|25|970|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-199|25|984|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/ slides read by ll & jr.,MPATH: 549 - carcinoma|
1003-20-25|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|196 records survival 460 ± 17 lifespan study|1003-20-25-200|25|1003|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-1|26|123|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-2|26|123|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-3|26|123|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-4|26|123|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-5|26|123|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-6|26|124|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-7|26|127|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-8|26|129|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-9|26|130|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-10|26|130|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-11|26|132|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-12|26|134|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-13|26|135|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-14|26|135|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-15|26|135|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-16|26|135|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-17|26|135|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-18|26|137|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-19|26|137|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-20|26|138|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-21|26|138|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-22|26|138|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-23|26|208|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-24|26|225|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-25|26|228|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-26|26|232|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-27|26|247|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-28|26|248|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-29|26|253|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-30|26|260|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-31|26|263|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-32|26|264|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-33|26|266|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-34|26|266|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-35|26|276|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-36|26|283|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-37|26|288|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-38|26|288|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-39|26|306|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ttyg?, head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-40|26|306|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-41|26|307|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-42|26|311|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-43|26|312|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-44|26|314|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-45|26|314|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-46|26|318|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-47|26|320|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-48|26|327|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-49|26|336|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-50|26|337|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-51|26|345|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-52|26|346|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-53|26|348|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-54|26|351|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-55|26|352|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-56|26|358|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-57|26|360|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-58|26|362|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-59|26|367|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-60|26|373|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-61|26|379|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-62|26|390|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-63|26|391|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-64|26|392|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-65|26|393|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-66|26|399|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-67|26|404|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-68|26|408|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-69|26|410|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-70|26|411|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-71|26|429|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-72|26|437|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-73|26|438|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-74|26|441|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/ tuls/jhr. Metastases  tuac to mesentery & serosa of gut. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-75|26|459|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-76|26|459|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-77|26|463|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-78|26|463|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-79|26|480|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-80|26|489|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-81|26|495|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-82|26|498|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-83|26|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-84|26|509|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-85|26|512|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-86|26|514|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-87|26|522|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-88|26|527|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-89|26|551|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-90|26|555|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-91|26|557|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-92|26|561|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-93|26|565|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-94|26|567|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-95|26|578|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ cns ok.,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-96|26|583|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-97|26|585|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-98|26|586|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-99|26|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-100|26|592|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-101|26|597|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-102|26|599|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-103|26|600|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-104|26|604|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-105|26|606|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ forearm.|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-106|26|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-107|26|631|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-108|26|639|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-109|26|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-110|26|652|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-111|26|656|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ choleceptitis acute.  rupture of duodenum?Enteritis acute,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-112|26|659|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-113|26|660|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-114|26|660|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-115|26|662|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-116|26|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-117|26|672|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-118|26|677|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-119|26|681|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ brain.,MPATH: 551 - sarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-120|26|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-121|26|684|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-122|26|686|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-123|26|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-124|26|688|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-125|26|689|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ probably immediate cause of terminal illness was hemorrhage from vascular tumor of spleen.,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-126|26|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-127|26|700|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-128|26|707|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-129|26|710|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-130|26|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-131|26|714|Other deterministic changes|Whole body|MCDU/ Head neck thorax missing|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-132|26|714|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-133|26|716|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-134|26|717|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-135|26|722|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-136|26|725|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-137|26|725|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-138|26|726|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-139|26|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-140|26|736|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-141|26|737|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-142|26|739|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ lower hind leg; septicemiamuscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-143|26|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-144|26|742|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-145|26|742|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ region of throat.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-146|26|743|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-147|26|746|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-148|26|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-149|26|754|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-150|26|756|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-151|26|757|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ nonglandular stomach.,MPATH: 551 - sarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-152|26|757|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-153|26|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-154|26|760|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ pelvic region (mineral deposit).muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-155|26|761|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-156|26|764|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNUS/ vascular tumor; brain.,MPATH: 551 - sarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-157|26|765|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-158|26|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-159|26|768|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-160|26|770|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-161|26|775|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-162|26|775|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ duodenum; ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-163|26|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-164|26|778|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-165|26|779|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-166|26|779|Other deterministic changes|Whole body|MCDU/ cod probably pneumonitis. other contributors not known.|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-167|26|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-168|26|781|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-169|26|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-170|26|783|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-171|26|785|n/a|n/a|n/a|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-172|26|787|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ with hrg.,MPATH: 268 - adenocarcinoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-173|26|789|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-174|26|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-175|26|793|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-176|26|795|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-177|26|799|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute , Head neck missing,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-178|26|800|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-179|26|803|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-180|26|805|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-181|26|806|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-182|26|810|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-183|26|812|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-184|26|812|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-185|26|818|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-186|26|826|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-187|26|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-188|26|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-189|26|835|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-190|26|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-191|26|840|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ stomach.Enteritis acute,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-192|26|841|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-193|26|841|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-194|26|845|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-195|26|852|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-196|26|859|Other deterministic changes|Whole body|MCDU/  |
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-197|26|882|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/ murine pneumonia.Acute and subacute,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-198|26|922|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-199|26|928|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-26|n/a,S3|1| 100|gamma-rays Co-60|7.88|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 431 ± 17 lifespan study|1003-20-26-200|26|946|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-1|27|347|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-2|27|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-3|27|481|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-4|27|500|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-5|27|542|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-6|27|554|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO LN LOCATED IN MEDIASTINUM.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-7|27|570|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ salivary gl. Metastases  Lung txac of salivary gl. to lung. Metastases  Lymphoret.System txac of salivary gland to mediastinal ln. Metastases  Kidney txac to salivary gl. to kidney.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-8|27|576|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-9|27|582|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-10|27|606|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-11|27|626|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-12|27|628|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-13|27|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-14|27|635|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-15|27|639|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-16|27|647|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGSC TO PERIORBITAL MUSCLE.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-17|27|649|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. LN.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-18|27|661|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ w/hrg.,MPATH: 242 - hemangiosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-19|27|663|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-20|27|667|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGSC TO PERIORBITAL MUSCLE.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-21|27|671|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-22|27|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-23|27|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-24|27|684|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-25|27|692|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-26|27|694|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGSC TO PERIORBITAL MUSCLE.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-27|27|697|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-28|27|700|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-29|27|703|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ pelvic spine. Metastases  Muscle tbvs of pelvic spine to muscle of spine.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-30|27|705|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-31|27|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-32|27|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-33|27|720|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-34|27|731|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-35|27|732|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-36|27|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-37|27|736|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF PELVIC SPINE TO MUSCLE OF SPINE.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-38|27|737|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWY: TYVS TO LUNG.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-39|27|742|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-40|27|751|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-41|27|756|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-42|27|757|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing, eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-43|27|760|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-44|27|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to sternal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-45|27|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-46|27|770|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-47|27|773|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of knee. Metastases Lung|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-48|27|777|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-49|27|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tgac to parathymic ln. Metastases  Muscle tgac to muscle of skull. Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-50|27|780|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. LN.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-51|27|781|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-52|27|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-53|27|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-54|27|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-55|27|788|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-56|27|792|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ mediastinum., Head neck missing|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-57|27|795|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-58|27|796|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-59|27|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-60|27|802|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-61|27|803|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-62|27|806|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-63|27|806|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-64|27|807|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-65|27|808|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-66|27|809|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-67|27|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-68|27|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-69|27|825|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB MUSCLE.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-70|27|827|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-71|27|827|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-72|27|829|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-73|27|834|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR VERT. TO MUSCLES OF LUMBAR REGION.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-74|27|834|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-75|27|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-76|27|843|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-77|27|843|Neoplasia unclassified|Endocrine system,MA: 0001247 - harderian gland|TGSC/  undifferentiated tumor Metastases Lung Metastases  tgsc to eye orbit. Metastases  Muscle tgsc to periorbital muscle.,MPATH: 218 - neoplasm|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-78|27|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-79|27|863|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-80|27|865|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-81|27|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-82|27|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-83|27|870|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  Lymphoret.System trac metast. to parathymic ln. Metastases  trac metast. to serosa.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-84|27|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-85|27|876|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. ln. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-86|27|878|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWC: TCVS OF ADNEXAL FAT AND C.T. ABOUT KID. TO KID.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-87|27|879|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-88|27|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-89|27|882|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-90|27|882|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-91|27|885|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-92|27|896|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-93|27|901|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-94|27|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-95|27|907|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-96|27|911|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-97|27|912|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-98|27|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscle. Metastases  trac to parietal pleura. Metastases  Lymphoret.System trac to ln located in mediastinum.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-99|27|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-100|27|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-101|27|920|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-102|27|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-103|27|922|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-104|27|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-105|27|925|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-106|27|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-107|27|933|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-108|27|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-109|27|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-110|27|935|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF UNKNOWN ORIGIN TO LIVER.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-111|27|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt. lns. Metastases  trac to parietal pleura. Metastases  Muscle trac to intercostal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-112|27|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-113|27|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-114|27|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-115|27|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-116|27|949|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileocecal junction.,MPATH: 218 - neoplasm|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-117|27|949|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-118|27|951|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ origin not known. Metastases  Lymphoret.System tbos of unknown origin to mediastinal ln. Metastases Lung|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-119|27|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-120|27|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-121|27|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-122|27|958|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-123|27|960|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO PARATHYMIC LN.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-124|27|962|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-125|27|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-126|27|965|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF UNKNOWN ORIGIN TO LIVER.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-127|27|966|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-128|27|968|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-129|27|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion of thorax, rib and costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-130|27|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-131|27|977|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-132|27|980|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-133|27|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-134|27|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-135|27|989|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib muscle. Metastases  trac to tracheal wall.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-136|27|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-137|27|1003|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-138|27|1004|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-139|27|1005|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-140|27|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-141|27|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-142|27|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-143|27|1013|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-144|27|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-145|27|1021|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-146|27|1022|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-147|27|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-148|27|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-149|27|1039|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ forearm.Skin|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-150|27|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-151|27|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-152|27|1046|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-153|27|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-154|27|1050|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ shoulder region.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-155|27|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-156|27|1053|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart Metastases Lung|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-157|27|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-158|27|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-159|27|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-160|27|1065|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PT. LN.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-161|27|1067|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-162|27|1071|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-163|27|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-164|27|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-165|27|1085|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-166|27|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-167|27|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-168|27|1091|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-169|27|1093|Other deterministic changes|Whole body|MCDU/   Metastases Liver|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-170|27|1096|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of lumbar vert. Metastases  Muscle tbos of lumbar vert. to muscles of lumbar region.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-171|27|1108|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-172|27|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-173|27|1114|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-174|27|1123|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-175|27|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-176|27|1131|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-177|27|1135|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-178|27|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-179|27|1138|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-180|27|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-181|27|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-182|27|1150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-183|27|1163|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-184|27|1164|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ adjacent to seminal vesicles.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-185|27|1167|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-186|27|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-187|27|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-188|27|1187|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-189|27|1188|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-190|27|1202|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-191|27|1210|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adnexal tissue about kidney. Metastases  Kidney tcvs of adnexal fat and c.t. about kid. to kid.|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-192|27|1216|Other deterministic changes|Whole body|MCDU/  |
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-193|27|1216|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-194|27|1227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-195|27|1245|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-196|27|1268|n/a|n/a|n/a|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-197|27|1272|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tgac to muscles of face.,MPATH: 268 - adenocarcinoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-198|27|1278|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ foreleg.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-199|27|1278|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-27|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 710 ± 13 lifespan study|1003-20-27-200|27|1346|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-1|28|330|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-2|28|472|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-3|28|537|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-4|28|540|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-5|28|543|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-6|28|548|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abdominal fat pads.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-7|28|549|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-8|28|555|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-9|28|562|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-10|28|589|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-11|28|613|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-12|28|639|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-13|28|655|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-14|28|662|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-15|28|668|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-16|28|670|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-17|28|676|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-18|28|712|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWO: TOGC TO PARIETAL PERITONEUM.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-19|28|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-20|28|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-21|28|739|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-22|28|751|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-23|28|754|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-24|28|764|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-25|28|764|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-26|28|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-27|28|785|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinum. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-28|28|785|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-29|28|791|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-30|28|813|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-31|28|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Lung tmrs of thigh metas. to lung.,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-32|28|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-33|28|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-34|28|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-35|28|854|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-36|28|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-37|28|860|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-38|28|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-39|28|877|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-40|28|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-41|28|883|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-42|28|884|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-43|28|891|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-44|28|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-45|28|895|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-46|28|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-47|28|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-48|28|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-49|28|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-50|28|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-51|28|916|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pancreas.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-52|28|920|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-53|28|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-54|28|927|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/ Head neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-55|28|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-56|28|928|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-57|28|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-58|28|930|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-59|28|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-60|28|939|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-61|28|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-62|28|940|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-63|28|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-64|28|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-65|28|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-66|28|964|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases  togc to parietal peritoneum.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-67|28|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-68|28|970|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-69|28|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-70|28|975|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-71|28|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-72|28|981|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-73|28|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-74|28|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-75|28|993|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ colon wall.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-76|28|995|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-77|28|1010|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  Head/neck missing, eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-78|28|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-79|28|1021|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebrae. Metastases  tbos of lumbar vert. to parietal peritoneum. Metastases  Muscle tbos of lumbar vert. to lumbar muscle.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-80|28|1033|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-81|28|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-82|28|1053|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-83|28|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-84|28|1074|n/a|n/a|n/a|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-85|28|1074|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-86|28|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-87|28|1093|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ dorsal pelvis. Metastases  tbos of dorsal pelvis to serosa of ureter. Metastases  Muscle tbos of dorsal pelvis to pelvic muscle.|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-88|28|1113|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-89|28|1115|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-90|28|1120|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-91|28|1131|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-92|28|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-93|28|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-94|28|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-95|28|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-96|28|1153|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-97|28|1181|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-98|28|1220|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-99|28|1293|Other deterministic changes|Whole body|MCDU/  |
1003-20-28|n/a,Y2|1| 194|gamma-rays Co-60|2.68|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 693 ± 18 lifespan study|1003-20-28-100|28|1334|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-1|29|200|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-2|29|204|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF ABDOMEN TO REGIONAL MUSCLE.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-3|29|204|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-4|29|204|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-5|29|204|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-6|29|206|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-7|29|207|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-8|29|207|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-9|29|211|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-10|29|214|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-11|29|215|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-12|29|219|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-13|29|325|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-14|29|325|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-15|29|355|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-16|29|365|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-17|29|368|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-18|29|380|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-19|29|388|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-20|29|391|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-21|29|408|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-22|29|410|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-23|29|411|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-24|29|417|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-25|29|418|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-26|29|422|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-27|29|427|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-28|29|428|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-29|29|435|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWB: TBOS OF PELVIS TO GAST. L.N.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-30|29|441|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-31|29|446|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-32|29|448|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-33|29|451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-34|29|452|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-35|29|456|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWI: TIAC OF JEJUNUM TO PANCREAS.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-36|29|457|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-37|29|463|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-38|29|464|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-39|29|465|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-40|29|470|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-41|29|474|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-42|29|477|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-43|29|479|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-44|29|480|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-45|29|487|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-46|29|488|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF ABDOMEN TO REGIONAL MUSCLE.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-47|29|494|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-48|29|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-49|29|510|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-50|29|516|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-51|29|535|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-52|29|536|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-53|29|538|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-54|29|541|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-55|29|547|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscles of ribcage.,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-56|29|548|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-57|29|558|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-58|29|561|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-59|29|572|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-60|29|579|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-61|29|583|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-62|29|589|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-63|29|592|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-64|29|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-65|29|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-66|29|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-67|29|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-68|29|601|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-69|29|602|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-70|29|603|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-71|29|604|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-72|29|607|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-73|29|610|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-74|29|617|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-75|29|625|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-76|29|626|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-77|29|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-78|29|642|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-79|29|645|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-80|29|647|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-81|29|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlls also included in diagnosis as separate entity.,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-82|29|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-83|29|659|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-84|29|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-85|29|675|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ squamous cell ca of tongue; highly invasive.,MPATH: 446 - squamous cell carcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-86|29|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-87|29|683|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-88|29|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-89|29|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-90|29|694|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-91|29|695|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-92|29|697|Neoplasia unclassified|Other local manifestations and miscellaneus|THWC: TCVS OF LEFT ING. REG. TO LIVER.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-93|29|698|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-94|29|703|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/  Transitional cell,MPATH: 549 - carcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-95|29|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-96|29|712|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-97|29|715|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-98|29|719|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-99|29|726|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-100|29|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-101|29|734|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-102|29|734|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-103|29|735|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-104|29|736|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/  parotid sal.gl.malignant.mixed tumor Metastases txac of sal.gl.to nerve fibers incl.trigem.nerve Metastases Lung txac of sal.gl.to lung Metastases txac of sal.gl.to muscle of lip Metastases Lymphoret.System to cerv. ln.,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-105|29|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-106|29|742|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-107|29|744|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-108|29|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-109|29|748|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-110|29|750|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-111|29|752|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-112|29|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-113|29|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-114|29|771|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-115|29|772|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-116|29|773|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-117|29|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-118|29|773|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Eyes, thorax missing,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-119|29|774|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum. Metastases  tiac of jejunum to pancreas.,MPATH: 218 - neoplasm|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-120|29|778|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ abdomen. Metastases  tcfs of abdomen to regional nerve. Metastases  Muscle tcfs of abdomen to regional muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-121|29|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-122|29|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-123|29|792|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO MUSCLES OF RIBCAGE.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-124|29|793|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-125|29|800|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-126|29|800|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-127|29|801|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-128|29|801|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-129|29|803|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-130|29|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-131|29|809|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-132|29|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-133|29|809|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach, glandular pt.,MPATH: 218 - neoplasm|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-134|29|812|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-135|29|816|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-136|29|823|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-137|29|829|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-138|29|837|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-139|29|839|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-140|29|841|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Head/neck missing, eyes missing|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-141|29|841|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-142|29|844|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-143|29|848|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-144|29|848|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-145|29|854|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-146|29|854|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-147|29|855|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ anal region.Skin Metastases Heart|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-148|29|855|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-149|29|858|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ adnexal tissue surr. kidney.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-150|29|864|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-151|29|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-152|29|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-153|29|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-154|29|889|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-155|29|893|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-156|29|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-157|29|898|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-158|29|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-159|29|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-160|29|898|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-161|29|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-162|29|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-163|29|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-164|29|907|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-165|29|908|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ lft. ing. region. Metastases Liver|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-166|29|916|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-167|29|918|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-168|29|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-169|29|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-170|29|922|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ chest wall.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-171|29|923|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-172|29|924|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-173|29|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-174|29|930|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-175|29|930|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-176|29|932|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-177|29|934|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-178|29|937|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-179|29|938|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-180|29|940|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-181|29|943|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-182|29|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-183|29|946|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-184|29|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-185|29|949|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-186|29|949|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis. Metastases  tbos of pelvis to visc. perit. Metastases Lung Metastases  Lymphoret.System tbos of pelvis to gast. l.n.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-187|29|956|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-188|29|958|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-189|29|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-190|29|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-191|29|967|n/a|n/a|n/a|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-192|29|968|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ mandible.|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-193|29|973|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-194|29|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-195|29|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-196|29|987|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-197|29|994|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-198|29|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-199|29|1018|Other deterministic changes|Whole body|MCDU/  |
1003-20-29|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 492 ± 15 lifespan study|1003-20-29-200|29|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-1|30|218|Other deterministic changes|Whole body|MCDU/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-2|30|369|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-3|30|371|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ rib.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-4|30|371|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-5|30|376|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-6|30|379|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-7|30|382|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle tbos of rib to thoracic muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-8|30|400|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-9|30|411|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-10|30|417|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-11|30|419|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow|MBMZ/  ,MPATH: 127 - atrophy|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-12|30|424|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-13|30|427|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-14|30|443|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-15|30|457|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow|MBMZ/  ,MPATH: 127 - atrophy|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-16|30|466|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-17|30|471|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow|MBMZ/  ,MPATH: 127 - atrophy|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-18|30|494|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-19|30|495|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-20|30|495|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow|MBMZ/  ,MPATH: 127 - atrophy|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-21|30|498|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-22|30|505|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-23|30|506|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/   Metastases  Muscle tmaa to chest muscle.,MPATH: 218 - neoplasm|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-24|30|514|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-25|30|515|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF FEMUR TO THIGH MUSCLE.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-26|30|537|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-27|30|541|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-28|30|541|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-29|30|544|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-30|30|545|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-31|30|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-32|30|567|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-33|30|569|Other deterministic changes|Whole body|MCDU/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-34|30|588|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-35|30|610|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-36|30|620|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-37|30|639|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-38|30|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-39|30|688|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-40|30|688|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ thigh.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-41|30|691|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-42|30|692|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ shoulder. Muscle|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-43|30|695|Other deterministic changes|Whole body|MCDU/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-44|30|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-45|30|711|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: TNNS OF SUBCUTIS OF LEFT AXILLA TO MUSCLE OF LEFT THORAX.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-46|30|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-47|30|719|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWM: TMAA TO CHEST MUSCLE.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-48|30|720|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-49|30|734|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPO/ pylorus.,MPATH: 491 - polyp|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-50|30|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-51|30|740|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE MUSCLE.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-52|30|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-53|30|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-54|30|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-55|30|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-56|30|774|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tbos of femur to thigh muscle.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-57|30|775|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-58|30|779|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-59|30|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-60|30|784|Neoplasia unclassified|Other local manifestations and miscellaneus|THWA: TACC TO LIVER.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-61|30|786|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Liver,MPATH: 549 - carcinoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-62|30|789|Other deterministic changes|Whole body|MCDU/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-63|30|790|Other deterministic changes|Whole body|MCDU/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-64|30|794|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa Metastases Lung|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-65|30|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-66|30|803|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: TNNS OF SUBCUTIS OF LEFT AXILLA TO MUSCLE OF LEFT THORAX.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-67|30|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-68|30|810|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-69|30|813|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-70|30|813|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE MUSCLE.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-71|30|819|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-72|30|820|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-73|30|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-74|30|829|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-75|30|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-76|30|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-77|30|836|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-78|30|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-79|30|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-80|30|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tnns of subcutis of left axilla to muscle of left thorax.,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-81|30|845|n/a|n/a|n/a|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-82|30|847|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO RIB CAGE MUSCLE.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-83|30|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-84|30|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-85|30|866|Other deterministic changes|Whole body|MCDU/  |
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-86|30|871|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-87|30|880|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-88|30|882|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-89|30|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-90|30|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-91|30|891|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-92|30|892|Neoplasia unclassified|Other local manifestations and miscellaneus|THWA: TACC TO LIVER.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-93|30|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-94|30|905|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle trac to rib cage muscle.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-95|30|910|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine.|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-96|30|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-97|30|928|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-98|30|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-99|30|937|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-30|n/a,Y3|1| 194|gamma-rays Co-60|7.88|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 486 ± 18 lifespan study|1003-20-30-100|30|949|Neoplasia malignant|Bloodvessels among cardiovascular system|TPVS/  Pituitary|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-1|31|279|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-2|31|279|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-3|31|311|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-4|31|377|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-5|31|383|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKTC TO LUNG.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-6|31|446|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-7|31|446|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-8|31|505|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-9|31|530|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-10|31|555|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-11|31|600|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ lateral abdomen.,MPATH: 446 - squamous cell carcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-12|31|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-13|31|614|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-14|31|620|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMRS OF GASTROC. MUSC. TO LIVER.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-15|31|621|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-16|31|628|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to bronchial and mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-17|31|642|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-18|31|655|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-19|31|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to sternal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-20|31|668|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System trac to bronchial ln. Metastases Liver Metastases Lung Metastases  Muscle tgac to costal muscle.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-21|31|668|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWM: TMVS OF LUMBAR MUSCLE TO KIDNEY.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-22|31|673|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-23|31|677|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-24|31|677|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-25|31|677|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-26|31|677|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-27|31|677|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-28|31|684|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-29|31|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ is tspl in gross dx.,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-30|31|697|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ gastroc. musc. Metastases Heart,MPATH: 428 - rhabdomyosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-31|31|701|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-32|31|702|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKTC TO LUNG.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-33|31|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-34|31|714|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-35|31|715|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKTC TO LUNG.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-36|31|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-37|31|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-38|31|720|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-39|31|721|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAO TO MUSCLE OF FACE.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-40|31|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-41|31|721|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-42|31|735|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-43|31|741|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-44|31|747|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO STERNAL MUSCLE.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-45|31|748|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-46|31|756|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-47|31|761|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-48|31|761|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-49|31|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-50|31|775|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-51|31|779|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-52|31|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-53|31|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-54|31|789|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-55|31|799|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-56|31|805|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-57|31|805|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-58|31|806|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-59|31|806|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-60|31|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-61|31|810|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-62|31|811|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-63|31|812|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-64|31|813|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-65|31|815|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-66|31|819|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-67|31|820|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWM: TMVS OF LUMBAR MUSCLE TO KIDNEY.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-68|31|820|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region, Head neck missing,MPATH: 491 - polyp|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-69|31|826|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-70|31|827|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-71|31|828|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-72|31|830|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-73|31|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-74|31|838|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-75|31|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-76|31|848|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-77|31|849|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-78|31|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-79|31|855|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-80|31|857|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-81|31|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-82|31|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-83|31|859|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-84|31|860|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-85|31|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-86|31|869|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-87|31|872|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO BRONCHIAL AND MEDIASTINAL LN.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-88|31|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-89|31|875|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-90|31|877|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-91|31|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-92|31|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-93|31|885|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-94|31|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-95|31|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-96|31|901|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-97|31|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-98|31|904|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-99|31|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-100|31|905|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ Trunk missing|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-101|31|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-102|31|915|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-103|31|918|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-104|31|930|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-105|31|932|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-106|31|933|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-107|31|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-108|31|946|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-109|31|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-110|31|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-111|31|950|Neoplasia unclassified|Kidney among urinary system diseases,MA: 0000368 - kidney|TKTC/  Transitional cells Metastases Lung Metastases  trac invasion of vascular structure.,MPATH: 218 - neoplasm|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-112|31|950|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-113|31|952|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-114|31|952|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-115|31|953|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-116|31|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-117|31|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-118|31|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-119|31|957|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ lumbar muscle. Muscle|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-120|31|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-121|31|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-122|31|963|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/    invasion site not specified. Eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-123|31|963|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-124|31|968|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-125|31|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-126|31|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-127|31|977|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-128|31|982|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-129|31|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-130|31|985|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-131|31|990|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tcfs of region of rib cage to parathymic ln. Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-132|31|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-133|31|998|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-134|31|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-135|31|1003|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-136|31|1004|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ s.c. of skin over thigh. Metastases  Muscle tcvs of skin over thigh to muscle of thigh.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-137|31|1006|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-138|31|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-139|31|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-140|31|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-141|31|1013|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-142|31|1017|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-143|31|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-144|31|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-145|31|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-146|31|1022|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-147|31|1024|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-148|31|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-149|31|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-150|31|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-151|31|1034|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-152|31|1037|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-153|31|1039|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-154|31|1044|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tcfs of region of rib cage to sternal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-155|31|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-156|31|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-157|31|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-158|31|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-159|31|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-160|31|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-161|31|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-162|31|1069|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-163|31|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-164|31|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-165|31|1086|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-166|31|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-167|31|1100|n/a|n/a|n/a|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-168|31|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-169|31|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-170|31|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-171|31|1111|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle trac to muscles of rib cage and sternum.,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-172|31|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-173|31|1121|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-174|31|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-175|31|1124|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-176|31|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-177|31|1127|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-178|31|1155|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-179|31|1158|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-180|31|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-181|31|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-182|31|1178|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-183|31|1179|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-184|31|1181|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-185|31|1187|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-186|31|1188|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-187|31|1190|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIC/ unspecified regions.Enteritis chronic,MPATH: 212 - inflammation|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-188|31|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-189|31|1222|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-190|31|1222|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-191|31|1225|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-192|31|1237|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-193|31|1241|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-194|31|1254|Other deterministic changes|Whole body|MCDU/  |
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-195|31|1255|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Kidney tmvs of lumbar muscle to kidney.,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-196|31|1277|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-197|31|1279|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebrae. Metastases  Muscle tbos of lumbar vert. to lumbar muscle. Metastases  GI tract tbos of lumbar vert. to sm. intestines.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-198|31|1289|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-199|31|1289|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tgao to muscle of face.|
1003-20-31|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|193 records survival 635 ± 14 lifespan study|1003-20-31-200|31|1377|Other deterministic changes|Whole body|MCDU/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-1|32|422|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-2|32|460|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-3|32|518|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-4|32|522|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-5|32|543|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-6|32|572|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-7|32|596|Other deterministic changes|Whole body|MCDU/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-8|32|603|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-9|32|624|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-10|32|659|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ spinal muscle.,MPATH: 428 - rhabdomyosarcoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-11|32|685|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-12|32|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to sternal and rib cage muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-13|32|690|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-14|32|695|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-15|32|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-16|32|708|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-17|32|716|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-18|32|719|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-19|32|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-20|32|737|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF FORELEG TO MUSCLE OF FORELEG.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-21|32|737|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-22|32|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-23|32|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-24|32|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-25|32|765|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-26|32|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-27|32|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-28|32|771|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-29|32|785|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF FORELEG TO MUSCLE OF FORELEG.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-30|32|785|Other deterministic changes|Whole body|MCDU/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-31|32|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-32|32|793|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-33|32|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-34|32|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-35|32|804|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-36|32|822|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-37|32|826|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO STERNAL AND RIB CAGE MUSCLES.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-38|32|828|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal,MPATH: 218 - neoplasm|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-39|32|841|Other deterministic changes|Whole body|MCDU/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-40|32|847|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-41|32|851|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-42|32|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-43|32|859|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-44|32|859|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-45|32|862|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBCS/ nose.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-46|32|863|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-47|32|866|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-48|32|877|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-49|32|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-50|32|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-51|32|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-52|32|893|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-53|32|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-54|32|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-55|32|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-56|32|899|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-57|32|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-58|32|906|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sternabrae.|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-59|32|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-60|32|911|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-61|32|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-62|32|919|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-63|32|919|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-64|32|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle tcvs of foreleg to muscle of foreleg.,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-65|32|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-66|32|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-67|32|945|Other deterministic changes|Whole body|MCDU/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-68|32|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-69|32|948|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-70|32|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-71|32|957|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-72|32|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-73|32|963|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-74|32|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-75|32|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-76|32|995|n/a|n/a|n/a|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-77|32|1003|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-78|32|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-79|32|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-80|32|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-81|32|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-82|32|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-83|32|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-84|32|1034|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-85|32|1041|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-86|32|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-87|32|1062|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ abdomen.Skin|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-88|32|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-89|32|1125|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-90|32|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-91|32|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-92|32|1141|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-93|32|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-94|32|1180|Other deterministic changes|Whole body|MCDU/  |
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-95|32|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-96|32|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-97|32|1230|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ neck.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-98|32|1239|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-99|32|1240|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ head, behind ear.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-32|n/a,Z2|1| 287|gamma-rays Co-60|2.68|grays|External exposure| code Z2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 601 ± 18 lifespan study|1003-20-32-100|32|1291|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-1|33|294|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-2|33|404|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-3|33|444|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-4|33|450|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWG: TGAC METAST. SITE NOT IDENTIFIED.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-5|33|456|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-6|33|459|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-7|33|460|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-8|33|474|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-9|33|477|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-10|33|478|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-11|33|484|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-12|33|484|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-13|33|484|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-14|33|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-15|33|499|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE ABOUT ORBIT.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-16|33|500|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO STERNAL MUSCLE.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-17|33|500|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-18|33|513|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-19|33|515|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-20|33|516|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-21|33|522|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-22|33|530|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-23|33|540|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvis. Metastases  Muscle tcvs of pelvis to pelvic muscle.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-24|33|552|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-25|33|554|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-26|33|554|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-27|33|555|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-28|33|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-29|33|568|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-30|33|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-31|33|589|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-32|33|590|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-33|33|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-34|33|596|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-35|33|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-36|33|598|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-37|33|600|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-38|33|600|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-39|33|611|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO STERNAL MUSCLE.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-40|33|614|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-41|33|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-42|33|627|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-43|33|630|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ADJACENT MUSCLE.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-44|33|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-45|33|635|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-46|33|636|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-47|33|646|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-48|33|659|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-49|33|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-50|33|664|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlls & tlxs both dx/lsl., Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-51|33|666|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac to sternum. Metastases  Muscle tgac to adjacent muscle.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-52|33|671|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-53|33|676|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-54|33|691|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-55|33|694|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-56|33|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-57|33|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-58|33|705|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-59|33|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-60|33|708|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-61|33|709|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-62|33|710|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-63|33|711|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-64|33|712|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cod based on gross report only.,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-65|33|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-66|33|717|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-67|33|719|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing, eyes missing,MPATH: 242 - hemangiosarcoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-68|33|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-69|33|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to sternal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-70|33|725|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-71|33|726|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-72|33|729|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-73|33|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-74|33|733|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscles of head and thorax. Metastases Kidney Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-75|33|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-76|33|737|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWG: TGAC METAST. SITE NOT IDENTIFIED.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-77|33|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-78|33|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-79|33|747|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-80|33|749|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-81|33|751|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-82|33|753|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-83|33|762|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWI: TIVS (CECUM) METAST. TO REGIONAL LN.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-84|33|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-85|33|773|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-86|33|774|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-87|33|775|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-88|33|777|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMVS OF CAUDAL MUSCLE TO LUNG.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-89|33|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-90|33|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-91|33|791|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-92|33|792|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-93|33|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-94|33|796|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-95|33|798|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-96|33|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-97|33|806|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ caudal muscle. Muscle Metastases Lung tmvs of caudal muscle to lung.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-98|33|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to sternal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-99|33|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-100|33|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-101|33|819|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-102|33|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-103|33|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-104|33|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-105|33|835|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-106|33|836|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-107|33|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-108|33|844|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-109|33|847|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-110|33|849|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-111|33|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-112|33|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-113|33|862|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ intestine.,MPATH: 218 - neoplasm|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-114|33|863|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-115|33|867|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-116|33|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-117|33|869|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-118|33|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-119|33|873|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-120|33|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-121|33|876|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Heart Metastases Lung|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-122|33|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-123|33|879|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-124|33|880|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCVS OF PELVIS TO PELVIC MUSCLE.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-125|33|885|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-126|33|887|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-127|33|888|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-128|33|890|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-129|33|893|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-130|33|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-131|33|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-132|33|908|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-133|33|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-134|33|913|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-135|33|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-136|33|918|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-137|33|918|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-138|33|918|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-139|33|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-140|33|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-141|33|925|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-142|33|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-143|33|928|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-144|33|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-145|33|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-146|33|941|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-147|33|941|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-148|33|945|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-149|33|947|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-150|33|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-151|33|949|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-152|33|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-153|33|952|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-154|33|953|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-155|33|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-156|33|955|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to diaphragm muscle.,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-157|33|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-158|33|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-159|33|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-160|33|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tgac metast. site not identified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-161|33|965|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-162|33|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-163|33|970|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-164|33|971|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-165|33|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-166|33|974|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/   Metastases  Muscle tgac to muscle about orbit.,MPATH: 1 - cell and tissue damage|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-167|33|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-168|33|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-169|33|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-170|33|981|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-171|33|982|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-172|33|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-173|33|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-174|33|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-175|33|989|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-176|33|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-177|33|1001|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-178|33|1003|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-179|33|1008|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-180|33|1009|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Kidney|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-181|33|1012|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-182|33|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-183|33|1017|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ cecum. Metastases  Lymphoret.System tivs (cecum) metast. to regional ln. Metastases  tivs (cecum) metast. to pancreas.|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-184|33|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-185|33|1038|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-186|33|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-187|33|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-188|33|1051|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ cecum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-189|33|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-190|33|1058|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-191|33|1080|n/a|n/a|n/a|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-192|33|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-193|33|1088|Other deterministic changes|Whole body|MCDU/  |
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-194|33|1088|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-195|33|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-196|33|1098|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-197|33|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-198|33|1128|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-199|33|1132|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-33|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 520 ± 13 lifespan study|1003-20-33-200|33|1251|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-1|34|399|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-2|34|422|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-3|34|435|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-4|34|444|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-5|34|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-6|34|459|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-7|34|465|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-8|34|472|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-9|34|492|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-10|34|522|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-11|34|535|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-12|34|541|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-13|34|554|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-14|34|571|Neoplasia unclassified|Other local manifestations and miscellaneus|THWX: TXUS OF SAL. GLAND. TO LIVER.|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-15|34|584|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-16|34|591|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-17|34|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-18|34|607|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-19|34|622|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-20|34|626|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-21|34|630|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-22|34|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-23|34|641|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-24|34|645|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-25|34|646|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-26|34|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-27|34|657|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ sal. gland.|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-28|34|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-29|34|668|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-30|34|678|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ duodenum.,MPATH: 551 - sarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-31|34|690|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ cerebellum.,MPATH: 551 - sarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-32|34|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-33|34|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-34|34|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-35|34|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-36|34|729|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-37|34|732|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-38|34|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-39|34|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-40|34|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-41|34|773|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-42|34|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-43|34|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-44|34|787|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-45|34|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-46|34|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-47|34|805|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-48|34|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-49|34|814|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ mandible. Metastases Lung|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-50|34|824|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-51|34|826|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-52|34|827|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-53|34|830|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-54|34|835|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ ganglioneuroblastoma abdomen. Metastases  Muscle tnns of abdomen to abdominal skeletal muscle.,MPATH: 437 - neurofibrosarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-55|34|837|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-56|34|838|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: TNNS OF ABDOMEN TO ABDOMINAL SKELETAL MUSCLE.|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-57|34|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-58|34|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-59|34|855|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-60|34|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-61|34|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-62|34|875|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-63|34|883|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-64|34|888|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-65|34|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-66|34|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-67|34|899|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-68|34|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-69|34|907|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-70|34|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-71|34|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-72|34|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-73|34|914|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ muscle of thoracic wall.,MPATH: 428 - rhabdomyosarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-74|34|924|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-75|34|924|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-76|34|926|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-77|34|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-78|34|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-79|34|943|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-80|34|945|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-81|34|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-82|34|949|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-83|34|966|n/a|n/a|n/a|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-84|34|974|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-85|34|975|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-86|34|976|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-87|34|976|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-88|34|976|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF MANDIBLE TO LUNG.|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-89|34|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-90|34|992|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-91|34|1013|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-92|34|1016|Other deterministic changes|Whole body|MCDU/  |
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-93|34|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-94|34|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-34|n/a,Z3|1| 287|gamma-rays Co-60|7.88|grays|External exposure| code Z3 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 498 ± 18 lifespan study|1003-20-34-95|34|1048|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-1|35|180|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-2|35|180|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-3|35|180|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-4|35|180|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-5|35|180|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-6|35|248|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METASTASIS TO LYMPH NODE ASSOCIATED WITH DIAPHRAGM.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-7|35|255|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-8|35|275|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-9|35|297|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-10|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-11|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-12|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-13|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-14|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-15|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-16|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-17|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-18|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-19|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-20|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-21|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-22|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-23|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-24|35|303|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-25|35|310|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ diagnosed grossly ttyl. pnu diagnosed as contributing cod grossly. no lung t found at microscopy.,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-26|35|327|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-27|35|331|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-28|35|333|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-29|35|336|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-30|35|341|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of mandible.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-31|35|350|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-32|35|351|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cod tadn w/hrg contributing.,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-33|35|353|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-34|35|353|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-35|35|353|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-36|35|353|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-37|35|353|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-38|35|359|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-39|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-40|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-41|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-42|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-43|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-44|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-45|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-46|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-47|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-48|35|360|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-49|35|379|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-50|35|386|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-51|35|395|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-52|35|401|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-53|35|402|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-54|35|406|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-55|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-56|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-57|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-58|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-59|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-60|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-61|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-62|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-63|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-64|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-65|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-66|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-67|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-68|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-69|35|417|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-70|35|421|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-71|35|422|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-72|35|442|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWS: TSEC OF SKIN OF NOSE TO BRAIN.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-73|35|444|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-74|35|445|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-75|35|446|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-76|35|458|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-77|35|459|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWS: TSEC OF SKIN OF NOSE TO CERVICAL LN.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-78|35|472|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-79|35|473|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of thigh.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-80|35|474|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-81|35|474|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-82|35|477|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-83|35|480|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-84|35|485|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ chs?,MPATH: 242 - hemangiosarcoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-85|35|489|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ leiomyosarcoma; stomach.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-86|35|502|Other deterministic changes|Whole body|MCDU/ no histology traa/taca(?); cod unknown/jhr.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-87|35|505|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-88|35|506|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-89|35|509|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-90|35|512|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-91|35|516|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-92|35|516|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-93|35|523|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-94|35|523|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-95|35|526|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ jaw.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-96|35|536|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-97|35|544|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-98|35|547|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-99|35|547|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-100|35|550|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-101|35|551|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-102|35|552|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-103|35|556|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-104|35|565|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ thigh. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-105|35|573|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-106|35|573|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-107|35|576|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of pelvis.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-108|35|579|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-109|35|579|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-110|35|580|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-111|35|585|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-112|35|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-113|35|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-114|35|600|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-115|35|610|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-116|35|613|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-117|35|615|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-118|35|620|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-119|35|621|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-120|35|622|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-121|35|622|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-122|35|624|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-123|35|624|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ tadr of gross dx not found.,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-124|35|628|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ base of tail. Metastases  Kidney tcfs of thigh to kidney.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-125|35|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-126|35|639|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-127|35|642|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-128|35|648|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-129|35|651|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-130|35|662|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-131|35|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-132|35|669|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-133|35|676|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-134|35|680|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of femur. Metastases Liver Metastases Lung|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-135|35|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-136|35|687|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-137|35|695|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-138|35|705|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-139|35|709|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-140|35|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-141|35|711|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-142|35|711|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pelvic mass.|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-143|35|721|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-144|35|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-145|35|729|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-146|35|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-147|35|733|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ jejunum.,MPATH: 551 - sarcoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-148|35|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-149|35|740|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-150|35|740|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-151|35|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-152|35|745|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ nose. Metastases  Lung trac metastasis unspecified. Metastases  tsec of skin of nose to brain.,MPATH: 218 - neoplasm|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-153|35|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-154|35|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-155|35|748|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenal/adeno ca.,MPATH: 218 - neoplasm|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-156|35|750|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-157|35|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ lxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-158|35|756|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-159|35|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-160|35|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-161|35|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-162|35|771|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-163|35|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-164|35|780|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-165|35|784|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-166|35|788|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-167|35|805|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-168|35|806|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-169|35|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-170|35|850|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac metastasis to lymph node associated with diaphragm.,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-171|35|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-172|35|852|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-173|35|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-174|35|853|n/a|n/a|n/a|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-175|35|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-176|35|856|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-177|35|869|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-178|35|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-179|35|886|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-180|35|887|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-181|35|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-182|35|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-183|35|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Lymphoret.System tgac to cervical ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-184|35|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-185|35|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-186|35|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-187|35|941|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/   Metastases  Lymphoret.System taps to pancreatic ln. Metastases Lung Metastases Liver|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-188|35|946|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/ stomach, pylorus.Plaque pylorique region,MPATH: 491 - polyp|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-189|35|950|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-190|35|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ lhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-191|35|961|Other deterministic changes|Whole body|MCDU/  |
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-192|35|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Lymphoret.System tsec of skin of nose to cervical ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-193|35|979|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-194|35|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-195|35|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-196|35|1030|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-197|35|1041|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-198|35|1072|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-199|35|1091|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-35|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|151 records survival 546 ± 16 lifespan study|1003-20-35-200|35|1136|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-1|36|110|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-2|36|141|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-3|36|222|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-4|36|222|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-5|36|222|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-6|36|222|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-7|36|222|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-8|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-9|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-10|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-11|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-12|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-13|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-14|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-15|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-16|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-17|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-18|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-19|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-20|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-21|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-22|36|269|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-23|36|276|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-24|36|276|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-25|36|276|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-26|36|276|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-27|36|276|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-28|36|291|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF SKULL TO LUNG.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-29|36|309|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-30|36|311|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-31|36|337|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-32|36|339|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-33|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-34|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-35|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-36|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-37|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-38|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-39|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-40|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-41|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-42|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-43|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-44|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-45|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-46|36|353|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-47|36|360|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-48|36|360|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-49|36|372|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-50|36|375|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-51|36|380|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-52|36|384|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ adenoca of ileum.,MPATH: 218 - neoplasm|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-53|36|394|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-54|36|397|Neoplasia malignant|Other local manifestations and miscellaneus|TCSS/ TCSS/ TCSS/ TCSS/ undifferentiated sarcoma of conn. tissue of anal region.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-55|36|404|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-56|36|408|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-57|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-58|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-59|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-60|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-61|36|411|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ane grossly seen as cod.,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-62|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-63|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-64|36|411|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-65|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-66|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-67|36|411|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-68|36|413|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-69|36|418|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-70|36|424|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-71|36|428|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-72|36|430|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/ region of shoulder.Predominantly ductal,MPATH: 218 - neoplasm|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-73|36|432|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-74|36|435|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-75|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-76|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-77|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-78|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-79|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-80|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-81|36|437|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-82|36|438|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod given as ttyg w/pnc and bdy (thorax) contributing.,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-83|36|439|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-84|36|439|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-85|36|439|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-86|36|441|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-87|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-88|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-89|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-90|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-91|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-92|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-93|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-94|36|444|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-95|36|446|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ basal cell carcinoma (hair follicle?).,MPATH: 446 - squamous cell carcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-96|36|449|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMLS OF FLANK AND SIDE MUSCLE TO LUNG.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-97|36|456|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-98|36|456|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-99|36|459|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-100|36|460|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-101|36|460|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-102|36|460|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-103|36|460|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-104|36|461|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-105|36|467|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-106|36|467|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-107|36|467|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-108|36|467|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-109|36|467|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-110|36|470|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlhl?,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-111|36|481|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ pelvic cavity region.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-112|36|488|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-113|36|488|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-114|36|488|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-115|36|488|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-116|36|493|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-117|36|495|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-118|36|495|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-119|36|495|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-120|36|499|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-121|36|505|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWX: CARCINOMA, ORIGIN UNKNOWN, METAST. TO KID.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-122|36|508|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-123|36|508|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-124|36|517|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cause of death autopsy sheet tadn; summary sheet pnu.,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-125|36|520|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-126|36|522|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-127|36|530|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung tmab from region of shoulder to lung.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-128|36|534|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-129|36|535|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-130|36|543|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-131|36|544|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-132|36|544|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-133|36|544|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-134|36|544|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-135|36|544|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ muscle tumor unidentified region of flank and side. Metastases Lung tmls of flank and side muscle to lung.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-136|36|544|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-137|36|545|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ brain.,MPATH: 551 - sarcoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-138|36|550|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-139|36|551|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-140|36|551|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-141|36|551|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-142|36|569|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-143|36|572|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-144|36|574|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCSS OF CONN. TISS. OF ANAL REGION TO LUNG.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-145|36|575|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-146|36|579|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-147|36|580|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-148|36|588|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-149|36|595|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWX: CARCINOMA, ORIGIN UNKNOWN, METAST. TO KID.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-150|36|598|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases Lung tmab to lung. Metastases  Muscle tmab to adjacent muscle.,MPATH: 218 - neoplasm|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-151|36|598|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-152|36|609|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-153|36|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lung carcinoma, origin unknown, metast. to lung. Metastases  Kidney carcinoma, origin unknown, metast. to kid.,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-154|36|617|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-155|36|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-156|36|646|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-157|36|647|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-158|36|648|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-159|36|653|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-160|36|655|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-161|36|656|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ scapula.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-162|36|658|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWC: TCSS OF CONN. TISS. OF ANAL REGION TO LUNG.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-163|36|659|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-164|36|660|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-165|36|665|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-166|36|668|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute Metastases  Kidney tmab to kidney.,MPATH: 212 - inflammation|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-167|36|672|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-168|36|673|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-169|36|689|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-170|36|694|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-171|36|698|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-172|36|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-173|36|706|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOAC/   Metastases Kidney Metastases Liver,MPATH: 218 - neoplasm|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-174|36|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-175|36|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-176|36|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-177|36|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-178|36|715|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-179|36|723|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-180|36|731|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-181|36|732|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWM: TMAB TO KIDNEY.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-182|36|749|n/a|n/a|n/a|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-183|36|754|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-184|36|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-185|36|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-186|36|778|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-187|36|779|Other deterministic changes|Whole body|MCDU/  |
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-188|36|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-189|36|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-190|36|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-191|36|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-192|36|814|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine. Metastases  Kidney tbos of lumbar spine to kidney.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-193|36|835|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ origin leg.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-194|36|848|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-195|36|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-196|36|897|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvic region.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-197|36|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-198|36|903|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ maxilla.|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-199|36|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-36|n/a,AI|1| 100|neutrons fission|2.4|grays|External exposure| code AI 72 fractions 15 m 3/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|108 records survival 505 ± 15 lifespan study|1003-20-36-200|36|978|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-1|37|106|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-2|37|106|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-3|37|106|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-4|37|106|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-5|37|106|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-6|37|109|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-7|37|146|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-8|37|146|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-9|37|146|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-10|37|146|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-11|37|146|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-12|37|166|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-13|37|195|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-14|37|195|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-15|37|195|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-16|37|195|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-17|37|195|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-18|37|213|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-19|37|229|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-20|37|229|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-21|37|229|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-22|37|229|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-23|37|229|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-24|37|232|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWS: TSFS OF UPPER THORACIC REGION TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-25|37|296|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-26|37|296|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-27|37|296|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-28|37|296|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-29|37|296|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-30|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-31|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-32|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-33|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-34|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-35|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-36|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-37|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-38|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-39|37|303|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-40|37|306|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ notes do not suggest thymic origin. quote from summary sheet "lymphocytic leu fairly well differentiated".,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-41|37|316|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-42|37|353|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-43|37|358|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-44|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-45|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-46|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-47|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-48|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-49|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-50|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-51|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-52|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-53|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-54|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-55|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-56|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-57|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-58|37|360|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-59|37|364|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-60|37|372|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-61|37|380|Other deterministic changes|Whole body|MCDU/ cod unknown/jhr.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-62|37|382|Neoplasia malignant|Endocrine system|TGAC/ cod at gross thgl.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-63|37|394|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ diaphragm.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-64|37|394|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-65|37|397|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-66|37|401|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-67|37|403|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-68|37|403|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-69|37|403|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-70|37|403|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-71|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-72|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-73|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-74|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-75|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-76|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-77|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-78|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-79|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-80|37|417|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-81|37|418|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-82|37|418|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-83|37|431|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-84|37|435|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-85|37|438|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-86|37|446|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cod tadn w/bdy (thorax); check liver masses. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-87|37|449|Other deterministic changes|Whole body|MCDU/ "mediastinal hemorrhage; source or course not found"/rjmf.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-88|37|453|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-89|37|453|Other deterministic changes|Whole body|MCDU/ /jhr|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-90|37|454|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-91|37|458|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-92|37|460|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestion|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-93|37|460|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-94|37|462|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-95|37|462|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-96|37|467|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-97|37|468|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-98|37|483|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-99|37|485|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-100|37|487|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ omentum.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-101|37|488|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-102|37|489|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-103|37|494|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-104|37|495|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-105|37|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-106|37|505|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-107|37|508|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-108|37|519|Neoplasia unclassified|Other local manifestations and miscellaneus|TIWT: TTAC METAST. TO ABDOM. LN.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-109|37|523|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-110|37|528|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-111|37|534|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-112|37|537|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-113|37|539|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-114|37|548|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-115|37|548|Neoplasia malignant|Reproductive system,MA: 0000411 - testis|TTAC/  Carcinoma Metastases  GI tract ttac metast. to abdom. ln. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-116|37|550|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-117|37|552|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-118|37|554|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ vascular t.; site? ; tcvs:/lsl.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-119|37|557|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-120|37|564|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-121|37|569|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-122|37|584|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-123|37|589|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-124|37|597|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-125|37|601|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-126|37|605|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-127|37|608|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-128|37|608|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ back.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-129|37|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-130|37|611|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitisHead/neck missing,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-131|37|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-132|37|622|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-133|37|626|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ top of skull.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-134|37|627|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ skin of tail.Skin|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-135|37|630|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-136|37|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-137|37|648|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-138|37|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-139|37|655|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-140|37|660|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-141|37|660|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-142|37|666|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-143|37|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-144|37|670|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-145|37|674|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-146|37|677|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-147|37|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-148|37|681|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-149|37|683|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln. Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-150|37|687|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-151|37|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-152|37|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-153|37|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-154|37|701|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ shoulder area.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-155|37|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-156|37|707|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-157|37|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-158|37|714|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ ribs. Metastases Lung Metastases  Lymphoret.System tbos of ribs to mediastinal ln. Metastases Liver|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-159|37|718|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-160|37|721|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-161|37|730|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-162|37|734|Neoplasia malignant|Other local manifestations and miscellaneus|TDLS/  Urinary bladder|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-163|37|740|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-164|37|749|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-165|37|752|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-166|37|754|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver,MPATH: 549 - carcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-167|37|759|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-168|37|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-169|37|768|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-170|37|768|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ leg. Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-171|37|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-172|37|778|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ upper thoracic region. Metastases Lung,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-173|37|779|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-174|37|782|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-175|37|784|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-176|37|794|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/  ,MPATH: 549 - carcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-177|37|796|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-178|37|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-179|37|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-180|37|806|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-181|37|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-182|37|815|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-183|37|816|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-184|37|816|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-185|37|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-186|37|841|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-187|37|845|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-188|37|848|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-189|37|865|Other deterministic changes|Whole body|MCDU/  |
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-190|37|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-191|37|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-192|37|883|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-193|37|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-194|37|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-195|37|918|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-196|37|936|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Kidney|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-197|37|937|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-198|37|950|n/a|n/a|n/a|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-199|37|962|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-37|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|134 records survival 518 ± 16 lifespan study|1003-20-37-200|37|972|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-1|38|106|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-2|38|106|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-3|38|106|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-4|38|106|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-5|38|106|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-6|38|115|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-7|38|115|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-8|38|115|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-9|38|115|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-10|38|115|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-11|38|171|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-12|38|183|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-13|38|204|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-14|38|277|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-15|38|290|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ diagnosed as ttyg grossly (with note "non thy"); one sheet says cod tllb. diagnosis thymic lymphoma, lymphocytic, leukemic.,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-16|38|297|Other deterministic changes|Whole body|MCDU/ grossly cod ascribed to tmgl on autopsy sheet, on summary sheet ulc. cod unknown.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-17|38|304|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-18|38|314|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-19|38|332|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-20|38|346|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ no histology. tvas on autopsy sheet - on rjmf diagnostic sheet not mentioned.,MPATH: 242 - hemangiosarcoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-21|38|346|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ cod given as tchs.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-22|38|347|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-23|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-24|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-25|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-26|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-27|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-28|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-29|38|355|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-30|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-31|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-32|38|355|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-33|38|362|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-34|38|379|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-35|38|380|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-36|38|380|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-37|38|381|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of throat.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-38|38|390|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ cod at autopsy carcinoma or tshf.,MPATH: 446 - squamous cell carcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-39|38|393|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-40|38|394|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ taca?,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-41|38|399|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-42|38|404|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-43|38|404|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-44|38|404|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-45|38|404|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-46|38|404|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-47|38|411|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-48|38|411|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-49|38|411|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-50|38|411|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tove not diagnosed.,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-51|38|411|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-52|38|415|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-53|38|418|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-54|38|431|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-55|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-56|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-57|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-58|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-59|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-60|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-61|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-62|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-63|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-64|38|432|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-65|38|435|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-66|38|437|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-67|38|439|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-68|38|450|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-69|38|456|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-70|38|458|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-71|38|460|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-72|38|460|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ adrenal (?) tumor not found; probably tlls., Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-73|38|460|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-74|38|460|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-75|38|460|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-76|38|465|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ peritonitis.,MPATH: 213 - acute inflammation|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-77|38|467|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-78|38|467|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-79|38|467|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-80|38|467|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-81|38|467|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-82|38|470|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-83|38|471|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ suspect metastasis but tissue of lung (main?) not saved? jhr.,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-84|38|477|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-85|38|479|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-86|38|481|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-87|38|484|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-88|38|488|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-89|38|488|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-90|38|488|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-91|38|488|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-92|38|495|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-93|38|495|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-94|38|495|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-95|38|498|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region of thigh.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-96|38|501|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-97|38|505|Other deterministic changes|Whole body|MCDU/ Eyes missing|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-98|38|507|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-99|38|509|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-100|38|510|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-101|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-102|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-103|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-104|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-105|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-106|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-107|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-108|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-109|38|516|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-110|38|519|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-111|38|523|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-112|38|523|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-113|38|523|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-114|38|523|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-115|38|534|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-116|38|545|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-117|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-118|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-119|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-120|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-121|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-122|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-123|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-124|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-125|38|551|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-126|38|556|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pancreas; vascular tumor.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-127|38|565|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-128|38|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-129|38|569|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-130|38|569|Neoplasia malignant|Bloodvessels among cardiovascular system|TLVS/ mesenteric ln. Lymphoret.tissue|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-131|38|572|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-132|38|572|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-133|38|580|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-134|38|588|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-135|38|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tllb/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-136|38|596|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-137|38|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-138|38|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-139|38|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ "class as leukemic leukemia"/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-140|38|602|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-141|38|603|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-142|38|607|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-143|38|610|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-144|38|611|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-145|38|612|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-146|38|613|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TYRS/  Heart Metastases Lung,MPATH: 428 - rhabdomyosarcoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-147|38|617|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-148|38|620|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-149|38|623|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-150|38|625|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of base of tail.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-151|38|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-152|38|632|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-153|38|644|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-154|38|646|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-155|38|648|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|TBFS/ skull.,MPATH: 551 - sarcoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-156|38|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-157|38|648|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-158|38|651|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-159|38|656|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-160|38|657|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of neck.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-161|38|675|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-162|38|681|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-163|38|687|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-164|38|688|Other deterministic changes|Whole body|MCDU/   Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-165|38|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-166|38|697|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-167|38|697|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-168|38|697|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-169|38|699|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-170|38|704|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-171|38|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-172|38|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-173|38|710|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-174|38|715|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-175|38|717|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-176|38|719|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-177|38|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-178|38|725|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/ heart angiosarcoma.Heart|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-179|38|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-180|38|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-181|38|733|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-182|38|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-183|38|749|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-184|38|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-185|38|770|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-186|38|771|n/a|n/a|n/a|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-187|38|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-188|38|778|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-189|38|779|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-190|38|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-191|38|784|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-192|38|788|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ colon.,MPATH: 549 - carcinoma|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-193|38|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-194|38|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-195|38|803|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ foreleg, shoulder.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-196|38|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlhs/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-197|38|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlxs/jhr. Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-198|38|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-199|38|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-38|n/a,BI|1| 100|neutrons fission|2.4|grays|External exposure| code BI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|121 records survival 499 ± 13 lifespan study|1003-20-38-200|38|913|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-1|39|125|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-2|39|131|Neoplasia unclassified|Other local manifestations and miscellaneus|THWS: TSFS OF CHEST TO LIVER.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-3|39|274|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-4|39|284|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-5|39|314|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-6|39|341|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-7|39|365|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-8|39|397|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ gross cod tadn; gross lesions in liver & heart; diagnosis unknown histologicaly.,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-9|39|408|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-10|39|421|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-11|39|439|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-12|39|456|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-13|39|456|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-14|39|456|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-15|39|456|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-16|39|456|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-17|39|458|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-18|39|458|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-19|39|458|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-20|39|458|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-21|39|458|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-22|39|460|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-23|39|464|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-24|39|464|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-25|39|464|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-26|39|464|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-27|39|464|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-28|39|471|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ taca,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-29|39|476|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-30|39|483|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-31|39|486|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-32|39|493|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-33|39|495|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-34|39|499|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-35|39|507|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-36|39|507|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-37|39|507|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-38|39|507|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-39|39|507|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-40|39|513|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-41|39|513|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-42|39|513|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-43|39|513|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-44|39|513|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-45|39|514|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-46|39|520|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-47|39|520|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-48|39|520|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-49|39|520|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-50|39|520|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-51|39|528|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-52|39|530|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-53|39|545|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-54|39|547|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-55|39|550|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-56|39|552|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-57|39|558|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-58|39|562|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-59|39|576|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-60|39|576|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-61|39|576|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-62|39|576|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-63|39|576|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-64|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-65|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-66|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-67|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-68|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-69|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-70|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-71|39|577|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-72|39|581|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-73|39|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-74|39|603|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-75|39|613|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-76|39|619|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-77|39|620|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ original statement rct; unclassified but final dx tlhs/lsl.  jhr original dx tlxs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-78|39|620|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWS: TSEC OF FACE TO LUNG.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-79|39|624|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-80|39|631|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ tefs/lsl.,MPATH: 242 - hemangiosarcoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-81|39|637|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-82|39|637|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-83|39|637|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWS: TSEC OF FACE TO LUNG.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-84|39|640|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-85|39|643|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ gross diagnosis.,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-86|39|645|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-87|39|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-88|39|654|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-89|39|658|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/   Metastases Lung,MPATH: 242 - hemangiosarcoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-90|39|659|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-91|39|662|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-92|39|663|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-93|39|673|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-94|39|673|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-95|39|673|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  Muscle tkac to loin muscle.,MPATH: 549 - carcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-96|39|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-97|39|683|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-98|39|685|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-99|39|687|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-100|39|692|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-101|39|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-102|39|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-103|39|709|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-104|39|714|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-105|39|715|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-106|39|720|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-107|39|726|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ chest. Metastases  Muscle tsfs of chest to regional muscle. Metastases Lung Metastases Liver Metastases Heart,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-108|39|726|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ face.,MPATH: 218 - neoplasm|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-109|39|733|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-110|39|734|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-111|39|735|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-112|39|737|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-113|39|740|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-114|39|740|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-115|39|740|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-116|39|740|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-117|39|740|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-118|39|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-119|39|744|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-120|39|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-121|39|753|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ with vascular tumor bolus/lsl.,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-122|39|758|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ muscle unidentified. Muscle|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-123|39|765|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-124|39|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-125|39|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Thorax missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-126|39|782|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-127|39|789|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-128|39|789|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-129|39|790|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-130|39|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-131|39|796|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-132|39|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-133|39|805|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-134|39|813|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-135|39|818|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-136|39|818|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-137|39|820|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-138|39|824|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-139|39|837|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ chest wall.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-140|39|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-141|39|841|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-142|39|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-143|39|845|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-144|39|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tcec.,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-145|39|846|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver Metastases LungEye(s) missing Head/neck missing,MPATH: 549 - carcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-146|39|849|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-147|39|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-148|39|851|Neoplasia unclassified|Other local manifestations and miscellaneus|THWS: TSFS OF CHEST TO LIVER.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-149|39|851|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-150|39|864|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-151|39|865|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ pelvic region. Muscle|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-152|39|867|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-153|39|872|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-154|39|876|n/a|n/a|n/a|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-155|39|879|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-156|39|879|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-157|39|880|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-158|39|885|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-159|39|891|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-160|39|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-161|39|897|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-162|39|897|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-163|39|898|Neoplasia malignant|Reproductive system|TTGC/   Metastases  Muscle ttgc to diaphragm muscle. Metastases  Lymphoret.System ttgc to renal ln. Metastases Lung|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-164|39|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-165|39|901|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-166|39|903|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-167|39|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-168|39|903|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ anal region blockage.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-169|39|911|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-170|39|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-171|39|918|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-172|39|919|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-173|39|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-174|39|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-175|39|943|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-176|39|948|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ auricle of heart.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-177|39|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-178|39|963|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-179|39|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-180|39|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-181|39|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-182|39|977|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-183|39|987|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-184|39|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-185|39|999|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCA/ abscesses (includes seminal vesicle and cowper's gland).Cystitis|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-186|39|1001|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-187|39|1015|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-188|39|1018|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-189|39|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-190|39|1023|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-191|39|1030|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-192|39|1034|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-193|39|1067|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-194|39|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-195|39|1089|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-196|39|1101|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-197|39|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-198|39|1121|Other deterministic changes|Whole body|MCDU/  |
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-199|39|1153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-39|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 544 ± 14 lifespan study|1003-20-39-200|39|1223|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-1|40|139|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-2|40|139|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-3|40|139|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-4|40|139|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-5|40|139|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-6|40|185|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-7|40|185|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-8|40|185|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-9|40|185|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-10|40|185|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-11|40|229|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-12|40|229|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-13|40|229|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-14|40|229|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-15|40|229|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-16|40|277|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-17|40|277|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-18|40|277|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-19|40|277|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-20|40|277|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-21|40|394|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-22|40|396|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cod taca (tadn).,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-23|40|430|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-24|40|442|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWH: THAC TO RENAL LN.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-25|40|444|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-26|40|453|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAC/   Metastases  Lymphoret.System tmac metast. to cervical ln.,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-27|40|463|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-28|40|467|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-29|40|507|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-30|40|520|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-31|40|528|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ cod variously pnu & hep w/rcs contributing.acute,MPATH: 212 - inflammation|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-32|40|548|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-33|40|550|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-34|40|551|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-35|40|555|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Lymphoret.System thac to renal ln.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-36|40|558|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-37|40|561|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-38|40|570|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-39|40|571|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-40|40|576|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-41|40|587|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-42|40|588|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-43|40|599|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWG: TGAC TO BRAIN.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-44|40|607|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-45|40|611|Neoplasia benign|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXFA/ fibroadenoma of jaw; probably indirectly cod by starvation.,MPATH: 266 - fibroadenoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-46|40|613|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-47|40|613|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-48|40|613|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-49|40|615|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF FEMUR TO LIVER.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-50|40|617|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWA: TACC TO LUNG.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-51|40|626|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-52|40|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-53|40|646|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-54|40|649|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-55|40|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-56|40|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-57|40|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-58|40|666|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-59|40|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-60|40|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-61|40|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ dx tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-62|40|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-63|40|669|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  tuac to visceral pleura. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-64|40|670|Neoplasia unclassified|Central nervous system among nervous system|TNAS/ Eyes missing|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-65|40|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-66|40|673|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of pelvis. Muscle|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-67|40|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-68|40|675|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-69|40|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ dx/jhr & rjmf; tlhs/lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-70|40|683|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-71|40|684|Other deterministic changes|Whole body|MCDU/   Metastases Heart|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-72|40|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-73|40|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-74|40|691|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-75|40|692|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-76|40|696|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-77|40|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-78|40|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-79|40|717|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-80|40|718|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ trac tissue lost.,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-81|40|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ dx/lsl; tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-82|40|725|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-83|40|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-84|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-85|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-86|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-87|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-88|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-89|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-90|40|726|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-91|40|731|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  tgac to pleura.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-92|40|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-93|40|733|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-94|40|733|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-95|40|733|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-96|40|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-97|40|733|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-98|40|733|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-99|40|733|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-100|40|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-101|40|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-102|40|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-103|40|747|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ origin unknown but in pelvic region.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-104|40|747|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-105|40|750|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/ Head neck missing|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-106|40|750|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-107|40|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-108|40|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-109|40|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-110|40|756|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac to brain. Metastases Lung|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-111|40|757|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-112|40|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ gross dx tute is tlhs., Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-113|40|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-114|40|770|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-115|40|772|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-116|40|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-117|40|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-118|40|776|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-119|40|778|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-120|40|778|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-121|40|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-122|40|782|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-123|40|789|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar region.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-124|40|792|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-125|40|794|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-126|40|795|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-127|40|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-128|40|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-129|40|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung tmac metast. to lung; wbc indic. of infectious disease.,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-130|40|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-131|40|805|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-132|40|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tliv of gross dx not identified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-133|40|809|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-134|40|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-135|40|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-136|40|833|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-137|40|833|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-138|40|836|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-139|40|837|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-140|40|838|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-141|40|838|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ small intestine.,MPATH: 218 - neoplasm|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-142|40|838|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-143|40|845|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-144|40|845|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-145|40|847|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-146|40|848|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis or femur?|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-147|40|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-148|40|855|n/a|n/a|n/a|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-149|40|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-150|40|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ plasma cell sarc./lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-151|40|859|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-152|40|859|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-153|40|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-154|40|864|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pancreatic area and pelvic area.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-155|40|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-156|40|869|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ dorsal spine.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-157|40|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-158|40|870|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-159|40|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-160|40|883|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Liver Metastases Lung|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-161|40|885|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-162|40|896|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ probably spine. Metastases Liver|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-163|40|901|Neoplasia unclassified|Central nervous system among nervous system|TNNB/ ependymoma.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-164|40|907|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases  Lymphoret.System tbos of femur to mediastinal ln. Metastases Lung|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-165|40|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-166|40|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-167|40|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-168|40|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-169|40|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-170|40|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-171|40|936|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-172|40|950|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-173|40|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-174|40|967|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-175|40|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-176|40|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-177|40|969|Other deterministic changes|Whole body|MCDU/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-178|40|969|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ sm. int. t missed.,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-179|40|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-180|40|984|Other deterministic changes|Whole body|MCDU/ cod possibly mbmz and mspz.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-181|40|989|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-182|40|1003|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-183|40|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-184|40|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-185|40|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-186|40|1027|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-187|40|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-188|40|1051|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-189|40|1053|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ region of parotid gland.|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-190|40|1056|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-191|40|1060|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-192|40|1063|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ region of prepuce.Skin|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-193|40|1066|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-194|40|1074|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-195|40|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-196|40|1101|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-197|40|1145|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-198|40|1154|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-199|40|1163|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-40|n/a,EI|1| 100|neutrons fission|2.4|grays|External exposure| code DI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|128 records survival 495 ± 12 lifespan study|1003-20-40-200|40|1197|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ rectal prolapse (+ vagina).Enteritis acute,MPATH: 212 - inflammation|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-1|41|225|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-2|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-3|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-4|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-5|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-6|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-7|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-8|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-9|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-10|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-11|41|296|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-12|41|303|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-13|41|303|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-14|41|303|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-15|41|303|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-16|41|303|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-17|41|311|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-18|41|311|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-19|41|311|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-20|41|311|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-21|41|311|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-22|41|324|Neoplasia unclassified|Other local manifestations and miscellaneus|THWG: TGAC TO LIVER.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-23|41|326|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-24|41|327|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ gross cod dx ttyg.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-25|41|352|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ on summary sheet cod grossly taca w/hrg contributing. on autopsy sheet only hrg.,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-26|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-27|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-28|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-29|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-30|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-31|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-32|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-33|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-34|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-35|41|353|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-36|41|360|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-37|41|360|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-38|41|360|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-39|41|360|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-40|41|360|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-41|41|362|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-42|41|366|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ at autopsy contributing cods were given as hnp and poo.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-43|41|369|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-44|41|386|Other deterministic changes|Whole body|MCDU/ no mention on rjmf's diagnosis of ttst.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-45|41|389|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-46|41|397|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ autopsy diagnosis tadn.,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-47|41|410|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-48|41|410|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-49|41|410|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-50|41|410|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-51|41|410|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-52|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-53|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-54|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-55|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-56|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-57|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-58|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-59|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-60|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-61|41|417|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-62|41|432|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-63|41|432|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod pnc gross dx ttyl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-64|41|437|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ttyg?,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-65|41|439|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region of pelvis.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-66|41|441|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-67|41|446|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-68|41|446|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ cod at autopsy pulmonary tadn (taca).,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-69|41|448|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-70|41|449|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-71|41|450|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC METAST. TO AXILLARY LN.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-72|41|454|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-73|41|462|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-74|41|467|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-75|41|470|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-76|41|470|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-77|41|471|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-78|41|474|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ gross dx cod tadn.,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-79|41|478|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ttyg? rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-80|41|481|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-81|41|481|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-82|41|485|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-83|41|486|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-84|41|488|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWI: TIPL TO ADJACENT GASTRIC LN.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-85|41|488|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-86|41|495|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Muscle trac to costal muscle.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-87|41|499|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-88|41|501|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-89|41|509|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-90|41|515|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/ transitional cell ca of bladder or ureter.Transitional cell Metastases  Muscle tdtc of bladder or ureter to diaphragm.,MPATH: 549 - carcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-91|41|522|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-92|41|522|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-93|41|526|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-94|41|526|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWX: TXLS OF UNKNOWN ORIGIN TO KIDNEY.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-95|41|526|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-96|41|530|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac metast. to axillary ln.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-97|41|533|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-98|41|537|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ mixed tumor of salivary gland.,MPATH: 218 - neoplasm|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-99|41|551|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-100|41|556|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-101|41|561|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-102|41|562|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-103|41|574|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-104|41|575|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-105|41|577|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-106|41|579|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-107|41|582|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-108|41|582|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac metast. to various parts; eyes, head, etc. involved. Metastases Liver|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-109|41|586|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-110|41|589|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-111|41|602|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-112|41|603|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-113|41|605|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-114|41|606|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-115|41|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-116|41|608|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-117|41|613|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-118|41|614|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-119|41|614|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-120|41|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-121|41|619|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-122|41|628|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-123|41|640|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-124|41|641|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-125|41|645|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-126|41|646|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-127|41|650|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-128|41|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-129|41|656|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-130|41|658|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-131|41|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-132|41|668|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ vascular tumor of cowper's gland. Metastases  Kidney txls of unknown origin to kidney. Metastases  txls of unknown origin to adjacent muscle.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-133|41|671|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-134|41|681|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-135|41|686|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWI: TIPL TO ADJACENT GASTRIC LN.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-136|41|687|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-137|41|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-138|41|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-139|41|698|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-140|41|705|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-141|41|707|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-142|41|708|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-143|41|715|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-144|41|716|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-145|41|717|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ pelvic region.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-146|41|724|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ lung not found; dx - obviously trac cod.,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-147|41|725|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-148|41|725|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-149|41|726|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-150|41|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-151|41|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-152|41|737|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pelvic area exact origin unknown.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-153|41|739|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-154|41|739|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-155|41|740|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-156|41|740|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-157|41|746|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-158|41|757|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-159|41|760|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ origin testes or prostate r; gi tract most likely.,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-160|41|762|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-161|41|763|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-162|41|765|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ sarcoma along spine unclassified.,MPATH: 218 - neoplasm|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-163|41|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-164|41|776|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-165|41|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-166|41|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-167|41|793|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-168|41|800|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-169|41|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-170|41|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-171|41|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlxs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-172|41|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-173|41|816|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-174|41|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-175|41|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-176|41|826|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-177|41|832|Other deterministic changes|Whole body|MCDU/   Metastases  Lymphoret.System tiac of stomach to gastric ln.|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-178|41|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-179|41|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-180|41|840|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-181|41|852|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-182|41|859|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-183|41|872|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-184|41|873|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-185|41|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-186|41|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-187|41|901|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-188|41|904|Other deterministic changes|Whole body|MCDU/  |
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-189|41|911|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-190|41|911|n/a|n/a|n/a|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-191|41|926|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region Metastases  Lymphoret.System tipl to adjacent gastric ln.,MPATH: 491 - polyp|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-192|41|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-193|41|935|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ ileum.,MPATH: 549 - carcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-194|41|950|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-195|41|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-196|41|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-197|41|1010|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-198|41|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-199|41|1025|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-41|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 572 ± 14 lifespan study|1003-20-41-200|41|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-1|42|130|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWM: TMAB TO KIDNEY.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-2|42|135|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-3|42|135|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-4|42|139|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-5|42|139|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-6|42|139|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-7|42|139|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-8|42|139|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-9|42|177|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-10|42|180|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLES OF THE HEAD.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-11|42|184|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-12|42|213|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ diagnosed grossly as ttyg; pnf(?).,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-13|42|253|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/ cod at autopsy tute.  quote from micro-exam of autopsy sheet "hemangiosarcoma of uterine wall pliomorphism.  areas of fibroblastic proliferation. area,MPATH: 242 - hemangiosarcoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-14|42|298|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWB: TBOS OF TIBIA WITH AN AORTA EXTENSION.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-15|42|305|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-16|42|316|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-17|42|327|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine. Metastases  Muscle tbos of lumbar spine to local skeletal muscle.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-18|42|334|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-19|42|348|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-20|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-21|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-22|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-23|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-24|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-25|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-26|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-27|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-28|42|355|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-29|42|369|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-30|42|383|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases Lung tmab to lung.,MPATH: 218 - neoplasm|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-31|42|394|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/  ,MPATH: 218 - neoplasm|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-32|42|395|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-33|42|403|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-34|42|404|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-35|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-36|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-37|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-38|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-39|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-40|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-41|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-42|42|411|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-43|42|419|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWB: TBOS OF TIBIA WITH AN AORTA EXTENSION.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-44|42|421|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-45|42|425|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-46|42|432|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-47|42|432|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-48|42|432|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-49|42|432|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-50|42|432|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-51|42|439|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-52|42|439|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-53|42|439|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-54|42|439|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-55|42|439|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-56|42|442|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-57|42|444|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ cod tvas; tumor origin uncertain but probably muscle. Muscle|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-58|42|446|Other deterministic changes|Whole body|MCDU/   Metastases  Kidney tmab to kidney.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-59|42|446|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-60|42|446|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of thigh.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-61|42|454|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-62|42|456|Other deterministic changes|Lower respiratory system|MPNC/ autopsy cod pnc and contributing mky (thorax).Lung congestion|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-63|42|459|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of forearm. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-64|42|459|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-65|42|460|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-66|42|460|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-67|42|460|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-68|42|460|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-69|42|460|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-70|42|460|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-71|42|465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-72|42|467|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-73|42|467|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-74|42|467|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-75|42|467|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-76|42|476|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-77|42|484|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-78|42|487|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-79|42|487|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-80|42|492|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-81|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-82|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-83|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-84|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-85|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-86|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-87|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-88|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-89|42|495|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-90|42|495|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-91|42|499|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-92|42|513|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-93|42|513|Other deterministic changes|Whole body|MCDU/ cod unknown; tumor noted grossly but not histologically.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-94|42|515|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-95|42|516|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-96|42|516|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-97|42|516|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-98|42|516|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-99|42|516|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-100|42|517|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-101|42|519|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWX: TXEC OF NARES TO BRAIN.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-102|42|522|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-103|42|522|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestion|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-104|42|522|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-105|42|523|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-106|42|523|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-107|42|523|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-108|42|523|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-109|42|527|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-110|42|530|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-111|42|536|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ type b.,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-112|42|537|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ aca.,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-113|42|540|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-114|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-115|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-116|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-117|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-118|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-119|42|544|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-120|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-121|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-122|42|544|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-123|42|548|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-124|42|549|Neoplasia unclassified|Central nervous system among nervous system|TNAS/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-125|42|551|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-126|42|551|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-127|42|555|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-128|42|556|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-129|42|557|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-130|42|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-131|42|561|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-132|42|562|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-133|42|563|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-134|42|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ trcb/rjmf; tlus/lsl., Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-135|42|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tkac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-136|42|565|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of lumbar spine. Metastases  Lymphoret.System tbos of lumbar spine to intestinal ln.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-137|42|572|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-138|42|575|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-139|42|579|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/ acute metritis.Metritis|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-140|42|579|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-141|42|589|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/ Head neck missing|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-142|42|590|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-143|42|593|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-144|42|602|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR SPINE TO LOCAL SKELETAL MUSCLE.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-145|42|615|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-146|42|627|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-147|42|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-148|42|638|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBCS/ femur.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-149|42|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-150|42|645|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-151|42|645|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-152|42|649|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWB: TBOS OF LUMBAR SPINE TO INTESTINAL LN.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-153|42|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-154|42|654|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-155|42|658|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-156|42|664|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-157|42|665|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-158|42|665|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-159|42|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-160|42|675|Neoplasia unclassified|Central nervous system among nervous system|TNXS/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-161|42|675|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-162|42|675|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-163|42|676|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-164|42|679|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-165|42|683|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-166|42|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-167|42|685|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ region of foreleg.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-168|42|686|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-169|42|687|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-170|42|691|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-171|42|706|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-172|42|707|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-173|42|718|n/a|n/a|n/a|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-174|42|722|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ osteosarcoma lower jaw.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-175|42|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-176|42|733|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-177|42|734|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-178|42|738|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thoracic spine. Metastases  Muscle trac to costal muscle.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-179|42|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-180|42|752|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-181|42|761|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-182|42|770|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-183|42|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-184|42|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-185|42|776|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver,MPATH: 549 - carcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-186|42|781|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-187|42|782|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-188|42|792|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-189|42|793|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR SPINE TO LOCAL SKELETAL MUSCLE.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-190|42|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-191|42|802|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ nares. Metastases  txec of nares to brain.,MPATH: 446 - squamous cell carcinoma|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-192|42|805|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ tibia. Metastases  tbos of tibia with an aorta extension.|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-193|42|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ type b.,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-194|42|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-195|42|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-196|42|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-197|42|831|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-198|42|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tgac to regional muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-199|42|848|Other deterministic changes|Whole body|MCDU/  |
1003-20-42|n/a,HI|1| 100|neutrons fission|2.4|grays|External exposure| code EI 24 fractions 45 m 1/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|136 records survival 528 ± 12 lifespan study|1003-20-42-200|42|877|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tgac to muscles of the head.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-1|43|225|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-2|43|230|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-3|43|230|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-4|43|230|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-5|43|230|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-6|43|230|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-7|43|267|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-8|43|277|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-9|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-10|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-11|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-12|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-13|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-14|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-15|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-16|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-17|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-18|43|296|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-19|43|303|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-20|43|303|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-21|43|303|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-22|43|303|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-23|43|303|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-24|43|319|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-25|43|330|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod ttyg w/pnu & trx contributing.,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-26|43|350|Neoplasia unclassified|Other local manifestations and miscellaneus|THWC: TCFS OF UNKNOWN ORIGIN (PROB. RIBCAGE) TO LIVER.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-27|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-28|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-29|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-30|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-31|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-32|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-33|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-34|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-35|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-36|43|353|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-37|43|360|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-38|43|360|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-39|43|360|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-40|43|360|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-41|43|360|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-42|43|369|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCA/  Cystitis|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-43|43|388|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-44|43|390|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ tadn cod; contributing bdy thorax.,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-45|43|392|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-46|43|400|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-47|43|414|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-48|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-49|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-50|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-51|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-52|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-53|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-54|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-55|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-56|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-57|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-58|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-59|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-60|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-61|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-62|43|417|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-63|43|424|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-64|43|428|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-65|43|445|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-66|43|452|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ region of eye.,MPATH: 428 - rhabdomyosarcoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-67|43|453|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-68|43|467|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-69|43|469|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-70|43|474|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-71|43|474|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ taca?; no tissue.,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-72|43|486|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-73|43|488|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-74|43|491|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-75|43|500|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-76|43|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-77|43|502|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-78|43|502|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-79|43|504|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-80|43|508|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-81|43|516|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-82|43|517|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-83|43|532|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-84|43|540|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ adenocarcinoma of pancreas; ductal.,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-85|43|544|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-86|43|544|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestion|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-87|43|548|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-88|43|554|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-89|43|555|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-90|43|558|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-91|43|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-92|43|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-93|43|559|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-94|43|559|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-95|43|563|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver,MPATH: 549 - carcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-96|43|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-97|43|565|Neoplasia systemic|Haematolymphatic system|TLML/  Eye(s) missing Head/neck missing|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-98|43|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-99|43|568|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-100|43|572|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-101|43|583|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-102|43|584|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-103|43|596|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMRS OF REGION OF EYE TO LUNG.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-104|43|597|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-105|43|599|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-106|43|600|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-107|43|601|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-108|43|613|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-109|43|614|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-110|43|617|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-111|43|633|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-112|43|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-113|43|635|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-114|43|642|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-115|43|643|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-116|43|644|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-117|43|649|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-118|43|651|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ scapular region of the back.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-119|43|661|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-120|43|662|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-121|43|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-122|43|664|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-123|43|668|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-124|43|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-125|43|675|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ brain.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-126|43|676|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKVS/  ,MPATH: 551 - sarcoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-127|43|679|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-128|43|680|Other deterministic changes|Whole body|MCDU/   Metastases Liver Metastases  Muscle trac to costal muscle.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-129|43|685|Hyperplastic changes|Other local manifestations and miscellaneus|MURH/  Ureter epithelium|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-130|43|686|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tgac to cervical ln.,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-131|43|695|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-132|43|698|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-133|43|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-134|43|705|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF PELVIS TO LIVER.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-135|43|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-136|43|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-137|43|715|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-138|43|719|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWA: TACC TO LUNG.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-139|43|719|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-140|43|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-141|43|738|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ malignant; origin?|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-142|43|740|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-143|43|741|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-144|43|742|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-145|43|743|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-146|43|746|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-147|43|746|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-148|43|748|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestion|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-149|43|757|Other deterministic changes|Whole body|MCDU/ cod probably related to the very severe fibrocytic proliferations in pleural, peritoneal and pelvic cavities.  i've called it various things but the l|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-150|43|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-151|43|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-152|43|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-153|43|779|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-154|43|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-155|43|781|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-156|43|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr. Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-157|43|796|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-158|43|798|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/ ileum.acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-159|43|799|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-160|43|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-161|43|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-162|43|817|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-163|43|825|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-164|43|825|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-165|43|827|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-166|43|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-167|43|831|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis; chondrosarcoma/jhr. Metastases Lung Metastases Lung Metastases Liver|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-168|43|838|Other deterministic changes|Whole body|MCDU/   Metastases Lung tmrs of region of eye to lung.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-169|43|838|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-170|43|840|n/a|n/a|n/a|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-171|43|840|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-172|43|844|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-173|43|846|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-174|43|848|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-175|43|851|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thigh; secondary ca; origin?/lsl.|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-176|43|852|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-177|43|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-178|43|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-179|43|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-180|43|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-181|43|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-182|43|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-183|43|875|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-184|43|884|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ origin unknown, prob ribcage. Metastases Liver Metastases  tcfs of unknown origin (prob. ribcage) to duodenum.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-185|43|887|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Eye(s) missing|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-186|43|890|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-187|43|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ jhr.  gross dx tadn is tlxs.,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-188|43|892|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-189|43|896|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-190|43|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-191|43|904|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|TBFS/ jaw.,MPATH: 551 - sarcoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-192|43|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-193|43|926|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/  ,MPATH: 549 - carcinoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-194|43|936|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-195|43|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlhs/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-196|43|997|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-197|43|1003|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/   Metastases  Muscle tcfs of unknown origin (prob. ribcage) to muscle of ribcage.   age.,MPATH: 1 - cell and tissue damage|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-198|43|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-199|43|1089|Other deterministic changes|Whole body|MCDU/  |
1003-20-43|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|149 records survival 666 ± 15 lifespan study|1003-20-43-200|43|1136|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/   Metastases Lung,MPATH: 242 - hemangiosarcoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-1|44|235|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-2|44|297|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ left axilla.,MPATH: 446 - squamous cell carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-3|44|313|Other deterministic changes|Whole body|MCDU/ diagnosed microscopically as possibly tlll but later diagnosis changed to reactive spleen and lymph node. cod unknown.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-4|44|316|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-5|44|325|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWM: TMAA TO MUSCLES IN THE REGION.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-6|44|341|Other deterministic changes|Whole body|MCDU/ cod originally thought to be an injury. on autopsy sheet cdu.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-7|44|348|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-8|44|348|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-9|44|348|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-10|44|348|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-11|44|348|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-12|44|355|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-13|44|355|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-14|44|355|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-15|44|355|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-16|44|355|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-17|44|358|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ aca Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-18|44|369|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-19|44|384|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ on summary sheet contributing cod grossly diagnosed pnu,  bdy (thorax). on aut. sheet, cod hrg.,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-20|44|390|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/  ,MPATH: 218 - neoplasm|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-21|44|393|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-22|44|400|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-23|44|404|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-24|44|404|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-25|44|404|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-26|44|404|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-27|44|404|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-28|44|404|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-29|44|411|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-30|44|411|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-31|44|411|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-32|44|411|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-33|44|411|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-34|44|411|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ right axilla; grossly cod ascribed to tshf on summary sheet, on autopsy sheet tmgl.,MPATH: 446 - squamous cell carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-35|44|411|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ taca.,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-36|44|418|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-37|44|423|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: ?/LSL, NO HGL PRIMARY.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-38|44|424|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-39|44|425|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod at autopsy ntyg.  quote from summary sheet "thymic lymphoma lymphocytic well diff.",MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-40|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-41|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-42|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-43|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-44|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-45|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-46|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-47|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-48|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-49|44|439|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-50|44|442|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|TMAT/  ,MPATH: 255 - adenoacanthoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-51|44|449|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-52|44|451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-53|44|460|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ rjmf sheet taca.,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-54|44|460|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-55|44|463|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-56|44|466|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases Liver,MPATH: 218 - neoplasm|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-57|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-58|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-59|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-60|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-61|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-62|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-63|44|467|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ cod aci. on summary sheet aci.,MPATH: 1 - cell and tissue damage|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-64|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-65|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-66|44|467|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-67|44|471|Other deterministic changes|Whole body|MCDU/   Metastases Lung tmaa to lung.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-68|44|472|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-69|44|480|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-70|44|484|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-71|44|488|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-72|44|488|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-73|44|488|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-74|44|488|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-75|44|488|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-76|44|488|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-77|44|492|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-78|44|495|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-79|44|495|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-80|44|495|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-81|44|495|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-82|44|495|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-83|44|498|Other deterministic changes|Whole body|MCDU/ gross (autopsy) suggests ?leuk.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-84|44|505|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to adjacent muscle. Metastases Lung|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-85|44|507|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWM: TMAA TO MUSCLES IN THE REGION.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-86|44|510|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO REGIONAL LYMPH NODE.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-87|44|515|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-88|44|516|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAB TO LIVER.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-89|44|516|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAB TO LIVER.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-90|44|516|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAB TO LIVER.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-91|44|516|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-92|44|516|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMAB TO LIVER.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-93|44|516|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-94|44|516|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-95|44|516|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-96|44|530|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-97|44|533|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-98|44|540|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-99|44|540|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Head neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-100|44|543|Other deterministic changes|Whole body|MCDU/   Metastases  Lymphoret.System trac to regional lymph node.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-101|44|544|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-102|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-103|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-104|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-105|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-106|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-107|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-108|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-109|44|551|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-110|44|555|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO REGIONAL LYMPH NODE.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-111|44|556|Other deterministic changes|Whole body|MCDU/   Metastases  tmab to peritoneum.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-112|44|565|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-113|44|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-114|44|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-115|44|575|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-116|44|577|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ lxs/jhr. Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-117|44|585|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-118|44|586|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-119|44|592|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-120|44|593|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-121|44|597|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWX: TXAC OF PANCREAS TO KIDNEY.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-122|44|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-123|44|599|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-124|44|607|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-125|44|609|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-126|44|615|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-127|44|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-128|44|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-129|44|620|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-130|44|631|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-131|44|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-132|44|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-133|44|642|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/ probably indirect cod by hemorrhage.Ovary or testis,MPATH: 62 - cyst|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-134|44|649|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-135|44|656|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-136|44|656|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ squamous cell ca of stomach.,MPATH: 549 - carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-137|44|659|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenal ca. Metastases Lung tiac of duodenum to lung.,MPATH: 218 - neoplasm|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-138|44|660|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-139|44|663|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-140|44|670|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-141|44|672|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-142|44|674|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-143|44|675|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-144|44|680|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Lymphoret.System trac to renal ln.,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-145|44|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-146|44|681|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-147|44|688|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO REGIONAL LYMPH NODE.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-148|44|691|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-149|44|692|Other deterministic changes|Hepato-pancreatic system|MHHD/  Hydropic degeneration|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-150|44|693|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ flank. Metastases Heart tcfs of flank to heart.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-151|44|695|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-152|44|695|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-153|44|697|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-154|44|703|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-155|44|707|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-156|44|708|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-157|44|708|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-158|44|712|Other deterministic changes|Whole body|MCDU/ Head neck missing|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-159|44|712|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-160|44|715|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-161|44|715|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-162|44|719|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-163|44|722|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-164|44|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlxs/jhr; and togc & mmch/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-165|44|727|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-166|44|728|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-167|44|733|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases  togc to brain. Metastases  togc to sternal marrow. Metastases  Lymphoret.System togc to ln. not specified. Metastases Lung|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-168|44|740|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/   Metastases Lung tmaa metast. to lung.,MPATH: 218 - neoplasm|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-169|44|742|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-170|44|744|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-171|44|747|n/a|n/a|n/a|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-172|44|749|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-173|44|754|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ pancreas? Metastases  Kidney txac of pancreas to kidney. Metastases  Lymphoret.System txac of pancreas to pancreatic ln.,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-174|44|754|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ region of eye. Metastases Lung,MPATH: 446 - squamous cell carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-175|44|759|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases Liver|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-176|44|766|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ peritonitis.,MPATH: 213 - acute inflammation|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-177|44|777|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-178|44|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-179|44|784|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/   Metastases  Muscle tmaa to muscles in the region.,MPATH: 218 - neoplasm|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-180|44|784|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-181|44|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ lsl.,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-182|44|791|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-183|44|797|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-184|44|811|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-185|44|814|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-186|44|817|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAC/ origin not known.,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-187|44|818|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-188|44|819|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-189|44|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-190|44|827|Neoplasia unclassified|Central nervous system among nervous system|TNAS/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-191|44|831|Other deterministic changes|Whole body|MCDU/  |
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-192|44|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-193|44|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-194|44|851|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-195|44|856|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-196|44|876|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis and femur.|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-197|44|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-198|44|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-199|44|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-44|n/a,DI|1| 100|neutrons fission|0.8|grays|External exposure| code HI 6 fractions 180 m 1/mo|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|167 records survival 673 ± 13 lifespan study|1003-20-44-200|44|934|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-1|45|115|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-2|45|197|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-3|45|226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ cod given as ttyg w/bdy (thorax) contributing.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-4|45|242|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWK: TKAC PERITONEAL INVASION, SEVERE.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-5|45|257|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-6|45|267|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-7|45|280|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THCC/ hepatic cholangioca.,MPATH: 354 - cholangiocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-8|45|317|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-9|45|375|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-10|45|378|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-11|45|383|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWP: TPAO TO KIDNEY IS SUSPECTED.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-12|45|417|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-13|45|467|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-14|45|495|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT IDENTIFIED.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-15|45|496|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-16|45|518|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-17|45|546|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ nasal cavity fs.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-18|45|547|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-19|45|562|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWP: TPAC TO BRAIN.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-20|45|563|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-21|45|568|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-22|45|578|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-23|45|578|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ maybe tlls/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-24|45|585|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-25|45|589|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-26|45|589|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-27|45|590|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|TBFS/ forearm w/septicemia.,MPATH: 551 - sarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-28|45|596|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-29|45|602|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-30|45|607|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-31|45|607|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-32|45|613|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-33|45|618|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-34|45|626|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-35|45|626|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-36|45|626|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-37|45|629|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-38|45|642|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-39|45|648|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-40|45|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-41|45|653|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur and pelvis. Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-42|45|659|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosaEye(s) missing|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-43|45|660|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Lymphoret.System trac to mediastinal ln.Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-44|45|668|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-45|45|668|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-46|45|668|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-47|45|668|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-48|45|669|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-49|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-50|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-51|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-52|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-53|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-54|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-55|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-56|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-57|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-58|45|675|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-59|45|676|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-60|45|679|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWT: TTVS TO LUNG.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-61|45|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-62|45|689|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-63|45|694|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-64|45|694|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-65|45|698|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ muscle of cheek; myoepithelioma. Metastases Heart Metastases  txus of cheek to costal muscle. Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-66|45|701|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-67|45|702|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-68|45|708|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-69|45|710|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-70|45|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ epithelioid type.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-71|45|711|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-72|45|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-73|45|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-74|45|716|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-75|45|718|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-76|45|719|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-77|45|719|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-78|45|719|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-79|45|724|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ no tissue.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-80|45|724|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/ hrg probably.,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-81|45|728|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT IDENTIFIED.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-82|45|728|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-83|45|729|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWT: TTVS TO LUNG.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-84|45|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-85|45|734|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-86|45|734|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWP: TPAO TO KIDNEY IS SUSPECTED.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-87|45|737|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-88|45|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-89|45|739|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-90|45|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-91|45|744|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-92|45|744|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-93|45|748|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-94|45|749|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-95|45|749|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-96|45|751|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-97|45|757|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-98|45|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-99|45|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-100|45|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-101|45|761|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-102|45|761|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-103|45|761|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-104|45|764|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ region of eye.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-105|45|766|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-106|45|769|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-107|45|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-108|45|770|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-109|45|773|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-110|45|773|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow| ,MPATH: 127 - atrophy|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-111|45|777|Neoplasia unclassified|Other local manifestations and miscellaneus|THWM: TMFS OF AXILLARY REGION TO LIVER.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-112|45|782|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-113|45|782|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-114|45|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-115|45|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-116|45|786|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-117|45|787|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-118|45|787|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh muscle. Muscle|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-119|45|793|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscle and pleura. Metastases  Lymphoret.System trac to cervical ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-120|45|794|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ anal region; possibly glomus body origin.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-121|45|796|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ axillary region.muscle Metastases Liver,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-122|45|796|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-123|45|796|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-124|45|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-125|45|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-126|45|799|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-127|45|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-128|45|804|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-129|45|805|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWP: TPAO TO KIDNEY IS SUSPECTED.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-130|45|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-131|45|807|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-132|45|808|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-133|45|808|Other deterministic changes|Lower respiratory system|MPNC/  Lung congestionHead/neck missing|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-134|45|810|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MNIA/ cerebrum.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-135|45|811|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-136|45|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-137|45|813|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-138|45|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to diaphragm.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-139|45|817|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-140|45|818|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-141|45|820|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-142|45|821|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-143|45|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-144|45|827|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-145|45|827|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-146|45|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-147|45|830|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-148|45|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-149|45|832|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-150|45|835|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-151|45|837|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-152|45|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-153|45|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-154|45|844|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-155|45|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-156|45|846|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-157|45|849|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-158|45|854|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE UNSPECIFIED.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-159|45|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-160|45|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Liver Metastases  Muscle trac to cost. musc.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-161|45|860|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-162|45|861|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/  ,MPATH: 278 - follicular adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-163|45|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-164|45|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-165|45|863|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/  Transitional cell,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-166|45|864|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-167|45|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-168|45|866|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac metast. to costal muscle. Metastases  Lymphoret.System trac metast. to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-169|45|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac invasion site not specified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-170|45|871|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-171|45|871|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma Metastases  tpac to brain.,MPATH: 218 - neoplasm|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-172|45|874|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ kidney adnexa.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-173|45|875|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-174|45|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-175|45|876|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-176|45|879|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-177|45|879|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to diaphragm muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-178|45|881|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-179|45|883|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPNA/  Pancreatitis|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-180|45|885|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/ immature type.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-181|45|886|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-182|45|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-183|45|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-184|45|888|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-185|45|890|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TYRS/  Heart,MPATH: 428 - rhabdomyosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-186|45|890|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-187|45|890|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ brain.,MPATH: 551 - sarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-188|45|890|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ possibly seminal vesicle.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-189|45|890|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-190|45|891|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-191|45|892|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-192|45|894|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-193|45|897|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-194|45|897|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Trunk missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-195|45|899|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS TO LUNG.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-196|45|899|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-197|45|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-198|45|900|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-199|45|905|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MNIA/ meningitis, acute, severe.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-200|45|906|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Heart Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-201|45|907|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Lymphoret.System txfs of region of eye to cervical ln. Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-202|45|908|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-203|45|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-204|45|912|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-205|45|913|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-206|45|913|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ axillary region. Metastases Liver,MPATH: 218 - neoplasm|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-207|45|917|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-208|45|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-209|45|921|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-210|45|921|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis Metastases Lung|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-211|45|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-212|45|922|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not identified.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-213|45|923|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-214|45|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-215|45|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-216|45|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-217|45|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-218|45|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-219|45|929|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-220|45|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-221|45|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-222|45|932|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-223|45|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-224|45|932|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-225|45|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-226|45|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-227|45|933|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC METAST. TO PARATHYMIC LN.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-228|45|934|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-229|45|934|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-230|45|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-231|45|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-232|45|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-233|45|938|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-234|45|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-235|45|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-236|45|943|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-237|45|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-238|45|944|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-239|45|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-240|45|945|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-241|45|945|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-242|45|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-243|45|950|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRVS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-244|45|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-245|45|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-246|45|950|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-247|45|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-248|45|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-249|45|954|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-250|45|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-251|45|955|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-252|45|956|Neoplasia malignant|Bloodvessels among cardiovascular system|TDVS/  Urinary bladder|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-253|45|958|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-254|45|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-255|45|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-256|45|963|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-257|45|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-258|45|963|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  tkac peritoneal invasion, severe.,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-259|45|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-260|45|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-261|45|967|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-262|45|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-263|45|968|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-264|45|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-265|45|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-266|45|970|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-267|45|973|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-268|45|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-269|45|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-270|45|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  trac invasion site not identified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-271|45|977|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-272|45|977|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-273|45|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-274|45|978|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-275|45|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-276|45|980|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System tgac to cervical ln. Metastases  Muscle trac to costal muscle. Metastases Kidney Metastases  Lymphoret.System trac to cervical ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-277|45|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-278|45|983|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-279|45|983|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-280|45|986|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-281|45|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-282|45|987|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-283|45|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-284|45|990|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ perineum.Skin|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-285|45|990|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-286|45|990|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-287|45|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-288|45|995|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases Kidney Metastases  trac to brown fat.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-289|45|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-290|45|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-291|45|996|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-292|45|997|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-293|45|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-294|45|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-295|45|998|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-296|45|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-297|45|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-298|45|1004|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-299|45|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not identified.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-300|45|1015|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-301|45|1015|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to other unspecified site. Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-302|45|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-303|45|1019|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-304|45|1019|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-305|45|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-306|45|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-307|45|1025|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site unspecified. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-308|45|1031|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to aortic serosa.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-309|45|1032|n/a|n/a|n/a|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-310|45|1034|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-311|45|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-312|45|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-313|45|1035|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-314|45|1040|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-315|45|1040|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-316|45|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-317|45|1045|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ face and neck. Muscle Metastases  tmvs of face and neck to trigeminal nerve trunk from face & neck.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-318|45|1046|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-319|45|1046|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-320|45|1047|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-321|45|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-322|45|1053|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ right rear leg. Muscle|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-323|45|1054|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-324|45|1057|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-325|45|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-326|45|1061|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-327|45|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-328|45|1065|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases Heart Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-329|45|1065|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Liver,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-330|45|1066|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-331|45|1068|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ abdominal muscle. Metastases Kidney Metastases  Lymphoret.System tmls of abdominal muscle to lumbar ln.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-332|45|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-333|45|1073|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-334|45|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-335|45|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-336|45|1082|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-337|45|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-338|45|1086|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-339|45|1086|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lung metastatic carcinoma origin liver, adrenal or other unknown site to lung.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-340|45|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-341|45|1094|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-342|45|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-343|45|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-344|45|1102|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-345|45|1109|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-346|45|1111|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-347|45|1113|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-348|45|1113|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-349|45|1115|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-350|45|1120|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-351|45|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-352|45|1127|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  trac to an unspecified invasion site.,MPATH: 242 - hemangiosarcoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-353|45|1135|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-354|45|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-355|45|1141|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ peritonitis, acute suppurative.,MPATH: 213 - acute inflammation|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-356|45|1145|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-357|45|1145|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-358|45|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-359|45|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-360|45|1151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-361|45|1152|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-362|45|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-363|45|1159|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-364|45|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-365|45|1166|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-366|45|1171|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-367|45|1175|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-368|45|1175|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-369|45|1176|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-370|45|1177|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-371|45|1180|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-372|45|1180|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-373|45|1189|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-374|45|1189|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-375|45|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-376|45|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-377|45|1192|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-378|45|1200|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-379|45|1201|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-380|45|1204|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-381|45|1205|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-382|45|1206|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-383|45|1214|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-384|45|1214|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-385|45|1230|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-386|45|1232|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-387|45|1239|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-388|45|1244|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-389|45|1247|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-390|45|1250|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-391|45|1256|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-392|45|1271|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-393|45|1277|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-394|45|1280|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-395|45|1285|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-396|45|1292|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ mandible. Metastases  Muscle tbos of mandible to adjacent muscle.|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-397|45|1318|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-398|45|1330|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-399|45|1331|Other deterministic changes|Whole body|MCDU/  |
1003-20-45|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|383 records survival 789 ± 10 lifespan study|1003-20-45-400|45|1357|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-1|46|258|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-2|46|281|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-3|46|291|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-4|46|361|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-5|46|398|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-6|46|420|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-7|46|429|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-8|46|431|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-9|46|441|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ forelimb.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-10|46|446|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-11|46|449|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-12|46|449|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-13|46|456|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-14|46|459|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-15|46|463|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-16|46|472|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-17|46|472|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-18|46|472|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-19|46|472|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-20|46|472|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-21|46|479|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-22|46|479|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-23|46|479|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-24|46|479|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-25|46|479|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-26|46|481|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-27|46|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-28|46|492|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-29|46|496|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-30|46|507|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-31|46|508|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-32|46|512|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ chest wall.Skin|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-33|46|522|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-34|46|528|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-35|46|529|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/ hrg from tmaa cod.,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-36|46|534|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-37|46|553|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-38|46|555|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-39|46|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-40|46|576|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-41|46|584|Neoplasia benign|Bloodvessels among cardiovascular system|TBVO/ spinal vertebrae.sternal marrow|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-42|46|586|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-43|46|587|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-44|46|595|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-45|46|602|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-46|46|616|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvic area.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-47|46|617|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ tail. Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-48|46|619|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-49|46|619|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-50|46|625|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-51|46|625|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-52|46|630|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-53|46|630|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-54|46|632|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-55|46|632|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-56|46|634|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-57|46|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-58|46|640|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ spine. Metastases Liver Metastases  Lymphoret.System tbos of spine to gastric ln. Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-59|46|642|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-60|46|643|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ adamantuoma; txfs fibrosarcoma of mandible/lsl.,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-61|46|647|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-62|46|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-63|46|654|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-64|46|656|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-65|46|656|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-66|46|656|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-67|46|656|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-68|46|656|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-69|46|656|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-70|46|656|Hyperplastic changes|Cardiovascular system|MPAN/ sternum, heart.Polyarteritis nodosa|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-71|46|663|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-72|46|663|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-73|46|663|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-74|46|663|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-75|46|663|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-76|46|669|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-77|46|670|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-78|46|670|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-79|46|672|Inflammation and/or fibrotic diseases|Integumentary system|MSDA/  acute|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-80|46|674|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-81|46|674|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-82|46|676|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-83|46|677|Neoplasia benign|Bloodvessels among cardiovascular system|TBVO/ femur.sternal marrow|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-84|46|681|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-85|46|683|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-86|46|687|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-87|46|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-88|46|694|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-89|46|695|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln. Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-90|46|695|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ pancreas ca.,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-91|46|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-92|46|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-93|46|702|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/ kidney has large infarcted area.,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-94|46|703|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/ hrg of gross dx and cod.,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-95|46|704|Hyperplastic changes|Reproductive system,MA: 0000389 - uterus|MMCH/ ruptured cyst; hemmorhage.,MPATH: 134 - hyperplasia|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-96|46|710|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS OF SKULL TO LIVER.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-97|46|713|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing, eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-98|46|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-99|46|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-100|46|722|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-101|46|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-102|46|730|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-103|46|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-104|46|732|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKVS/  ,MPATH: 551 - sarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-105|46|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-106|46|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-107|46|740|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-108|46|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-109|46|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-110|46|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-111|46|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-112|46|749|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  trac invasion site unspecified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-113|46|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-114|46|759|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-115|46|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-116|46|764|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-117|46|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-118|46|764|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/ hrg severe (or tuvs). probably togc as well.,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-119|46|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-120|46|768|Neoplasia unclassified|Mammary gland,MA: 0000145 - mammary gland|TMUO/ tumor given for em examination/no paraffin. Metastases Lung tmuo to lung.,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-121|46|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-122|46|769|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/ chromophobe.Adenoma,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-123|46|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-124|46|771|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-125|46|771|Neoplasia benign|Liver among hepato-pancreatic system diseases|THAA/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-126|46|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-127|46|773|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvic spine.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-128|46|774|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-129|46|775|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TULS/  ,MPATH: 551 - sarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-130|46|775|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-131|46|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-132|46|779|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-133|46|779|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-134|46|783|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-135|46|787|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-136|46|790|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-137|46|790|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-138|46|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-139|46|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-140|46|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-141|46|796|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-142|46|797|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-143|46|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-144|46|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-145|46|801|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-146|46|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-147|46|803|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWK: TKAC TO ADNEXA.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-148|46|806|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ Head neck missing,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-149|46|809|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-150|46|809|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-151|46|811|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-152|46|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-153|46|815|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-154|46|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-155|46|820|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-156|46|820|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-157|46|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-158|46|820|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-159|46|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-160|46|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-161|46|823|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/  ,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-162|46|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-163|46|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-164|46|826|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-165|46|827|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-166|46|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-167|46|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-168|46|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-169|46|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-170|46|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-171|46|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-172|46|843|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-173|46|844|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-174|46|845|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-175|46|847|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-176|46|847|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/ tans or taps/lsl is cod.acute/chronic,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-177|46|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-178|46|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-179|46|852|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-180|46|853|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-181|46|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lung txac of pancreas to lung.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-182|46|856|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-183|46|858|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-184|46|861|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-185|46|862|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/ acidophilic and telangiectatic.Adenoma,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-186|46|864|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull. Metastases  Kidney tbos of skull to kidney. Metastases Liver Metastases  Lymphoret.System tbos of skull to renal ln.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-187|46|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-188|46|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based upon hematology. Metastases  tkac to adnexa.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-189|46|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-190|46|865|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-191|46|865|Other deterministic changes|Whole body|MCDU/  Head/neck missing, eyes missing|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-192|46|867|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-193|46|869|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-194|46|870|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-195|46|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ also based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-196|46|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-197|46|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-198|46|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based upon hematology. Metastases  tcfs of peritoneum to visceral peritoneum. Metastases  Lymphoret.System tcfs of peritoneum to renal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-199|46|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-200|46|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-201|46|874|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-202|46|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-203|46|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-204|46|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-205|46|887|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-206|46|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ dx by hematology is/wouuld be tlml.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-207|46|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-208|46|894|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-209|46|899|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-210|46|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-211|46|901|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-212|46|901|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-213|46|903|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-214|46|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-215|46|904|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-216|46|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-217|46|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-218|46|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-219|46|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-220|46|907|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-221|46|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-222|46|911|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-223|46|912|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUVO/  ,MPATH: 236 - angiofibroma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-224|46|913|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-225|46|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-226|46|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-227|46|915|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-228|46|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-229|46|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-230|46|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-231|46|918|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-232|46|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-233|46|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-234|46|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-235|46|925|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWH: THAC TO LUNG.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-236|46|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-237|46|928|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-238|46|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-239|46|930|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-240|46|931|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-241|46|932|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CERVICAL LN.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-242|46|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-243|46|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-244|46|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-245|46|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-246|46|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-247|46|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-248|46|938|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-249|46|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-250|46|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-251|46|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-252|46|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-253|46|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-254|46|946|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ region of flank.muscle Metastases  Muscle tmfs of flank to adj. muscle. Metastases Liver Metastases  tmfs of flank to peritoneum. Metastases  Lymphoret.System tmfs of flank to regional ln.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-255|46|948|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-256|46|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-257|46|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-258|46|949|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTC/  Metritis|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-259|46|952|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-260|46|952|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-261|46|952|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-262|46|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-263|46|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-264|46|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-265|46|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-266|46|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ Eyes missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-267|46|959|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-268|46|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-269|46|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-270|46|961|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-271|46|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-272|46|963|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ region of thoracic-lumbar spine.muscle Metastases  tmfs of region of thoracic-lumbar spine to peritoneum. Metastases  Muscle tmfs of region of thoracic-lumbar spine to adjacent skeletal muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-273|46|963|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-274|46|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-275|46|964|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-276|46|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-277|46|968|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac to abdom fat. Metastases Lung Metastases  Lymphoret.System tgac to cervical ln. Metastases Liver|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-278|46|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-279|46|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-280|46|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-281|46|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-282|46|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-283|46|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-284|46|978|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-285|46|980|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-286|46|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-287|46|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-288|46|984|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-289|46|985|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-290|46|987|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-291|46|988|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-292|46|988|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-293|46|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-294|46|990|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ rib. Metastases  tbos of rib to sternum. Metastases  Muscle tbos of rib to costal muscle.|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-295|46|990|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-296|46|991|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ rib cage and face.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-297|46|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-298|46|992|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ thigh muscle. Metastases  Muscle tnns of thigh muscle to diaphragm. Metastases Liver,MPATH: 437 - neurofibrosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-299|46|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-300|46|995|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-301|46|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-302|46|998|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-303|46|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-304|46|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-305|46|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-306|46|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-307|46|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-308|46|1008|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-309|46|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-310|46|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-311|46|1011|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-312|46|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-313|46|1013|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-314|46|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-315|46|1015|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-316|46|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-317|46|1017|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-318|46|1017|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-319|46|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-320|46|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-321|46|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-322|46|1022|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-323|46|1024|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-324|46|1026|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-325|46|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-326|46|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-327|46|1033|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-328|46|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-329|46|1035|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-330|46|1036|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-331|46|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tsec of jaw region to adjacent muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-332|46|1043|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-333|46|1045|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIC/ prolapse, anal.Enteritis chronic,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-334|46|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-335|46|1047|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-336|46|1054|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-337|46|1055|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-338|46|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-339|46|1055|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ region of jaw. Metastases  Lymphoret.System tsec of jaw to cervical ln. Metastases  tsec of jaw to  salivary glands. Metastases  Muscle tsec of jaw to adjacent muscles.,MPATH: 218 - neoplasm|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-340|46|1059|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-341|46|1060|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-342|46|1064|Hyperplastic changes|Cardiovascular system|MPAN/ adrenal artery.Polyarteritis nodosa|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-343|46|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-344|46|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-345|46|1066|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-346|46|1070|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-347|46|1072|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-348|46|1073|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ region of head. Metastases  Muscle tmrs of head to regional muscle. Metastases  Lymphoret.System tmrs of head to regional ln. Metastases  Muscle no hgl primary examined, but metast. to muscles adjac. to region of hgl.,MPATH: 428 - rhabdomyosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-349|46|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-350|46|1081|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-351|46|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-352|46|1086|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of lumbar vertebrae. Metastases  Muscle tcfs of lumbar vertebrae to sternal muscles. Metastases Lung Metastases  Kidney tcfs of lumbar vertebrae to kidney.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-353|46|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-354|46|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-355|46|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-356|46|1090|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ lateral abd. wall. Metastases  Muscle tnns of lateral abd. wall to diaphragm muscle. Metastases  Lymphoret.System tnns of lateral abd. wall to mesenteric ln.,MPATH: 437 - neurofibrosarcoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-357|46|1092|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-358|46|1093|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-359|46|1095|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-360|46|1095|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-361|46|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-362|46|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-363|46|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-364|46|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-365|46|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-366|46|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-367|46|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-368|46|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-369|46|1110|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIC/ rectal prolapse.Enteritis chronic,MPATH: 212 - inflammation|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-370|46|1117|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-371|46|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-372|46|1127|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-373|46|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-374|46|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-375|46|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-376|46|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-377|46|1142|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-378|46|1147|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-379|46|1149|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-380|46|1150|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-381|46|1151|n/a|n/a|n/a|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-382|46|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-383|46|1159|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-384|46|1159|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-385|46|1164|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-386|46|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-387|46|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-388|46|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-389|46|1188|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MMTA/  Metritis|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-390|46|1189|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-391|46|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-392|46|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  tmfs of tibia-fibula region to adnexal tissues.,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-393|46|1201|Other deterministic changes|Whole body|MCDU/  |
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-394|46|1202|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-395|46|1219|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-396|46|1221|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-397|46|1224|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-398|46|1228|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-399|46|1248|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-46|n/a,S1|1| 100|neutrons fission|0.2|grays|External exposure| code S1 1 fraction 20 m|400 (400 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|380 records survival 759 ± 10 lifespan study|1003-20-46-400|46|1251|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-1|47|359|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ tlls/jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-2|47|361|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-3|47|367|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-4|47|381|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-5|47|415|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-6|47|464|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ vascular t of mesentery.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-7|47|473|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-8|47|473|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-9|47|509|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-10|47|509|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MSAA/ probably relates to middle ear infection.Sialadenitis|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-11|47|511|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-12|47|529|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-13|47|529|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-14|47|548|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-15|47|560|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-16|47|563|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-17|47|563|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-18|47|563|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-19|47|563|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-20|47|564|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-21|47|568|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-22|47|569|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-23|47|569|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-24|47|569|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-25|47|569|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-26|47|569|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-27|47|578|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-28|47|579|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-29|47|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-30|47|600|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-31|47|611|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-32|47|615|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-33|47|618|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-34|47|620|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-35|47|621|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/ probably squamous cell ca; thyroid undifferentiated. Metastases Lung,MPATH: 278 - follicular adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-36|47|637|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-37|47|644|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-38|47|653|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-39|47|655|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-40|47|656|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-41|47|660|Other deterministic changes|Whole body|MCDU/  Thorax missing Head/neck missing|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-42|47|661|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-43|47|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-44|47|665|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-45|47|669|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-46|47|669|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-47|47|669|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-48|47|669|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-49|47|670|Neoplasia unclassified|Central nervous system among nervous system|TNAS/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-50|47|672|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|TVFS/  Fibrosarcoma,MPATH: 551 - sarcoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-51|47|672|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-52|47|673|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-53|47|673|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKVS/ w/hrg.,MPATH: 551 - sarcoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-54|47|676|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-55|47|676|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-56|47|676|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-57|47|676|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-58|47|676|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-59|47|676|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-60|47|676|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-61|47|676|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-62|47|676|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-63|47|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-64|47|679|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-65|47|680|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-66|47|680|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-67|47|682|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-68|47|684|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tzac to neck muscle.,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-69|47|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ gross lesion tpit not found.,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-70|47|688|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPNA/  Pancreatitis|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-71|47|688|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-72|47|689|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-73|47|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-74|47|698|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-75|47|700|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-76|47|700|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-77|47|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-78|47|717|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-79|47|719|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-80|47|721|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-81|47|726|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-82|47|731|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-83|47|735|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-84|47|746|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-85|47|750|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO MEDIASTINAL AND CERVICAL LN.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-86|47|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-87|47|759|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-88|47|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-89|47|768|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-90|47|771|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWZ: TZAC TO NECK MUSCLE.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-91|47|774|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-92|47|778|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-93|47|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-94|47|788|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-95|47|791|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Head/neck missing Eye(s) missing|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-96|47|795|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-97|47|797|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-98|47|798|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-99|47|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-100|47|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-101|47|815|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-102|47|815|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-103|47|820|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-104|47|821|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-105|47|824|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to mediastinal and cervical ln. Metastases Lung Metastases  tgac to sternum.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-106|47|835|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-107|47|837|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-108|47|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle trac to intercostal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-109|47|848|Neoplasia unclassified|Nervous system and special sense organs|TANS/  Adrenal Metastases Liver|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-110|47|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-111|47|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-112|47|861|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/ acidophilic and telangiectatic.Adenoma,MPATH: 218 - neoplasm|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-113|47|862|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-114|47|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System taps to mesenteric ln. Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-115|47|866|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-116|47|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-117|47|870|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-118|47|872|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ duodenum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-119|47|873|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ entire pleural cavity.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-120|47|876|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000099 - pericardium|MPCC/  chronic,MPATH: 212 - inflammation|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-121|47|876|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to mediastinal ln. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-122|47|876|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney Metastases  trac to peritoneum.,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-123|47|880|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-124|47|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac invasion site not specified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-125|47|886|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-126|47|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-127|47|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-128|47|890|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-129|47|892|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-130|47|892|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-131|47|895|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-132|47|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-133|47|907|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-134|47|914|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-135|47|916|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac invasion of costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-136|47|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-137|47|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-138|47|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-139|47|922|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-140|47|926|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-141|47|931|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-142|47|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-143|47|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-144|47|937|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-145|47|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/ hematology diagnosis tlml.,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-146|47|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-147|47|957|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-148|47|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-149|47|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-150|47|972|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-151|47|972|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ over thorax. Metastases Liver Metastases Heart Metastases Lung,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-152|47|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-153|47|981|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ jaw.,MPATH: 218 - neoplasm|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-154|47|982|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-155|47|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-156|47|993|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-157|47|994|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-158|47|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  Muscle tcvs of axillary region to sternal muscle. Metastases Lung Metastases Heart tcvs of axillary region to a.v. valve.,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-159|47|999|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-160|47|1005|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion not specified.,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-161|47|1006|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-162|47|1007|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-163|47|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-164|47|1011|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-165|47|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-166|47|1017|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-167|47|1019|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-168|47|1023|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-169|47|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-170|47|1025|n/a|n/a|n/a|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-171|47|1028|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-172|47|1033|Neoplasia systemic|Haematolymphatic system|TLML/   Metastases  Lymphoret.System trac metast. to parathymic ln.|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-173|47|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-174|47|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-175|47|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-176|47|1040|Other deterministic changes|Whole body|MCDU/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-177|47|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-178|47|1044|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-179|47|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-180|47|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-181|47|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Lymphoret.System taps metast. to renal ln. Metastases Kidney,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-182|47|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-183|47|1050|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-184|47|1051|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-185|47|1068|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-186|47|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-187|47|1081|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-188|47|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-189|47|1090|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-190|47|1102|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-191|47|1113|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCC/  Cystitis|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-192|47|1115|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/   Metastases Lung,MPATH: 278 - follicular adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-193|47|1119|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-194|47|1125|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-195|47|1157|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-196|47|1159|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-197|47|1164|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-198|47|1177|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-199|47|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-47|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|178 records survival 724 ± 14 lifespan study|1003-20-47-200|47|1272|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-1|48|253|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-2|48|290|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-3|48|294|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-4|48|334|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWA: TAPS TO UNSPECIFIED LN.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-5|48|357|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-6|48|371|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-7|48|384|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-8|48|393|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWA: TAPS TO HEART.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-9|48|400|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ vascular tumor around anus; considered to be proximate cod/jhr.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-10|48|403|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-11|48|407|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-12|48|411|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-13|48|419|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-14|48|438|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-15|48|442|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-16|48|457|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-17|48|493|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ myelocytic?/rjmf.,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-18|48|504|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/   Metastases Lung tmaa to lung.,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-19|48|516|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-20|48|531|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-21|48|541|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ adeno ca of glandular stomach.Head/neck missing,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-22|48|544|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebrae.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-23|48|545|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-24|48|558|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-25|48|560|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-26|48|561|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to sternal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-27|48|562|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-28|48|565|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-29|48|565|Neoplasia unclassified|Central nervous system among nervous system|TNAS/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-30|48|567|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-31|48|570|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-32|48|576|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-33|48|578|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-34|48|589|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-35|48|599|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-36|48|614|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-37|48|621|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln. Metastases Lung|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-38|48|630|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-39|48|637|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-40|48|637|Other deterministic changes|Whole body|MCDU/ probably meningitis.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-41|48|638|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-42|48|639|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-43|48|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ largely liver.,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-44|48|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-45|48|643|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/ w/hrg.Ovary or testis,MPATH: 62 - cyst|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-46|48|650|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-47|48|656|Hyperplastic changes|Cardiovascular system|MPAN/ sternum, heart, intestine (mesen.).Polyarteritis nodosa|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-48|48|657|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-49|48|659|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-50|48|661|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-51|48|663|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO STERNAL MUSCLE.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-52|48|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ tlus/lsl. Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-53|48|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-54|48|670|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-55|48|675|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-56|48|676|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-57|48|686|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-58|48|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-59|48|689|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIT/  Toxic hepatitisEye(s) missing Head/neck missing,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-60|48|694|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-61|48|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-62|48|697|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-63|48|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-64|48|703|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-65|48|707|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-66|48|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-67|48|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-68|48|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-69|48|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ dx on bone marrow only; unquestionable however.,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-70|48|715|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum.,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-71|48|716|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIT/  Toxic hepatitis,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-72|48|720|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-73|48|722|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-74|48|722|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-75|48|722|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-76|48|725|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-77|48|728|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMAA TO LUNG.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-78|48|732|Other deterministic changes|Whole body|MCDU/ cod probably ruptured aorta.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-79|48|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/ leukemic form of ret. cell sarcoma. gross dx encephalopathy cause "unknown".,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-80|48|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-81|48|742|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-82|48|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-83|48|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-84|48|749|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-85|48|749|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-86|48|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-87|48|757|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-88|48|759|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-89|48|760|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-90|48|769|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ salivary gland and cervical ln.,MPATH: 446 - squamous cell carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-91|48|773|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-92|48|774|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-93|48|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-94|48|779|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ probably torsion of gut and diverticulitis.Enteritis acute,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-95|48|790|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-96|48|791|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-97|48|791|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-98|48|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-99|48|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-100|48|796|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-101|48|797|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-102|48|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-103|48|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-104|48|805|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-105|48|808|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-106|48|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-107|48|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-108|48|821|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-109|48|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-110|48|827|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-111|48|830|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-112|48|831|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-113|48|831|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-114|48|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-115|48|836|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac  metast. to ln; not identified.,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-116|48|838|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-117|48|839|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-118|48|841|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-119|48|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-120|48|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-121|48|848|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-122|48|854|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-123|48|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-124|48|858|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ duodenum (tipl?).,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-125|48|862|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/  ,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-126|48|869|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-127|48|870|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-128|48|871|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/   Metastases  Lymphoret.System taps to unspecified ln.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-129|48|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-130|48|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-131|48|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-132|48|873|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing, eyes missing,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-133|48|875|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-134|48|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-135|48|879|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-136|48|880|Neoplasia malignant|Other local manifestations and miscellaneus|TXFS/ TXFS/ TXFS/ TXFS/ throughout peritoneal cavity.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-137|48|883|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-138|48|887|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh-femur. Muscle|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-139|48|888|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-140|48|896|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-141|48|897|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-142|48|898|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sternum. Metastases Lung Metastases  Lymphoret.System tbos of sternum to parathymic ln.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-143|48|899|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-144|48|901|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-145|48|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-146|48|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-147|48|908|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/  ,MPATH: 218 - neoplasm|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-148|48|910|n/a|n/a|n/a|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-149|48|911|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-150|48|916|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-151|48|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-152|48|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-153|48|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-154|48|922|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ skin, anus to mammae in inguinal region.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-155|48|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-156|48|932|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-157|48|935|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-158|48|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-159|48|945|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-160|48|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-161|48|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-162|48|951|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-163|48|952|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-164|48|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-165|48|957|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  Eye(s) missing,MPATH: 1 - cell and tissue damage|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-166|48|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-167|48|961|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCA/ MMCA/ MMCA/ MMCA/  acute,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-168|48|964|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-169|48|966|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-170|48|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-171|48|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-172|48|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-173|48|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle trac to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-174|48|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-175|48|991|Other deterministic changes|Whole body|MCDU/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-176|48|994|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-177|48|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-178|48|1003|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region of kidney.|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-179|48|1006|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-180|48|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-181|48|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-182|48|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-183|48|1022|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-184|48|1028|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-185|48|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-186|48|1039|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-187|48|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-188|48|1045|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-189|48|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-190|48|1054|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-191|48|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-192|48|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-193|48|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-194|48|1082|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-195|48|1096|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-196|48|1097|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIC/ small intestine.Enteritis chronic,MPATH: 212 - inflammation|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-197|48|1130|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-198|48|1146|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-199|48|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-48|n/a,S2|1| 100|neutrons fission|0.8|grays|External exposure| code S2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|200 records survival 667 ± 14 lifespan study|1003-20-48-200|48|1254|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-1|49|275|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ ttyg?,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-2|49|299|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-3|49|316|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-4|49|317|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-5|49|359|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-6|49|360|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-7|49|360|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-8|49|360|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-9|49|360|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-10|49|360|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-11|49|361|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-12|49|361|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-13|49|361|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-14|49|361|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-15|49|361|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-16|49|367|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-17|49|367|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-18|49|367|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-19|49|367|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-20|49|367|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-21|49|376|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-22|49|409|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-23|49|414|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-24|49|414|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWG: TGAC TO BRAIN.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-25|49|416|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-26|49|422|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-27|49|422|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-28|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-29|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-30|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-31|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-32|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-33|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-34|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-35|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-36|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-37|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-38|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-39|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-40|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-41|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-42|49|424|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-43|49|436|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-44|49|445|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-45|49|453|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-46|49|458|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-47|49|461|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-48|49|466|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-49|49|474|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-50|49|478|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-51|49|478|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-52|49|478|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWR: TRAC TO HEART.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-53|49|478|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-54|49|478|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-55|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-56|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-57|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-58|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-59|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-60|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-61|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-62|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-63|49|480|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-64|49|488|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIA/  acute,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-65|49|493|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Thorax missing,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-66|49|494|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum. Metastases  tiac of duodenum to peritoneum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-67|49|502|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region of thigh.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-68|49|530|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-69|49|532|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-70|49|534|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS OF ANAL REGION TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-71|49|541|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ca of cecum.Eye(s) missing Head/neck missing,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-72|49|549|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-73|49|558|Other deterministic changes|Whole body|MCDU/   Metastases Lung|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-74|49|562|Neoplasia malignant|Reproductive system,MA: 0000411 - testis|TTFS/  Fibrosarcoma Metastases Heart,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-75|49|568|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-76|49|568|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWI: TIAC OF DUODENUM TO PERITONEUM.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-77|49|586|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-78|49|589|Neoplasia unclassified|Other local manifestations and miscellaneus|TYWT: TTFS TO HEART.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-79|49|590|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-80|49|592|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-81|49|592|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-82|49|594|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-83|49|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-84|49|604|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-85|49|606|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ small intestine. Metastases  tgac to brain. Metastases  tiac of small intestine to pancreas.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-86|49|609|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ small intestine.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-87|49|610|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-88|49|621|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-89|49|623|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWI: TIAC OF ILEUM INVASIVE ABOUT THE ILEUM.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-90|49|626|Neoplasia benign|Integumentary system,MA: 0000151 - skin|TSDO/ region of forearm. Sebaceous gland,MPATH: 407 - fibroma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-91|49|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-92|49|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-93|49|644|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-94|49|645|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWM: TMFS OF ANAL REGION TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-95|49|652|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-96|49|654|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ loin muscle & thigh.,MPATH: 428 - rhabdomyosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-97|49|662|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-98|49|667|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-99|49|670|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-100|49|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-101|49|679|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWV: TVAO(MALIGNANT) TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-102|49|688|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-103|49|689|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ anal region.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-104|49|693|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-105|49|706|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-106|49|708|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-107|49|709|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-108|49|723|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWA: TANS TO LUNG.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-109|49|736|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-110|49|737|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-111|49|739|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ mandible region.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-112|49|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-113|49|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-114|49|751|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-115|49|752|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ thigh.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-116|49|757|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-117|49|760|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-118|49|768|Neoplasia benign|Reproductive system,MA: 0000410 - seminal vesicle|TVAO/ malignant. Metastases Lung,MPATH: 270 - adenoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-119|49|768|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ nasal cavity.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-120|49|773|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ probably & also probably cod. Metastases Lung tmfs of anal region to lung.,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-121|49|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-122|49|779|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ shoulder region. Muscle|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-123|49|781|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-124|49|782|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-125|49|783|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-126|49|789|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-127|49|793|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum. Metastases  tiac of ileum invasive about the ileum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-128|49|794|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-129|49|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-130|49|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-131|49|804|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-132|49|805|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-133|49|805|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-134|49|809|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-135|49|810|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/  Head/neck missing,MPATH: 549 - carcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-136|49|810|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ belly wall.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-137|49|812|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-138|49|813|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ colon.Enteritis acute,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-139|49|827|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-140|49|838|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach wall.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-141|49|841|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-142|49|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-143|49|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-144|49|848|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ perirenal region.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-145|49|848|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-146|49|849|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum. Metastases  tiac of small intestine to pancreas.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-147|49|851|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-148|49|852|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ tail base.Skin|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-149|49|856|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-150|49|861|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-151|49|867|Neoplasia unclassified|Nervous system and special sense organs|TANS/  AdrenalEye(s) missing Head/neck missing|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-152|49|870|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-153|49|873|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-154|49|873|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-155|49|876|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cervical ln. Metastases  Muscle tgac to adjacent muscle. Metastases Lung|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-156|49|876|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not stated.,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-157|49|877|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-158|49|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-159|49|878|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum. Metastases  tiac of jejunum to pancreas.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-160|49|883|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-161|49|886|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-162|49|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-163|49|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-164|49|888|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-165|49|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-166|49|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-167|49|892|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-168|49|894|n/a|n/a|n/a|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-169|49|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-170|49|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-171|49|900|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ small intestine.Enteritis acute,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-172|49|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-173|49|906|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-174|49|907|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWI: TIPL TO SEROSA.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-175|49|914|Neoplasia unclassified|Central nervous system among nervous system|TNXS/ olfactory bulb.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-176|49|925|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ base of urinary bladder.,MPATH: 428 - rhabdomyosarcoma|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-177|49|929|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-178|49|929|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-179|49|933|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-180|49|934|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-181|49|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-182|49|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-183|49|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-184|49|965|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-185|49|967|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ region of jaw.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-186|49|968|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-187|49|970|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-188|49|974|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-189|49|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-190|49|987|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-191|49|991|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-192|49|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-193|49|1010|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to adjacent muscle.|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-194|49|1032|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region Metastases  tipl to serosa.,MPATH: 491 - polyp|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-195|49|1033|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-196|49|1038|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-197|49|1043|Other deterministic changes|Whole body|MCDU/  |
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-198|49|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-199|49|1058|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-49|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|157 records survival 632 ± 15 lifespan study|1003-20-49-200|49|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Lung,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-1|50|234|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ADJACENT MUSCLE.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-2|50|248|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWS: TSVS OF FACE TO SKELETAL MUSCLE OF FACE.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-3|50|253|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS ORIGIN OF OSTEOSARCOMA UNKNOWN METAST. TO LIVER.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-4|50|253|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWX: TNNO OF NASAL CAVITY TO BRAIN.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-5|50|257|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ gross dx ttyg.,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-6|50|280|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-7|50|305|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-8|50|309|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-9|50|309|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-10|50|319|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-11|50|327|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAA/   Metastases Lung tmaa to lung. Metastases Liver,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-12|50|329|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-13|50|331|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-14|50|339|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-15|50|348|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-16|50|355|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-17|50|362|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-18|50|369|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-19|50|369|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tsvs of face to skeletal muscle of face.,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-20|50|402|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWG: TGAC TO KIDNEY.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-21|50|407|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-22|50|419|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-23|50|431|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-24|50|441|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-25|50|446|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-26|50|469|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-27|50|476|Other deterministic changes|Hepato-pancreatic system|MHCY/  Hepatic cyst|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-28|50|487|Other deterministic changes|Whole body|MCDU/ cod apa/rjmf.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-29|50|502|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-30|50|504|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-31|50|515|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWX: TNNO OF NASAL CAVITY TO BRAIN.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-32|50|517|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-33|50|519|Neoplasia unclassified|Other local manifestations and miscellaneus|THWI: TIAC OF STOMACH TO LIVER.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-34|50|521|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ carcinoma cecum.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-35|50|526|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ adeno ca of cecum. Metastases  GI tract tmaa to stomach.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-36|50|534|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-37|50|540|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-38|50|546|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.Eye(s) missing Head/neck missing,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-39|50|550|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-40|50|553|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-41|50|557|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-42|50|557|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-43|50|565|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-44|50|568|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-45|50|572|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-46|50|578|Neoplasia unclassified|Other local manifestations and miscellaneus|TUWO: TOGC TO UTERUS.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-47|50|581|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-48|50|585|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-49|50|586|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach ca.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-50|50|588|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-51|50|592|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/  ,MPATH: 240 - hemangioma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-52|50|592|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-53|50|592|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-54|50|596|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-55|50|603|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-56|50|605|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-57|50|609|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-58|50|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-59|50|617|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-60|50|618|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-61|50|620|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of humerus.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-62|50|625|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MUCC/  Cystitis|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-63|50|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ kid & renal ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-64|50|634|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-65|50|636|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ massive ca of cecum.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-66|50|640|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-67|50|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-68|50|651|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-69|50|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-70|50|658|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-71|50|659|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-72|50|659|Neoplasia unclassified|Nervous system and special sense organs|TNNO/ nasal cavity. Metastases  tnno of nasal cavity to brain.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-73|50|659|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-74|50|666|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-75|50|668|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-76|50|670|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-77|50|677|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-78|50|682|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-79|50|687|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach. Metastases Liver,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-80|50|692|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-81|50|696|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-82|50|698|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-83|50|700|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach and oesophagus.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-84|50|702|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-85|50|702|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUEC/  squamous cell Ca Metastases Adrenal Metastases  GI tract tuec to colon.,MPATH: 268 - adenocarcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-86|50|703|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-87|50|704|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-88|50|705|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-89|50|706|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-90|50|707|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-91|50|709|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-92|50|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-93|50|710|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach ca.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-94|50|715|Neoplasia unclassified|Other local manifestations and miscellaneus|THWB: TBOS ORIGIN OF OSTEOSARCOMA UNKNOWN METAST. TO LIVER.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-95|50|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-96|50|716|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-97|50|717|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO REGIONAL MUSCLE.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-98|50|717|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-99|50|719|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-100|50|721|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-101|50|722|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-102|50|725|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-103|50|728|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWU: TUAC TO LUNG.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-104|50|730|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of pelvic spine.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-105|50|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-106|50|735|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-107|50|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  tiac of stomach to diaphragm.,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-108|50|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-109|50|737|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ADJACENT MUSCLE.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-110|50|739|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-111|50|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-112|50|744|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-113|50|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-114|50|747|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-115|50|749|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/   Metastases Liver,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-116|50|749|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO ADJACENT MUSCLE.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-117|50|750|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-118|50|750|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-119|50|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-120|50|759|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ region of eye.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-121|50|760|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-122|50|764|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/ chromophobe.Adenoma,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-123|50|767|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-124|50|771|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-125|50|774|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-126|50|776|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/ peritonitis.,MPATH: 213 - acute inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-127|50|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-128|50|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/ based on hematology.,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-129|50|782|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-130|50|785|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TISC/ oesophagus.,MPATH: 549 - carcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-131|50|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-132|50|788|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-133|50|788|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-134|50|789|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to regional muscle.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-135|50|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-136|50|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-137|50|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-138|50|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-139|50|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-140|50|795|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvic region.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-141|50|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-142|50|797|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-143|50|799|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-144|50|799|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-145|50|801|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-146|50|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-147|50|807|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Liver|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-148|50|809|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-149|50|813|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-150|50|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-151|50|814|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-152|50|817|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-153|50|817|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-154|50|823|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-155|50|826|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-156|50|833|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-157|50|834|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung Metastases  Muscle thac to muscle of peritoneal cavity.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-158|50|841|Neoplasia unclassified|Uterus among reproductive system diseases,MA: 0000389 - uterus|TUAC/ type unidentified. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-159|50|842|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-160|50|847|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-161|50|848|Degenerative changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MABA/  Adrenal brown atrophy,MPATH: 127 - atrophy|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-162|50|848|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-163|50|849|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-164|50|850|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-165|50|860|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-166|50|861|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-167|50|864|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases  Lymphoret.System thac to ln (not specified).|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-168|50|867|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-169|50|869|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-170|50|869|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-171|50|871|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ lumbar spine.,MPATH: 437 - neurofibrosarcoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-172|50|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-173|50|877|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-174|50|879|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-175|50|879|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-176|50|882|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum. Metastases  tiac of duodenum to unknown metastatic site.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-177|50|883|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-178|50|892|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-179|50|898|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAO/  Adenoma Metastases  tpao invasion of brain.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-180|50|899|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-181|50|900|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ small intestine.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-182|50|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-183|50|904|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute Metastases  Muscle tzac invasion of adnexa and muscle.,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-184|50|908|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-185|50|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-186|50|927|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-187|50|928|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-188|50|929|n/a|n/a|n/a|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-189|50|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-190|50|938|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases Lung tmab(inguinal) to lung.,MPATH: 218 - neoplasm|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-191|50|949|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull.|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-192|50|962|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region Metastases Uterus,MPATH: 491 - polyp|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-193|50|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-194|50|974|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region Metastases Heart Metastases  Muscle tgac to adjacent muscle.,MPATH: 491 - polyp|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-195|50|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases Kidney Metastases  tgac invasion of adnexa.,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-196|50|987|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-197|50|988|Other deterministic changes|Whole body|MCDU/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-198|50|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-199|50|997|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-50|n/a,S3|1| 100|neutrons fission|2.4|grays|External exposure| code S3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Female|Juvenile|199 records survival 580 ± 13 lifespan study|1003-20-50-200|50|1018|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ region of face.Skin|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-1|51|310|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-2|51|379|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-3|51|428|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-4|51|430|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-5|51|447|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-6|51|477|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-7|51|502|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-8|51|509|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-9|51|521|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-10|51|527|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-11|51|534|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-12|51|543|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to bronch or mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-13|51|544|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MPNA/  Pancreatitis|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-14|51|561|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-15|51|566|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ sq. cell ca of salivary gland/jhr; of oesophagus or skin/rjmf. Metastases Heart Metastases  Lymphoret.System txec of salivary gl. metast. to cervical ln.,MPATH: 446 - squamous cell carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-16|51|579|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Lung txec of salivary gl. metast. to lung.,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-17|51|583|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-18|51|588|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-19|51|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-20|51|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to sternal and rib muscles. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-21|51|605|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ base of tail. Metastases Heart,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-22|51|614|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-23|51|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-24|51|620|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-25|51|641|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-26|51|647|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ anal canal wall.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-27|51|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-28|51|651|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-29|51|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-30|51|656|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-31|51|673|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-32|51|680|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-33|51|682|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-34|51|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-35|51|687|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-36|51|688|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-37|51|690|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-38|51|692|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-39|51|695|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-40|51|700|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-41|51|711|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-42|51|715|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-43|51|715|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-44|51|717|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-45|51|720|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-46|51|729|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-47|51|730|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-48|51|732|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-49|51|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-50|51|742|Other deterministic changes|Hepato-pancreatic system|MHLD/  fatty metamorphosis liverHead/neck missing|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-51|51|743|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-52|51|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-53|51|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-54|51|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-55|51|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-56|51|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-57|51|764|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-58|51|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ deserves attention. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-59|51|767|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-60|51|768|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-61|51|768|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-62|51|781|Neoplasia unclassified|Other local manifestations and miscellaneus|TKWR: TRAC TO KIDNEY.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-63|51|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-64|51|785|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-65|51|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-66|51|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-67|51|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-68|51|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-69|51|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Kidney Metastases  Lymphoret.System trac to mediastinal and parathymic ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-70|51|805|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung Metastases  Lymphoret.System tkac to cervical ln. Metastases  Muscle trac metast. to costal muscle.,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-71|51|808|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-72|51|817|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT SPECIFIED.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-73|51|820|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-74|51|821|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscles.,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-75|51|826|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ muscle of thigh. Muscle Metastases  Seminal vesicle trac to seminal vesicle.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-76|51|827|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-77|51|827|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-78|51|827|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-79|51|830|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-80|51|837|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-81|51|841|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-82|51|850|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-83|51|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-84|51|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac invasion site not identified.,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-85|51|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-86|51|858|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC METAST. TO COSTAL MUSCLE.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-87|51|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-88|51|860|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-89|51|862|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ forelimb.muscle Metastases Lung tmfs of forelimb to lung.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-90|51|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-91|51|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-92|51|866|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-93|51|866|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ across shoulders.,MPATH: 437 - neurofibrosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-94|51|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-95|51|882|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-96|51|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-97|51|890|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWZ: TZAC TO REGIONAL MUSCLE.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-98|51|892|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-99|51|893|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-100|51|894|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not specified.,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-101|51|898|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-102|51|898|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-103|51|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-104|51|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-105|51|915|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac metast. to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-106|51|918|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-107|51|933|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-108|51|934|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-109|51|935|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ visc. peritoneum of ureter.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-110|51|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-111|51|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-112|51|939|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung Metastases Liver,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-113|51|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-114|51|941|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-115|51|943|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-116|51|945|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-117|51|948|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-118|51|953|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-119|51|953|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-120|51|956|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-121|51|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-122|51|960|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/ sarcomatous.Plaque pylorique region,MPATH: 491 - polyp|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-123|51|962|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-124|51|965|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-125|51|967|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-126|51|967|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-127|51|968|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-128|51|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-129|51|976|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-130|51|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-131|51|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-132|51|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-133|51|988|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-134|51|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-135|51|1004|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-136|51|1006|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-137|51|1006|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TKAC TO LUNG.|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-138|51|1006|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ lt. side thorax, s.c. Metastases  Muscle tcfs of side of thorax to muscle of thorax.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-139|51|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-140|51|1014|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-141|51|1018|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-142|51|1030|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-143|51|1031|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDEC/  Squamous cell carcinoma,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-144|51|1032|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-145|51|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-146|51|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-147|51|1045|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPO/ pylorus,MPATH: 491 - polyp|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-148|51|1048|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ muscle of lower leg (tibia-fibula). Muscle|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-149|51|1050|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-150|51|1059|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-151|51|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-152|51|1061|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-153|51|1061|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  Muscle tzac to regional muscle.,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-154|51|1062|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-155|51|1067|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-156|51|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-157|51|1072|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-158|51|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-159|51|1077|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-160|51|1079|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-161|51|1080|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-162|51|1089|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-163|51|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-164|51|1100|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-165|51|1103|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-166|51|1107|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-167|51|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-168|51|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/ either tlxs/tlhs (i.e. reticular tumor).,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-169|51|1114|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-170|51|1116|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-171|51|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-172|51|1133|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-173|51|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-174|51|1138|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-175|51|1143|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-176|51|1146|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-177|51|1147|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-178|51|1148|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-179|51|1153|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-180|51|1153|n/a|n/a|n/a|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-181|51|1153|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-182|51|1159|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-183|51|1162|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-184|51|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-185|51|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-186|51|1181|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-187|51|1185|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-188|51|1193|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-189|51|1195|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-190|51|1198|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-191|51|1208|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-192|51|1226|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-193|51|1229|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-194|51|1234|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-195|51|1234|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-196|51|1246|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-197|51|1247|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-198|51|1256|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-199|51|1263|Other deterministic changes|Whole body|MCDU/  |
1003-20-51|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 693 ± 15 lifespan study 194 d old|1003-20-51-200|51|1386|Other deterministic changes|Whole body|MCDU/  |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-1|52|369|Neoplasia unclassified|Other local manifestations and miscellaneus|TIWB: TBOS OF FEMUR TO RECTAL WALL.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-2|52|377|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-3|52|418|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa Metastases  Muscle tnns of nerve of lumbar spine to lumbar muscles.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-4|52|449|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-5|52|467|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-6|52|513|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWA: TACC TO LUNG.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-7|52|557|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-8|52|559|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to parathymic ln. Metastases  Muscle trac to muscle of chest wall. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-9|52|596|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-10|52|603|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-11|52|614|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ inguinal region. Metastases Lung Metastases  Muscle tcfs of inguinal & axil. region to rib cage, thigh and forearm. Metastases  Lymphoret.System tcfs of inguinal & axil. region to parathymic ln.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-12|52|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-13|52|643|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-14|52|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-15|52|663|Hyperplastic changes|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MOCY/  Ovary or testis,MPATH: 62 - cyst|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-16|52|673|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebrae. Metastases  Muscle tbos of lumbar vertebrae to lumbar muscle. Metastases  tbos of lumbar vertebrae to lumbar spinal cord.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-17|52|714|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-18|52|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-19|52|728|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TRAC TO KIDNEY.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-20|52|739|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-21|52|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-22|52|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-23|52|748|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-24|52|751|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-25|52|759|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Muscle tgac to muscles of face.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-26|52|761|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF SKULL TO HEAD MUSCLE.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-27|52|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-28|52|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-29|52|797|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-30|52|803|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-31|52|803|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ mandible. Metastases  tmls of mandible to skin of mandible.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-32|52|804|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|TMAB/  Predominantly ductal Metastases Lung tmab to lung. Metastases Liver,MPATH: 218 - neoplasm|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-33|52|807|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-34|52|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-35|52|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-36|52|823|Neoplasia benign|Ovary among reproductive system diseases| |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-37|52|824|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull. Metastases  tbos of skull to brain (cerebrum). Metastases  Muscle tbos of skull to head muscle. Metastases  tbos of skull to eye adnexa.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-38|52|827|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-39|52|838|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-40|52|843|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-41|52|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-42|52|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-43|52|853|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TULS/  ,MPATH: 551 - sarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-44|52|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-45|52|855|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF SKULL TO HEAD MUSCLE.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-46|52|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-47|52|855|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-48|52|856|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-49|52|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-50|52|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-51|52|871|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases  Muscle tbos of femur to thigh muscle. Metastases  GI tract tbos of femur to rectal wall. Metastases  Skin tbos of femur to skin of thigh.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-52|52|876|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWK: TRAC TO KIDNEY.|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-53|52|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-54|52|882|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-55|52|889|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing Thorax missing|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-56|52|890|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-57|52|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-58|52|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-59|52|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-60|52|914|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ lip.,MPATH: 218 - neoplasm|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-61|52|920|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-62|52|921|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-63|52|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-64|52|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-65|52|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-66|52|930|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases  togc to viscera. Metastases Kidney Metastases Liver Metastases Lung|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-67|52|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  tuls infilt. to adnexal tissue un-identifiable due to autolysis.,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-68|52|940|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-69|52|944|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-70|52|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-71|52|953|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-72|52|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-73|52|960|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-74|52|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-75|52|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-76|52|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-77|52|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-78|52|992|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-79|52|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-80|52|998|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-81|52|1006|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-82|52|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-83|52|1015|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-84|52|1015|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-85|52|1017|n/a|n/a|n/a|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-86|52|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-87|52|1023|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-88|52|1029|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-89|52|1054|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVO/  ,MPATH: 242 - hemangiosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-90|52|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-91|52|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-92|52|1081|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ nerve, lumbar spine.,MPATH: 437 - neurofibrosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-93|52|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-94|52|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-95|52|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-96|52|1123|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-97|52|1128|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-98|52|1135|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung,MPATH: 549 - carcinoma|
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-99|52|1146|Other deterministic changes|Whole body|MCDU/  |
1003-20-52|n/a,Y2|1| 194|neutrons fission|0.8|grays|External exposure| code Y2 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 655 ± 18 lifespan study 194 d 0ld|1003-20-52-100|52|1165|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-1|53|357|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-2|53|358|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-3|53|365|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-4|53|379|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWG: TGAC TO TRIGEMINAL NERVE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-5|53|408|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMFS OF XYPHOID REGION TO RENAL LN.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-6|53|422|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-7|53|446|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-8|53|449|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-9|53|457|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-10|53|465|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-11|53|471|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-12|53|500|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-13|53|505|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-14|53|512|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-15|53|512|Neoplasia unclassified|Other local manifestations and miscellaneus|TVWD: TDTC TO SEMINAL VESICLE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-16|53|513|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-17|53|519|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-18|53|529|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-19|53|536|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-20|53|553|Inflammation and/or fibrotic diseases|Kidney among urinary system diseases,MA: 0000368 - kidney|MPNE/  acute,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-21|53|558|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/  Transitional cell,MPATH: 549 - carcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-22|53|562|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-23|53|582|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-24|53|586|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-25|53|592|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-26|53|613|Neoplasia unclassified|Other local manifestations and miscellaneus|THWS: TSEC OF LEFT SIDE OF ABD. TO LIVER.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-27|53|622|Other deterministic changes|Whole body|MCDU/ probably related to brain hemorrhage noted on gross, but not noted histologically.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-28|53|628|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-29|53|630|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-30|53|636|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-31|53|641|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-32|53|646|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-33|53|646|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-34|53|647|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-35|53|652|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-36|53|664|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ acute ileitis w/abscess.Enteritis acute,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-37|53|669|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ parotid gland.,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-38|53|669|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-39|53|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-40|53|670|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-41|53|677|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac to skull muscle. Metastases Lung|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-42|53|684|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-43|53|691|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis or femur? Metastases Lung|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-44|53|691|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-45|53|694|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region Metastases Seminal vesicle,MPATH: 491 - polyp|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-46|53|696|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon. Metastases  trac invasion site unspecified.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-47|53|696|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-48|53|705|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWB: TBOS OF NOSE TO CN. L.N.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-49|53|710|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-50|53|714|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-51|53|715|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ stomach.Enteritis acute,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-52|53|717|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-53|53|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-54|53|722|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ ileum.,MPATH: 551 - sarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-55|53|722|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ foot.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-56|53|724|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ either peripheral nerve in nasal cavity or from olfactory bulb.,MPATH: 437 - neurofibrosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-57|53|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-58|53|726|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-59|53|729|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-60|53|729|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR VERTEBRA TO MUSCLE OF LUMBAR VERTEBRAE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-61|53|730|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum wall. Metastases  Muscle tnns of periph. ner. in nas. cav. or olf. bulb to muscle over nose. Metastases  tiac of cecum wall to mesenteric fat and visc. peritoneum.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-62|53|731|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-63|53|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-64|53|732|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-65|53|735|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWN: TNNS OF PERIPH. NER. IN NAS. CAV. OR OLF. BULB TO MUSCLE OVER NOSE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-66|53|735|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-67|53|736|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWG: TGAC TO TRIGEMINAL NERVE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-68|53|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-69|53|736|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-70|53|741|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ region of thigh. Muscle|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-71|53|743|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ located right shoulder; sarcoma type not recognized.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-72|53|745|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-73|53|746|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh region. Muscle|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-74|53|747|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-75|53|752|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-76|53|754|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-77|53|761|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-78|53|764|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-79|53|766|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-80|53|767|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-81|53|768|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-82|53|772|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ dorsal abdomen.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-83|53|774|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinal vessel.,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-84|53|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  Trunk missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-85|53|776|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-86|53|778|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-87|53|778|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-88|53|778|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ left side of abdomen. Metastases Liver Metastases  Muscle tsec of left side of abd. to muscle of abdomen. Metastases  tsec of left side of abd. to pancreas. Metastases  tsec of left side of abd. to nerve fibers of abdomen.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-89|53|782|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNU/  Acute and subacute,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-90|53|784|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-91|53|785|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-92|53|787|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-93|53|791|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ rectum.,MPATH: 551 - sarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-94|53|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-95|53|795|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-96|53|796|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-97|53|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscle of sternum. Metastases Kidney Metastases Heart Metastases  trac to mediastinal visc and pariet. pleura. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-98|53|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-99|53|809|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-100|53|809|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon. Metastases  tiac of colon to gut serosa of adnexa (spread).,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-101|53|812|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ prostate.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-102|53|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-103|53|820|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-104|53|822|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-105|53|827|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWB: TBOS OF NOSE TO CN. L.N.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-106|53|829|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  TestisEye(s) missing Head/neck missing|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-107|53|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-108|53|834|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ spine, caudal, pelvic region. Metastases Liver Metastases Lung Metastases  Lymphoret.System origin unknown metast. to cervical ln.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-109|53|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-110|53|837|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MNIA/ malacia-thoracic spinal cord.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-111|53|841|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitisEye(s) missing Head/neck missing,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-112|53|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-113|53|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-114|53|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-115|53|847|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-116|53|852|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ xyphoid region.muscle Metastases Lymphoret.System tmfs of xyphoid region to renal ln.also Lung tmfs of xyphoid region to lung also tmfs of xyphoid region to visceral peritoneum also Muscle tmfs of xyphoid region to adjac.muscles,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-117|53|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-118|53|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-119|53|856|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-120|53|856|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-121|53|858|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-122|53|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-123|53|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-124|53|864|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-125|53|865|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-126|53|869|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ cheek subcutis. Metastases Lung Metastases  Muscle tcfs of cheek subcutis to cheek muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-127|53|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-128|53|873|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine. Metastases  Muscle tbos of lumbar spine to lumbar muscle.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-129|53|875|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-130|53|877|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ rib cage muscle.,MPATH: 428 - rhabdomyosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-131|53|878|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-132|53|882|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWM: TMFS OF XYPHOID REGION TO RENAL LN.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-133|53|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-134|53|892|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  tgac to trigeminal nerve.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-135|53|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-136|53|899|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ jejunum.,MPATH: 551 - sarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-137|53|900|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-138|53|900|Neoplasia benign|Bloodvessels among cardiovascular system|TLVO/ mesent. l.n. Lymphoret.tissue|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-139|53|901|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum with invasion of muscularis mucosa. Metastases Lung,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-140|53|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-141|53|905|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-142|53|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-143|53|908|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-144|53|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-145|53|910|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-146|53|911|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-147|53|914|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ mandible.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-148|53|925|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of mandible.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-149|53|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-150|53|925|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ small intestine.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-151|53|929|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-152|53|932|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-153|53|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-154|53|942|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-155|53|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-156|53|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-157|53|959|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR SPINE TO LUMBAR MUSCLE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-158|53|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-159|53|964|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-160|53|964|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-161|53|965|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-162|53|968|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebra. Metastases  Muscle tbos of lumbar vertebra to muscle of lumbar vertebrae.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-163|53|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-164|53|974|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO SKULL MUSCLE.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-165|53|975|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-166|53|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-167|53|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-168|53|988|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-169|53|999|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-170|53|1003|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-171|53|1005|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-172|53|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-173|53|1012|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-174|53|1017|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWI: TIAC OF COLON TO GUT SEROSA OF ADNEXA (SPREAD).|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-175|53|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-176|53|1018|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-177|53|1024|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ nose. Metastases  Lymphoret.System tbos of nose to cn. l.n.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-178|53|1030|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-179|53|1033|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum. Metastases Liver Metastases  Kidney tiac of jejunum to kidney.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-180|53|1041|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-181|53|1043|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-182|53|1044|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-183|53|1045|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-184|53|1046|n/a|n/a|n/a|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-185|53|1046|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases  Muscle tbos of femur to thigh muscle.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-186|53|1049|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adipose tissue in scrotal area.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-187|53|1050|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-188|53|1051|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-189|53|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-190|53|1058|Neoplasia benign|Other local manifestations and miscellaneus|TCFO/ region of pancreas.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-191|53|1062|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-192|53|1067|Other deterministic changes|Whole body|MCDU/   Metastases  Skin tbos of lumbar spine to dors. lumbar skin.|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-193|53|1075|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum and peritoneum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-194|53|1094|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-195|53|1125|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon.,MPATH: 218 - neoplasm|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-196|53|1131|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-197|53|1133|Other deterministic changes|Whole body|MCDU/  |
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-198|53|1137|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-199|53|1153|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-53|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 612 ± 13 lifespan study 194 d old|1003-20-53-200|53|1261|Other deterministic changes|Whole body|MCDU/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-1|54|259|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF THORACIC SPINE TO THORACIC SPINAL MUSCLES.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-2|54|443|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-3|54|454|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-4|54|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-5|54|512|n/a|n/a|n/a|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-6|54|539|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-7|54|541|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-8|54|568|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSBC/ chest.,MPATH: 446 - squamous cell carcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-9|54|570|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-10|54|586|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ caecum.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-11|54|589|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-12|54|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-13|54|620|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ cervical spinal muscle. Muscle|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-14|54|621|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar spine.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-15|54|631|n/a|n/a|n/a|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-16|54|639|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBVS OF THIGH TO THIGH MUSCLE.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-17|54|652|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ post-nasal cavity.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-18|54|654|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-19|54|655|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ base of tail.Skin|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-20|54|657|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-21|54|659|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-22|54|660|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-23|54|660|Neoplasia malignant|Other local manifestations and miscellaneus|TXUS/ TXUS/ TXUS/ TXUS/ sal. gland. Metastases  Lung txus of sal. gland to lung.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-24|54|666|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF TIBIA AND FIBULA TO LEG MUSCLE.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-25|54|673|n/a|n/a|n/a|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-26|54|676|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/  ,MPATH: 551 - sarcoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-27|54|680|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF SPINE TO MUSCLE OF SPINE.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-28|54|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-29|54|688|Neoplasia malignant|Endocrine system|TGAC/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-30|54|701|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-31|54|703|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/ cerebral meninges.,MPATH: 551 - sarcoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-32|54|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-33|54|712|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLE OF HEAD.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-34|54|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-35|54|712|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus, papilloma.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-36|54|712|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF LUMBAR VERTEBRA TO MUSCLE OF LUMBAR REGION.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-37|54|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-38|54|736|n/a|n/a|n/a|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-39|54|738|n/a|n/a|n/a|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-40|54|744|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-41|54|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-42|54|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-43|54|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-44|54|759|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ spine. Metastases  tbos of spine to spinal cord. Metastases  Muscle tbos of spine to muscle of spine.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-45|54|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-46|54|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-47|54|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-48|54|783|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ right ear canal.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-49|54|785|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ thigh. Metastases  Muscle tbvs of thigh to thigh muscle.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-50|54|796|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-51|54|796|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sternum. Metastases  tbos of sternum to sternal bone marrow. Metastases Lung Metastases  tbos of sternum to meninges and on surface of cerebrum.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-52|54|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-53|54|812|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|TACC/   Metastases Lung Metastases Liver,MPATH: 549 - carcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-54|54|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-55|54|829|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum. Metastases  Muscle tcvs of right side of neck to muscle of neck.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-56|54|829|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ thoracic spine. Metastases  tbos of thoracic spine to thoracic spinal cord.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-57|54|831|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MSDC/  chronic|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-58|54|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-59|54|837|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-60|54|838|Neoplasia unclassified|Other local manifestations and miscellaneus|TNWB: TBOS OF STERNUM TO MENINGES AND ON SURFACE OF CEREBRUM.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-61|54|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-62|54|843|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases  Muscle tbos of femur to thigh muscle. Metastases  Kidney tbos of femur to kidney.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-63|54|850|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/  Eye(s) missing Head/neck missing|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-64|54|858|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-65|54|865|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus. Metastases Lung tiac of pylorus to lung.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-66|54|870|Neoplasia unclassified|Nervous system and special sense organs|TANS/  Adrenal Metastases  Muscle tbos of thoracic spine to thoracic spinal muscles. Metastases Heart Metastases Lung|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-67|54|876|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  Muscle tkac to dorsal thoracic-lumbar. Metastases  Muscle tgac to muscle of head.,MPATH: 549 - carcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-68|54|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-69|54|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-70|54|881|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ sternum.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-71|54|882|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  Eye(s) missing Head/neck missing,MPATH: 1 - cell and tissue damage|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-72|54|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-73|54|898|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  tbos of sternum to heart base (small).,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-74|54|904|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-75|54|910|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ lumbar muscle. Metastases Lung tmrs of lumbar muscle to lung. Metastases Heart,MPATH: 428 - rhabdomyosarcoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-76|54|912|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-77|54|914|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ pap. adca of gall bladder.,MPATH: 268 - adenocarcinoma|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-78|54|914|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ tibia and fibula. Metastases  Muscle tbos of tibia and fibula to leg muscle.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-79|54|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-80|54|928|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-81|54|931|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWB: TBOS OF FEMUR TO LUNG.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-82|54|943|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-83|54|948|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ intercostal muscles. Muscle|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-84|54|953|Neoplasia unclassified|Other local manifestations and miscellaneus|THWA: TACC TO LIVER.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-85|54|955|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tmab to axilary muscle, skeletal.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-86|54|962|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebra. Metastases Lung|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-87|54|969|Other deterministic changes|Whole body|MCDU/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-88|54|970|Other deterministic changes|Whole body|MCDU/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-89|54|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-90|54|981|Other deterministic changes|Whole body|MCDU/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-91|54|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-92|54|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-93|54|993|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur. Metastases Lung Metastases  Muscle tbos of femur to muscle over femur.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-94|54|1016|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebra. Metastases  Muscle tbos of lumbar vertebra to muscle of lumbar region.|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-95|54|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-96|54|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-97|54|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-98|54|1056|Other deterministic changes|Whole body|MCDU/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-99|54|1069|Other deterministic changes|Whole body|MCDU/  |
1003-20-54|n/a,Y3|1| 194|neutrons fission|2.4|grays|External exposure| code Y3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|99 records survival 593 ± 15 lifespan study  194 d old|1003-20-54-100|54|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-1|55|277|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-2|55|302|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-3|55|444|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ region of pelvis. Metastases Lung Metastases  Lymphoret.System tbos of pelvic region to lumbar ln.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-4|55|477|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-5|55|494|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/ tlml/rjmf & jhr.,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-6|55|515|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln. Metastases  Muscle trac to costal muscle. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-7|55|516|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-8|55|548|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-9|55|562|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-10|55|570|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-11|55|587|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-12|55|601|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ scapular area.,MPATH: 428 - rhabdomyosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-13|55|610|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-14|55|624|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-15|55|624|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-16|55|626|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-17|55|628|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-18|55|638|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-19|55|653|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-20|55|659|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-21|55|667|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-22|55|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-23|55|673|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC TO CN. LN.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-24|55|676|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ leg. Muscle|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-25|55|677|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-26|55|688|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-27|55|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-28|55|698|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ foreleg.,MPATH: 428 - rhabdomyosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-29|55|699|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  tgac to orbit.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-30|55|701|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-31|55|701|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE NOT IDENTIFIED.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-32|55|712|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-33|55|715|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-34|55|718|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-35|55|723|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-36|55|726|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-37|55|731|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-38|55|733|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-39|55|735|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-40|55|739|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-41|55|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-42|55|742|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-43|55|746|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-44|55|750|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-45|55|758|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-46|55|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-47|55|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-48|55|764|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-49|55|765|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-50|55|767|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-51|55|767|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-52|55|768|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWS: TSEC OF MAXILLARY AREA TO CERV. L.N.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-53|55|770|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-54|55|771|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-55|55|772|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-56|55|778|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-57|55|788|Neoplasia systemic|Haematolymphatic system|TLML/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-58|55|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-59|55|797|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  ,MPATH: 235 - blood vessel tumor|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-60|55|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to wall 0f trachea.,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-61|55|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-62|55|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-63|55|802|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-64|55|811|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-65|55|813|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ region kidney adnexa.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-66|55|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-67|55|814|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-68|55|817|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tgac to head.,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-69|55|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-70|55|819|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-71|55|820|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-72|55|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-73|55|821|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-74|55|822|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-75|55|822|Neoplasia systemic|Haematolymphatic system|TLML/ confirmed by hematology.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-76|55|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-77|55|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle trac to sternal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-78|55|824|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-79|55|826|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-80|55|827|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-81|55|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-82|55|830|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-83|55|836|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-84|55|836|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-85|55|837|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TMFS/ flank region.muscle,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-86|55|840|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-87|55|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-88|55|846|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-89|55|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-90|55|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-91|55|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-92|55|858|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-93|55|861|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC TO WALL 0F TRACHEA.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-94|55|862|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-95|55|865|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-96|55|873|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ pancreas.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-97|55|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-98|55|876|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO MUSCLES OF FACE.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-99|55|878|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-100|55|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-101|55|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-102|55|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-103|55|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-104|55|890|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-105|55|893|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-106|55|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-107|55|894|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-108|55|897|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-109|55|897|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-110|55|901|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-111|55|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-112|55|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-113|55|908|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-114|55|910|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-115|55|913|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-116|55|915|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ connective tiss.between cephalad pole of kid.and pancreas Metastases tcvs of conn.tiss.between cephalad pole of kid.and pancr.to pancreas Metastases Muscle tcvs of conn.tiss.between cephalad pole of kid.and pancr.to muscles of thoracic spine |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-117|55|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-118|55|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-119|55|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-120|55|921|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-121|55|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-122|55|922|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ muscle of spine and adjacent tissues. Muscle|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-123|55|922|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ stomach.,MPATH: 549 - carcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-124|55|927|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-125|55|928|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-126|55|932|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-127|55|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-128|55|943|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-129|55|948|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWG: TGAC METAST. TO CN L.N.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-130|55|948|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ maxillary area. Metastases  Lymphoret.System tsec of maxillary area to cerv. l.n.,MPATH: 218 - neoplasm|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-131|55|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-132|55|951|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not identified.,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-133|55|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-134|55|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-135|55|958|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  tiec  of stomach invasion locally. Metastases  Lymphoret.System trac to mediastinal ln. Metastases  trac invasion site not specified.,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-136|55|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-137|55|963|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIT/  Toxic hepatitis,MPATH: 212 - inflammation|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-138|55|967|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-139|55|977|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-140|55|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-141|55|983|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ acute ulcerative enteritis, jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-142|55|986|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-143|55|994|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-144|55|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-145|55|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-146|55|1003|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-147|55|1005|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-148|55|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-149|55|1007|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-150|55|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-151|55|1018|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-152|55|1021|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ duodenum.,MPATH: 549 - carcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-153|55|1023|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-154|55|1024|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-155|55|1038|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-156|55|1038|Neoplasia malignant|Other local manifestations and miscellaneus|TMLS/ chest wall, abdomen.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-157|55|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-158|55|1039|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-159|55|1041|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-160|55|1043|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ skin of chest and abdomen.,MPATH: 437 - neurofibrosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-161|55|1043|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Lymphoret.System tgac to cn. ln. Metastases  tgac to aortic wall. Metastases Lung|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-162|55|1044|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIAO/ stomach.,MPATH: 549 - carcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-163|55|1047|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-164|55|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-165|55|1052|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System tgac metast. to cn l.n. Metastases  tgac metast. to parietal pleura; rib cage.|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-166|55|1056|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-167|55|1059|Other deterministic changes|Whole body|MCDU/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-168|55|1061|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-169|55|1066|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-170|55|1067|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ probably adrenal.,MPATH: 218 - neoplasm|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-171|55|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-172|55|1078|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  Head/neck missing Eye(s) missing|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-173|55|1079|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-174|55|1082|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-175|55|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-176|55|1094|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-177|55|1095|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-178|55|1096|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MPNI/  acute/chronic,MPATH: 212 - inflammation|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-179|55|1098|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-180|55|1101|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-181|55|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-182|55|1112|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ face.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-183|55|1115|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-184|55|1116|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-185|55|1122|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-186|55|1135|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-187|55|1138|n/a|n/a|n/a|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-188|55|1156|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-189|55|1161|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-190|55|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-191|55|1171|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-192|55|1172|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-193|55|1174|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tgac to skull and rib muscles.,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-194|55|1174|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-195|55|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-196|55|1212|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-197|55|1217|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-198|55|1237|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-199|55|1241|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-55|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|199 records survival 609 ± 12 lifespan study 287 d old|1003-20-55-200|55|1353|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Muscle tgac to muscles of face.,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-1|56|373|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-2|56|393|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-3|56|402|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-4|56|564|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-5|56|568|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ abdominal fat pad.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-6|56|576|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-7|56|616|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-8|56|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-9|56|643|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-10|56|650|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-11|56|653|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-12|56|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-13|56|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-14|56|661|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-15|56|671|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-16|56|683|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-17|56|687|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO CHEEK MUSCLE.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-18|56|705|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-19|56|721|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-20|56|732|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-21|56|733|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-22|56|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-23|56|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-24|56|764|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-25|56|771|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-26|56|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-27|56|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-28|56|798|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-29|56|799|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-30|56|799|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-31|56|804|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-32|56|813|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-33|56|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-34|56|839|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIEC/ anus. Metastases  Lymphoret.System tiec of anus to in. l.n.,MPATH: 549 - carcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-35|56|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-36|56|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-37|56|859|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-38|56|873|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-39|56|877|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-40|56|878|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-41|56|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-42|56|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-43|56|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-44|56|892|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ rib. Metastases Lung Metastases  Muscle tbos of rib to intercostal muscle.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-45|56|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-46|56|897|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWG: TGAC TO CHEEK MUSCLE.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-47|56|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-48|56|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-49|56|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-50|56|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-51|56|906|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to intercostal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-52|56|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-53|56|910|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-54|56|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-55|56|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-56|56|926|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ jejunum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-57|56|932|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-58|56|933|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-59|56|934|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-60|56|939|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-61|56|941|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-62|56|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-63|56|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-64|56|962|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-65|56|967|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases  Muscle tgac to cheek muscle.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-66|56|967|Other deterministic changes|Whole body|MCDU/  |
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-67|56|974|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-68|56|976|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-69|56|981|Other deterministic changes|Whole body|MCDU/  |
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-70|56|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-71|56|995|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ salivary gland-mixed type tumor.,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-72|56|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-73|56|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-74|56|1015|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-75|56|1016|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-76|56|1027|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-77|56|1030|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-78|56|1030|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ pelvis or lumbar vert. Metastases  Muscle tbos of pelvis or lumbar vert. to pelvic and intercostal muscles.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-79|56|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-80|56|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-81|56|1051|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-82|56|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-83|56|1090|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-84|56|1100|Other deterministic changes|Whole body|MCDU/  |
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-85|56|1102|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vert. Metastases  Muscle tbos of lumbar vert. to lumbar muscles.|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-86|56|1107|n/a|n/a|n/a|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-87|56|1110|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-88|56|1117|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-89|56|1121|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|TOVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-90|56|1129|Other deterministic changes|Whole body|MCDU/  |
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-91|56|1131|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-92|56|1158|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-93|56|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-94|56|1181|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-56|n/a,Z2|1| 287|neutrons fission|0.8|grays|External exposure| code Z2 1 fraction 20 m|95 (95 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|95 records survival 600 ± 18 lifespan study  287 d old|1003-20-56-95|56|1202|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-1|57|386|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-2|57|425|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|MCIG/  ,MPATH: 213 - acute inflammation|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-3|57|457|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-4|57|486|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-5|57|500|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-6|57|505|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ pancreatic duct.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-7|57|513|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-8|57|534|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWZ: TZAC TO RENAL LN.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-9|57|542|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-10|57|547|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-11|57|554|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ region of pelvic peritoneum. Metastases  Kidney tcfs of pelvic peritoneum to kidney. Metastases Lung,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-12|57|554|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-13|57|557|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-14|57|562|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-15|57|571|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-16|57|578|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ carcinoma jejunum. Metastases  tiac of jejunum to pancreas.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-17|57|582|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-18|57|589|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-19|57|590|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-20|57|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-21|57|592|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-22|57|598|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWZ: TZAC TO RENAL LN.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-23|57|601|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-24|57|611|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ lumbar muscle. Metastases  tmrs of lumbar muscle to lumbar spinal cord.,MPATH: 428 - rhabdomyosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-25|57|612|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-26|57|612|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-27|57|616|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-28|57|617|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-29|57|643|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-30|57|645|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-31|57|648|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ adeno-squamous ca of stomach - kyriazis.  probably some tumor.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-32|57|649|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-33|57|652|Neoplasia unclassified|Other local manifestations and miscellaneus|TXWR: TRAC INVASION SITE UNSPECIFIED.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-34|57|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-35|57|665|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-36|57|673|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-37|57|675|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 242 - hemangiosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-38|57|677|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-39|57|680|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-40|57|688|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO MEDIASTINAL LN.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-41|57|691|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWR: TRAC TO COSTAL MUSCLE.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-42|57|691|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-43|57|694|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWI: TIFS OF STOMACH TO GASTRIC LN.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-44|57|697|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-45|57|697|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-46|57|697|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-47|57|698|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-48|57|700|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-49|57|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-50|57|701|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-51|57|703|Neoplasia unclassified|Other local manifestations and miscellaneus|TGWC: TCFS OF NOSE INVASION OF HARDERIAN GLAND.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-52|57|705|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib cage muscle. Metastases  Muscle tsec of scapular skin to scapular muscle. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-53|57|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-54|57|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-55|57|718|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ pelvis. Metastases  Muscle tsfs of pelvis to skeletal muscle of spine.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-56|57|721|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ colon.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-57|57|725|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-58|57|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-59|57|727|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ neck.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-60|57|730|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ stomach. Metastases  tifs  of stomach to visceral and parietal peritoneum.,MPATH: 551 - sarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-61|57|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-62|57|732|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-63|57|738|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-64|57|739|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-65|57|740|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-66|57|744|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-67|57|746|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-68|57|747|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHCN/  Coagulative focal hepatitis,MPATH: 212 - inflammation|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-69|57|748|Neoplasia unclassified|Other local manifestations and miscellaneus|TRWG: TGAC TO LUNG.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-70|57|757|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-71|57|766|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|TDTC/ new codes; transitional cell carcinoma of bladder.Transitional cell Metastases Seminal vesicle,MPATH: 549 - carcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-72|57|767|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-73|57|770|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ region of lower bowel.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-74|57|770|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-75|57|771|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-76|57|775|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-77|57|777|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-78|57|780|Neoplasia unclassified|Other local manifestations and miscellaneus|TGWC: TCFS OF NOSE INVASION OF HARDERIAN GLAND.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-79|57|781|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-80|57|781|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-81|57|781|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|TPAC/  Carcinoma,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-82|57|782|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-83|57|785|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-84|57|786|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-85|57|790|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ cecum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-86|57|792|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-87|57|799|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ duodenum.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-88|57|799|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-89|57|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-90|57|802|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ skull at ear canal.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-91|57|802|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-92|57|806|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle tcfs of neck to cervical muscles.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-93|57|806|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-94|57|808|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|TIFS/ ileum. Metastases  tifs of ileum to visc. and parietal peritoneum and pleura. Metastases Lung tifs of ileum to lung.,MPATH: 551 - sarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-95|57|818|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-96|57|822|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-97|57|824|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|TBFS/ periosteum of femur.,MPATH: 551 - sarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-98|57|836|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNNS/ stomach wall. Metastases Liver,MPATH: 437 - neurofibrosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-99|57|848|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ nose. Metastases Harderian gland Metastases  tcfs of nose invasion of brain. Metastases  Skin tcfs of nose invasion of adjacent skin.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-100|57|851|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-101|57|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-102|57|869|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-103|57|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-104|57|872|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-105|57|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-106|57|876|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-107|57|883|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-108|57|885|Neoplasia malignant|Endocrine system|TGAC/   Metastases  tgac metastasis to or invasion of frontal lobe of cerebrum and adnexa of eye. Metastases Lung|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-109|57|888|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-110|57|890|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-111|57|893|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-112|57|893|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-113|57|894|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-114|57|897|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-115|57|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-116|57|902|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-117|57|908|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-118|57|910|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ tail base.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-119|57|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-120|57|931|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-121|57|933|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus. Metastases  Lymphoret.System tifs of stomach to gastric ln.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-122|57|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-123|57|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site not stated.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-124|57|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-125|57|937|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-126|57|941|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-127|57|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-128|57|947|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-129|57|949|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-130|57|953|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|TMRS/ skin across shoulders.,MPATH: 428 - rhabdomyosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-131|57|953|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-132|57|953|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-133|57|955|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-134|57|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-135|57|957|Neoplasia malignant|Adrenal gland  among endocrine systems|TAPS/   Metastases  Muscle tnns of stomach wall to skeletal muscle adj. to stomach. Metastases Kidney Metastases  Lymphoret.System taps to pt. l.n. and spleen.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-136|57|957|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-137|57|960|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-138|57|963|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-139|57|964|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-140|57|966|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac invasion site unspecified.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-141|57|967|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-142|57|969|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-143|57|972|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-144|57|972|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ scapular region. Metastases  Muscle tcfs of scapular region to regional muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-145|57|975|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-146|57|976|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-147|57|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-148|57|978|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-149|57|982|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to mediastinum. Metastases Liver,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-150|57|982|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-151|57|990|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWC: TCFS OF NECK TO CERVICAL MUSCLES.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-152|57|996|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-153|57|999|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-154|57|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  tmrs of upper chest cavity to costal muscle.,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-155|57|1003|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-156|57|1006|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ ileum.Enteritis acute,MPATH: 212 - inflammation|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-157|57|1012|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-158|57|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-159|57|1017|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|TZAC/ 3/14/77/ll; 3/30/77/jhr. Metastases  Lymphoret.System tzac to renal ln.,MPATH: 278 - follicular adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-160|57|1019|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000164 - myocardium|MMCC/ MMCC/ MMCC/ MMCC/  chronic,MPATH: 212 - inflammation|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-161|57|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-162|57|1025|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-163|57|1029|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-164|57|1029|Neoplasia benign|Lower digestive tract,MA: 0000323 - gastrointestinal system|TIPL/  Plaque pylorique region,MPATH: 491 - polyp|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-165|57|1033|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-166|57|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-167|57|1036|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-168|57|1037|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-169|57|1042|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-170|57|1043|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-171|57|1046|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ jaw. Metastases Lung|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-172|57|1051|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to costal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-173|57|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-174|57|1055|Neoplasia malignant|Endocrine system|TGAC/   Metastases Lung Metastases  Lymphoret.System trac to mediastinal ln.|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-175|57|1063|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|TVFS/ region of pelvis.Fibrosarcoma,MPATH: 551 - sarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-176|57|1072|n/a|n/a|n/a|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-177|57|1072|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-178|57|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-179|57|1079|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-180|57|1082|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-181|57|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-182|57|1083|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ scrotum.Skin|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-183|57|1085|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-184|57|1089|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-185|57|1097|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-186|57|1109|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ site not specified.Enteritis acute,MPATH: 212 - inflammation|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-187|57|1109|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|TSFS/ abdominal region.,MPATH: 219 - adnexal and skin appendage tumor|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-188|57|1111|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ stomach.,MPATH: 218 - neoplasm|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-189|57|1115|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-190|57|1117|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-191|57|1128|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-192|57|1129|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-193|57|1131|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-194|57|1132|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-195|57|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Kidney tbos of mandible to kidney.,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-196|57|1146|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-197|57|1157|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-198|57|1166|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-199|57|1166|Other deterministic changes|Whole body|MCDU/  |
1003-20-57|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Adult|200 records survival 570 ± 13 lifespan study 287 d old|1003-20-57-200|57|1192|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-1|58|461|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-2|58|473|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-3|58|531|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ neck.Skin|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-4|58|553|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-5|58|583|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-6|58|596|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-7|58|596|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-8|58|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-9|58|639|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-10|58|652|Neoplasia unclassified|Other local manifestations and miscellaneus|TLWR: TRAC TO PARATHYMIC LN.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-11|58|656|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-12|58|663|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow|MBMZ/  ,MPATH: 127 - atrophy|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-13|58|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-14|58|665|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-15|58|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-16|58|677|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to rib muscle. Metastases  Lymphoret.System trac to parathymic ln.,MPATH: 268 - adenocarcinoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-17|58|677|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-18|58|679|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-19|58|690|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-20|58|696|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/   Metastases  Muscle trac to rib cage muscle. Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-21|58|701|Neoplasia unclassified|Other local manifestations and miscellaneus|TMWB: TBOS OF RIB SPREAD THRU MUSCLE.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-22|58|702|Neoplasia unclassified|Other local manifestations and miscellaneus|THWR: TRAC TO LIVER.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-23|58|704|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-24|58|715|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ jejunum.,MPATH: 218 - neoplasm|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-25|58|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-26|58|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-27|58|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-28|58|753|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-29|58|759|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-30|58|766|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Head/neck missing|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-31|58|767|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-32|58|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-33|58|770|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-34|58|791|Degenerative changes|Haematolymphatic system,MA: 0000134 - bone marrow|MBMZ/  ,MPATH: 127 - atrophy|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-35|58|799|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-36|58|802|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-37|58|809|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ rib. Metastases  Muscle tbos of rib spread thru muscle.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-38|58|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-39|58|820|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-40|58|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXL/  Mixed histiocyt.leukemia,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-41|58|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-42|58|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-43|58|840|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-44|58|844|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-45|58|847|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-46|58|848|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ calvarium. Metastases  tbvs of calvarium to dura mater (meningeal coat). Metastases  Muscle tbvs of calvarium to muscle of skull.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-47|58|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-48|58|859|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLSS/  undifferentiated lymphoma,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-49|58|859|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ ileum.,MPATH: 218 - neoplasm|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-50|58|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-51|58|870|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|TULS/ widespread local invasion.,MPATH: 551 - sarcoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-52|58|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-53|58|879|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-54|58|880|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-55|58|883|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-56|58|887|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ femur.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-57|58|893|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-58|58|904|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-59|58|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases  trac to parietal pleura of rib cage and mediastinum. Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-60|58|917|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine,MPATH: 212 - inflammation|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-61|58|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-62|58|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-63|58|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Liver,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-64|58|920|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-65|58|926|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ lumbar vertebra. Metastases  Muscle tbos of lumbar vertebra to lumbar muscle.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-66|58|926|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to parietal pleura. Metastases  Muscle trac to intercostal muscle.,MPATH: 268 - adenocarcinoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-67|58|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-68|58|927|Neoplasia malignant|Bloodvessels among cardiovascular system|TXVS/ visc. peritoneum about uterus and ovary.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-69|58|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-70|58|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-71|58|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-72|58|939|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ mandible.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-73|58|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-74|58|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-75|58|959|n/a|n/a|n/a|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-76|58|960|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ neck. Metastases  tcvs of neck to salivary gland.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-77|58|961|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-78|58|968|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ thigh. Muscle Metastases  Lymphoret.System trac to parathymic ln.|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-79|58|969|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-80|58|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-81|58|991|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcutis-mid shoulder. Metastases  Muscle tcfs of subcutis-mid shoulder to muscle-mid shoulder.,MPATH: 408 - soft tissue fibrosarcoma|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-82|58|999|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-83|58|1000|Neoplasia unclassified|Ovary among reproductive system diseases|TOGC/   Metastases Lung|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-84|58|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-85|58|1004|Neoplasia unclassified|Nervous system and special sense organs|TANS/  Adrenal|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-86|58|1009|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-87|58|1010|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-88|58|1013|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-89|58|1020|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-90|58|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-91|58|1071|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-92|58|1072|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-93|58|1075|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-94|58|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-95|58|1088|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-96|58|1093|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-97|58|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-98|58|1104|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-99|58|1107|Other deterministic changes|Whole body|MCDU/  |
1003-20-58|n/a,Z3|1| 287|neutrons fission|2.4|grays|External exposure| code Z3 1 fraction 20 m|100 (100 in ERA)|Mouse|Mouse, B6CF1|Female|Adult|100 records survival 573 ± 16 lifespan study287 d old|1003-20-58-100|58|1165|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
		
